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Breasts are considered an important symbol of femininity in Western societies and therefore 
are an important topic to most trans women. When you read the title of this thesis, breast 
cancer, breast implants, or sex are probably one of the first things that come to mind. But 
breasts are interesting organs, and, as not everyone may know, are present in both men 
and women. In addition, breasts can cause various (health) problems, both somatic and 
psychological. Therefore, with this thesis, we would like to increase the knowledge on 
(factors that influence) breast development, satisfaction with breast size, and possible health 
complaints of breast tissue and breast implants. The studies described in this thesis focus on 
breast care in transgender people from an internal medicine perspective. This knowledge 
may help to have an open conversation about breasts in the (outpatient) clinic and may help 
to expand the view about breasts in general. So, let’s talk about breasts!
Gender dysphoria
Gender dysphoria is defined as a persistent incongruence between one’s sex assigned at 
birth and one’s gender identity.1 In this thesis, people diagnosed with gender dysphoria will 
be referred to as transgender people, and people in whom sex assigned at birth an gender 
identity are aligned will be referred to as cisgender people. Estimations in 2015 in the 
Netherlands, showed that 1:2,800 birth- assigned males and 1:5,200 birth-assigned females 
receive medical care for gender dysphoria.2 A significant increase in the number of referrals 
for either psychological, endocrine, and/or surgical treatment is seen over the last years.2
Transgender people can receive gender-affirming hormones (sex steroids) to reduce distress 
and to induce desired physical changes such as changes in body hair and body composition.3,4 
In trans women (male sex assigned at birth, female gender identity), treatment usually 
consists of antiandrogens and estrogens. In Europe, cyproterone acetate is often used for 
antiandrogen treatment, which is a progestogenic antiandrogen. Other antiandrogens used 
are spironolactone and gonadotrophin-releasing hormone agonists (GnRH-agonists). In 
trans men (female sex assigned at birth, male gender identity), treatment usually consists 
of testosterone. People who start treatment at a younger age, often start with puberty 
suppression (GnRH-agonists) before treatment with either estrogens or testosterone is 
added.
Besides gender-affirming hormone treatment, transgender people may desire surgical 
transition as well. This can consist of breast augmentation and orchiectomy often combined 
with vaginoplasty in trans women, and subcutaneous mastectomy, uterus extirpation and/or 
oophorectomy, and metoidioplasty or phalloplasty in trans men. Subcutaneous mastectomy 
in trans men is often subtotal in order to obtain an aesthetically masculine thorax.
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Breast development is an important aim of gender-affirming hormone treatment in 
trans women. However, this topic has not been studied extensively and there are many 
unknowns. Moreover, hormone treatment with estrogens may increase breast cancer risk 
in trans women, but reliable data on this topic are lacking. To be able to understand the 
changes in breast tissue during gender- affirming hormone treatment and the reason why 
estrogen treatment may affect breast cancer risk in trans women, we will first describe 
breast development during typical cis male and cis female puberty and characteristics of 
benign and malignant breast disease.
Breast development during early life and cisgender puberty
Development of the mammary glands begins as early as in the 6th week of gestation, 
independent of the sex of the embryo, when the so-called milk lines are formed from 
endodermal elements. These milk lines or mammary ridges extend from the embryonic 
axilla to the inguinal region. Between the 6th and 12th week, these lines regress after 
which only two milk line residues are left. These residues are located in the area over the 
fourth intercostal space (Figure 1). Influenced by maternal hormones, asymmetric breast 
enlargement and a thin milky nipple discharge, called ‘witch’s milk’, can occur in newborn 
boys and girls. This usually resolves spontaneously in several weeks.
Figure 1. Development of mammary glands. (A) Diagram of the embryo at about 28 days, which shows 
the mammary ridges (milk lines). (B) Diagram of embryo at week 6, showing what remains of the 
mammary ridges. Reproduced with permission from Musumeci et al..5 No changes have been made 
to this figure. License number: 4983611153593.
In approximately 1% of newborns, accessory breast tissue is present.6 Polymastia refers to the 
presence of any accessory breast tissue, whereas polythelia refers to additional or accessory 
nipples. Surgical removal of polythelia may be indicated for aesthetical reasons. Surgical 
excision of polymastia may be warranted to prevent painful swelling during pregnancy7 and 
to prevent fibroadenomas and cancer in the accessory breast tissue.
Besides innate accessory breast tissue, people can be born with absence of a nipple (called 




athelia or amastia, other congenital anomalies may be present. Amastia may only become 
visible during puberty, when usually the cis female breasts further develop. Athelia and 
amastia may also be treated with corrective surgery for aesthetical reasons.
Breast development during cisgender puberty
Until puberty, mammary development in cis boys and cis girls is similar. During puberty, 
the cis female breast develops further under the influence of female sex hormones, with 
duct and lobule formation and an increase of the deposition of fat in the breasts (Figure 
2).8,9 Adipose tissue and lactiferous ducts grow in response to estrogens, while progesterone 
stimulation causes lobular growth and alveolar budding.7 With each menstrual cycle, more 
breast tissue is formed until approximately 18 to 20 years of age.10-12 This development is 
described according to the stages developed by Tanner in 1969.13 As shown in Figure 3, 
not only the size of the breasts increase during puberty, but also the size of the nipple-
areola complex increases. The cis female breast remains in a mature but inactive state until 
pregnancy. Besides functional breast tissue, the mature cis female breast contains abundant 
adipose tissue which largely determine breast volume.10,11 14
Figure 2. Schematic representation of breast tissue cells in different stages of development. 




Figure 3. Breast development as described by the stages developed by Tanner. Reproduced with 
permission from https://basicmedicalkey.com. No changes have been made to this figure.
Breast size and shape differ widely between people and are most likely due to genetic 
variation. However, breast hypoplasia or underdevelopment can also be caused by congenital 
disorders, hypothyroidism, ovarian failure, androgen excess, connective tissue disorders, or 
due to previous radiation to the chest wall.6,16 Also, after infection or trauma to the breast, 
breast development may be (asymmetrically) impaired. Though, breast asymmetry does 
not have to be abnormal. In fact, 25% of adult cis women have some degree of breast 
asymmetry.17
In cis males, no further breast development during puberty occurs due to increasing 
testosterone concentrations.10,18 Nonetheless, some structural changes in the breast occur, 
such as an increase of fibrous tissue.8,19 However, as testosterone is partially aromatized 
into estradiol, the estradiol concentration may be relatively higher than the testosterone 
concentration in the beginning of puberty. Due to this (temporary) imbalance in sex hormones, 
some cis boys experience an enlargement of the breast, which is called gynecomastia. Other 
causes of gynecomastia can be side effects of certain (prescribed) drugs, hyperthyroidism, 




breast and is in most cases self-limiting.20 Histologically and with imaging, gynecomastia 
can be distinguished from true breast development.20 When gynecomastia persists, the 
glandular disk of the breast can be surgically removed.
Another reason for ‘breast development’ in cis males is obesity, also called 
pseudogynecomastia. As adipose tissue can be stored in the breast area as well, it may lead 
to the impression that breast development occurs.20
Abnormalities in breast tissue: benign and malignant breast disease
Benign breast lesions
The mature cis male breast consists of skin, primitive ducts, stromal elements, and fat 
tissue. On the other hand, the mature cis female breast consists of skin, developed ducts, 
lobules, stromal elements, fat tissue, and Cooper’s ligaments (Figure 4).20 Because of this 
difference in breast structure between cis males and cis females, lobular pathology, such as 
fibroadenomas and cysts, is not expected in cis men. Benign breast lesions that do occur in 
cis men include gynecomastia (as described above), dermal cysts, lipomas and angiolipomas, 
mastitis and abscesses, granular cell tumors, and pseudoangiomatous stromal hyperplasia 
(PASH).20
In cis females, fibroadenomas are the most common benign breast lesions and occur 
commonly between 15-35 years of age.22 Complex fibroadenomas, fibroadenomas with 
adjacent proliferative disease, and fibroadenomas in people with a family history of breast 
cancer are seen as a risk factor for breast cancer.23-27 Other simple fibroadenomas are not 
related with an increase in breast cancer risk.23-27
Benign breast lesions can be histologically classified into three categories: non-proliferative, 
proliferative without atypia, and atypical hyperplasia. Examples of non-proliferative breast 
lesions are cysts, papillary apocrine changes, and mild hyperplasia of the usual type. Usual 
ductal hyperplasia, intraductal papillomas, sclerosing adenosis, and simple fibroadenomas 
are examples of proliferative breast lesions without atypia. In the last category, atypical 
hyperplasia, two types are distinguished: atypical ductal hyperplasia and atypical lobular 




Figure 4. Different elements of cis male and cis female breast tissue. Peter Lamb © 123RF.com
Breast cancer
Through their receptors, sex hormones are involved in proliferative signaling and growth 
suppression in cells, which are two major underlying mechanisms of carcinogenesis.31 Sex 
hormones may either play carcinogenic or tumor suppressive roles. Breast cancer subtypes 
can be divided in three major histological categories: infiltrating ductal carcinoma, infiltrating 
lobular carcinoma, and mixed ductal/lobular carcinoma.
Normal breast tissue has several hormone receptors: estrogen receptor (ER), progesterone 
receptor (PR), and androgen receptor (AR). In breast cancer, these receptors may not be 
present, which is associated with more aggressive breast cancer and worse survival than in 
ER and PR positive tumors.32 In addition to nuclear hormone receptors, breast cancer cells 





ER alpha is a major factor in the diagnosis and treatment of 70% of cis female breast cancer 
cases. Similar observations have been made in cis male breast cancer.33 In breast cancer in 
cis women, estrogens appear to be mainly important for breast cancer progression. AR is 
expressed in the majority of cis female and cis male breast tumors as well, and appears to 
have dual roles in breast carcinogenesis in cis women. In luminal tumors, AR has growth-
suppressive properties, whereas in ER-negative breast cancers AR functions as a driver of 
tumor cell proliferation.34
Breast cancer is the most common malignancy in cis females35 but is rare in cis males. The 
lifetime risk is 12% in the cis female population and 0.1% in the cis male population.8 Several 
risk factors for breast cancer have been identified. In cis females, these include advancing 
age, genetic factors (e.g. BReast CAncer 1/2 gene mutations [BRCA 1/2]), family history of 
breast cancer, overweight or obesity, ethnicity, breast density, tobacco use, alcohol use, 
and null parity.36,37 In cis males, risk factors for breast cancer are advancing age, ethnicity, 
family history of breast cancer, abnormal balance between estradiol and testosterone 
concentrations, or radiation exposition.20 Imbalances between estradiol and testosterone 
concentrations are seen in people with Klinefelter’s disease, in people using exogenous sex 
hormones, obese individuals, people with orchitis or epididymitis, or in people with prostate 
cancer who are treated with estrogens. In addition to different risk factors for breast cancer, 
the molecular pathogenesis of breast cancer differs between sexes as well.38 For instance, 
HER2-positive cancers are rare in cis males (1.7%), whereas 6-12% of the breast cancer in cis 
females express HER2.38-40
The influence of gender-affirming hormone treatment on breasts in 
transgender people
Breast development in trans women
Breast development is considered an important symbol of femininity in Western societies, 
and is therefore important to most trans women.41 In the Clinical Practice Guidelines for 
transgender healthcare of the Endocrine Society4, it is estimated that breast development 
starts two to three months after initiation of hormone treatment. The maximum effect 
of hormone treatment on breast development may be expected after two to three years 
according to these guidelines.
Several studies investigated breast development in trans women receiving hormone 
treatment. Although all studies showed modest, histologically normal18, breast development 
with hormone treatment in trans women41-43, these studies have small study populations 
and a limited follow-up time varying between three to 24 months. As described above, 
physiological breast development during cis female puberty takes several years, making 
it plausible that breast development in trans women receiving hormone treatment takes 
some time as well. Usually, hormone treatment in trans women consists of antiandrogen 
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and estrogen treatment as described earlier in this chapter. In some practices, (cyclically) 
progesterone is added to this treatment, as it is argued by the prescribing providers that 
one needs progesterone for normal breast development based on knowledge on breast 
development during cis female puberty.42,44,45 However, no large studies have been 
performed on the possible positive effect of progesterone on breast development in trans 
women. Moreover, progesterone treatment may have side effects as well, such as changes 
in sleeping, changes in serum lipid concentrations, and mood changes.44-46
Differences regarding the extent of breast development may also be observed due to 
different measurement methods, ranging from breast (hemi)circumference measurements, 
to Tanner stages, and imaging methods such as ultrasound or magnetic resonance imaging 
(MRI).41,42,47,48 More recently, 3D technology has been developed which can be used to 
measure breast volumes as well.49,50 The anatomy of the cis male and cis female chest differs 
in sternal width, position of the nipples on the chest, and width of the chest and shoulders 
(Figure 5). Because of these differences, breast size in trans women may appear smaller than 
the actual objectively measured volume.51-53 Therefore, volume measurements are thought 
to be the most reliable way to study breast development in trans women, combined with 
the measurement of the development of the nipple-areola complex.44
Figure 5. Difference between cis female and cis male chest: nipples further apart in cis men, wider 
chest, wider sternum, wider shoulders. Reproduced with permission from https://www.kamolhospital.
com. No changes have been made to this figure.
Judgement on what an esthetically good looking breast is, may differ between people and 
could be influenced by cultural aspects.52 So one perfect breast or breast shape does not 
exists, as the appearance of the breasts also depends on the proportion of the breasts to 
the chest and the rest of the body. Interestingly, no studies on satisfaction of trans women 
with their gained breast development during hormone treatment have been performed. A 
derivative marker for satisfaction in this case can be breast augmentation rate. Currently, it 
is estimated that 60-70% of trans women choose breast augmentation.54-56 Although breast 




may have side effects. Studies have shown that a small portion of cis women with silicone 
breast implants may experience local and/or systemic health complaints, such as silicone 
granulomas, fatigue, and myalgia.57
Hormone treatment can have undesired effects on breast tissue as well. By stimulating the 
receptors of breast tissue with exogenous hormones in trans women, breast lesions, both 
benign and malignant, may develop. As the physiologic cis male breast does not contain 
lobules20, lobular pathology rarely develops in cis males. As described earlier, hormone 
induced breast development in trans women result in breast tissue with ducts and lobules 
as seen in cis females.58 Therefore, lobular pathology in trans women may be expected. 
Indeed, cases of lobular pathology in trans women including fibroadenomas have been 
described.59-61 However, reliable estimations on the incidence of benign breast lesions and 
the ratio between benign and malignant breast disease in trans women is lacking. Besides 
hormone-induced benign breast lesions, several reports of silicone granulomas in trans 
women exist. 62,63
Whether (exogenous) sex steroids influence breast cancer risk and pathogenesis in 
transgender people is not fully understood. Several case reports have been published on 
trans women with breast cancer.64 However, reliable estimations on breast cancer risk 
in transgender people are lacking due to the heterogeneity in the population and study 
cohorts.65 As cis women, trans women with breast prostheses have a risk of breast implant 
related anaplastic large cell lymphoma (BIA-ALCL)66,67, a rare type of T-cell lymphoma.68 As it 
is estimated that 60-70% of trans women have silicone breast prostheses54-56, it is important 
to be aware of this recently discovered risk.
Since there is no literature on cancer treatment outcomes in transgender people specifically, 
there is no knowledge on whether cancer treatment in transgender people should be different 
from the treatment in cisgender people. However, there is some literature on mortality 
rates in transgender people, which in a way can be used for cancer survival estimates in this 
group.69-72 Most of these studies69,70,72 showed an increased mortality risk in transgender 
people compared with their cisgender counterparts. This risk was mainly increased because 
of increased rates of suicide in transgender people. Also, increased mortality risk because of 
Human Immunodeficiency Virus (HIV)-related disease, cardiovascular disease, drug abuse, 
infections and parasitic disease, diseases of the digestive system, and unknown causes of 
death was observed. Overall cancer-related mortality was not increased, but in the study 
of Asscheman et al.69, an increased risk of lung and hematological cancer was seen. Van 
Kesteren et al.71 did not observe an increased mortality risk among transgender people 
receiving hormone treatment. Although an overall increased mortality risk in transgender 




However, these reports are limited because of short follow-up time, a high number of 
missing data, and heterogeneity in study cohorts and control populations.
Breasts in trans men
Most trans men experience severe dysphoria towards their breasts. Therefore, prior to a 
mastectomy, most trans men bind their breasts closely to their chest so they will be least 
visible as possible.73 As the breast tissue may be pinched due to the breast binding, this may 
lead to inflammation or other lesions or complaints.74 Furthermore, hormone treatment 
with testosterone may induce some structural changes in mammary tissue of trans men.73,75 
As mastectomy in trans men is often subtotal, to obtain an aesthetic masculine thorax, some 
breast tissue still remains after the procedure. In this residual tissue, breast cancer still can 
develop.64 However, as in trans women, reliable estimations of the breast cancer risk are 
lacking.
Aims and hypotheses
The research project described in this thesis had several aims. The first aim was to study breast 
development in trans women and examine whether (clinical) determinants can be identified 
that may influence the extent of breast development in this population. We hypothesized 
that breast size in trans women was less than in cis women and that the degree of breast 
development was associated with serum estradiol levels and body mass index. Secondly, 
we aimed to study satisfaction with the gained breast development. We hypothesized that 
most trans women were not satisfied with their gained breast development, as we expected 
the gained volume to be small. The third aim was to study breast abnormalities, both benign 
and malignant in transgender people. For this question we hypothesized that the risk of 
breast cancer in trans women would be comparable to cis men, which was already shown 
by previous research. Although breast tissue of trans women is shown to be histologically 
comparable to breast tissue of cis women, we hypothesized that benign breast lesions were 
less frequent in trans women as their serum hormone levels are predominantly constant 
unlike the hormone levels during a menstrual cycle in cis women. Lastly, we aimed to 
study mortality risk in transgender people including breast cancer-related mortality. We 
hypothesized that overall mortality is slightly higher in trans people compared with cis 
people but that the breast cancer-related mortality is not increased.
Outline
As several study populations and methods have been used for this thesis, an overview of the 
methods and populations is described in Chapter 2. In Chapters 3 and 4, breast development 
during hormone treatment has been studied using breast circumference measurements and 
3D imaging, respectively. In Chapter 4 satisfaction with the gained breast development is 
also studied. Chapter 5 studies the number of breast augmentations in trans women, as 




of breast lesions in trans women. In Chapter 7, an overview of the already existing literature 
on (breast) cancer is provided, and in Chapter 8 breast cancer risk in transgender people is 
studied. With the gained CBS mortality data (to determine follow- up time in Chapter 8), we 
were able to study overall and cause-specific mortality risk in transgender people in Chapter 
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European Network for the Investigation of Gender Incongruence (ENIGI) – Endocrine part
The European Network for the Investigation of Gender Incongruence (ENIGI) study1 is 
a European collaboration to evaluate the effects of hormone treatment in transgender 
people. This study is a prospective study and includes several parameters, such as laboratory 
values, bone density, and well- being. The initiative was started in 2010 in Ghent and today 
the collaboration consist of five participating centers: the Amsterdam UMC location VUmc 
hospital in Amsterdam, the Netherlands; the University hospital in Florence, Italy; the 
Ghent University hospital in Ghent, Belgium; the University hospital in Oslo, Norway; and 
the Tel Aviv Sourasky medical center in Tel Aviv, Israel. Of the participants of the ENIGI study, 
several clinical parameters were collected including breast development during hormone 
treatment. At time of the study described in this thesis, the Tel Aviv center was not yet 
participating in the collaboration. A detailed description of the study design and protocol 
is described elsewhere.1 Briefly, people were eligible for participation in the ENIGI study 
if they were 18 years or older in the Amsterdam clinic or 16 years or older in the other 
centers, had a diagnosis of gender dysphoria confirmed by a mental health professional, 
and were about to start with hormone treatment. People were not eligible if they had ever 
used, or were currently using gender- affirming hormones, if they were treated following a 
different treatment protocol, or if there was insufficient knowledge of the nation’s language. 
Currently, over 2,500 people have been included in the endocrine part of this study. We 
used the trans women who were included in the ENIGI cohort until 2016, to study breast 
development during the first year of hormone treatment.
Hormone treatment protocol in the ENIGI study
Treatment for trans women in the ENIGI cohort consisted of antiandrogens, with either 
cyproterone acetate (10 to 100 mg daily) or spironolactone (100 to 150 mg daily), combined 
with administration of estradiol valerate (2 to 6 mg daily), estradiol patches (50 to 100 
mcg/24h twice weekly), or estradiol gel (0.75 to 3 mg daily). People above the age of 40 
were advised to use transdermal estradiol to reduce the risk of thrombosis.2 People who 
wish to undergo gender-affirming surgery are eligible to do so after at least one year of 
hormone treatment, according to the protocol.
Amsterdam Cohort of Gender dysphoria (ACOG)
The Amsterdam Cohort of Gender dysphoria (ACOG) study is a retrospective medical chart 
study. For this study, all people who visited the gender identity clinic of the Amsterdam UMC 
location VUmc, Amsterdam between 1972 and December 2018 for either psychological, 
endocrine and/or surgical treatment were identified. In total, 8,831 individuals were 
Chapter 2
30
included until 2019. In this study, two cohorts have been identified. First, people who started 
treatment between 1972 and 2016 were included.
Later, this cohort was expanded with people who started treatment until 2019. From 
the included people, data were extracted from the medical files and hospital registries 
and entered into a cumulative database. A detailed description of the study design and 
participants until 2016 is described elsewhere.3 For this thesis, the ACOG study until 2016 
was used to investigate the effect of hormone treatment on breast cancer. For the study on 
breast lesions and mortality risk we used the ACOG study until 2019. Furthermore, trans 
women in this cohort were asked to participate in a survey about breast augmentation.
Hormone treatment protocol in the ACOG study
In the ACOG cohort, most trans women were treated with a combination of antiandrogens 
and estrogens. Antiandrogen treatment usually consisted of cyproterone acetate (10 to 100 
mg daily) or spironolactone (100 to 200 mg daily), and was often ceased after orchiectomy. 
Estrogen was prescribed as ethinylestradiol (25 to 100 mcg daily), conjugated estrogens 
(0.625 to 1.25 mg daily), estradiol patches (50 to 150 mcg/24h twice weekly), estradiol 
implants (20 mg every 3 to 6 months), estradiol injections (10 to 100 mg every 2 to 4 
weeks), estradiol valerate (2 to 6 mg daily), or estradiol gel (0.75 to 3 mg daily). In recent 
years, mainly estradiol valerate, estradiol patches, or estradiol gel were used. In this cohort, 
trans men were treated with either testosterone gel (20 to 100 mg daily), intramuscular 
testosterone esters (150 to 250 mg every 2 to 3 weeks), or oral or intramuscular testosterone 
undecanoate (orally: 40 to 160 mg daily, intramuscularly: 1000 mg every 10 to 14 weeks). 
Trans men who experienced persistent menstrual blood loss during testosterone treatment 
were in some cases treated with additional progestogens such as lynestrenol (5 to 10 mg 
daily).
People who started with hormone treatment under the age of 18 years often started with 
gonadotrophin-releasing hormone agonists only (3.75 mg every 4 weeks) before addition of 
estrogen or testosterone treatment.
Other included subjects
To study breast development with 3D imaging, trans women who started hormone treatment 
at our clinic between February 2017 and December 2017 were eligible for participation. 
People were excluded if they ever used estrogens, if it was considered too much of a burden 
to participate because of psychological reasons, of if there was insufficient knowledge of the 
Dutch language. If hormone treatment was discontinued during follow-up, the participant 
was excluded from that point onwards.
The hormone treatment that the participants in this study received, consisted of our 




with either estradiol valerate (4 to 6 mg daily) or estradiol patches (50 to 150 mcg/24u twice 
a week). People over 40 years of age were advised to use transdermal estradiol to reduce 
the risk of thrombosis as described earlier.2
All study protocols described in this thesis were assessed by the Ethical Review Board of 
the Amsterdam UMC, VU University Medical Center Amsterdam. It was determined that 
the Medical Research Involving Human Subjects Act (WMO) did not apply to these studies.
Data collection
In the clinical registrations from the ENIGI and ACOG studies, data about medical history, 
family history, age at start of hormone treatment, type of hormone treatment, gender-
affirming surgery, body weight and body height, smoking habits, alcohol consumption, 
recreational drugs use, and date of last visit to our clinic were collected.
In addition to these clinical data in the cohort registrations, the ACOG database was linked to 
two national registries. The first was the Nationwide Network and Registry of Histopathology 
and Cytopathology in the Netherlands (PALGA). The PALGA database contains information 
about all pathology diagnoses in the Netherlands. This registry has nationwide coverage 
since 1991.4 For this thesis, information on breast lesions were retrieved from PALGA. The 
second registry to which the ACOG study was linked was Statistics Netherlands (CBS). CBS 
holds record of data about different topics of all residents and companies in the Netherlands. 
Available data include data on income and spending, nature and environment, construction 
and housing, population, businesses, education, and health and wellbeing. For this thesis, 
data on mortality (date and cause of death) was retrieved. Cause of death was available since 
1996 and determined from the decease forms which are filled out by the medical doctor at 
time of decease. If the cause of death was not known, the cause of death is registered on 
these forms as ‘unknown’. Each deceased person is registered with a single death cause 
(primary cause of death).
Breast measurements
Circumference measurements
Breast circumference was measured in centimeters (cm) with a tape measure horizontally 
placed around the thorax over the fullest part of the bare breasts. Chest circumference was 
measured with a tape measure horizontally placed around the thorax in the inframammary 
fold. See Figure 1 for the placement of the tape measure.
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Figure 1. Placement of the tape measure for circumference measurements.
For breast circumference measurement the tape measure was placed around the thorax over the 
fullest part of the breast (dotted line) and for chest circumference measurement in the inframammary 
fold (dash-dot line). Reproduced with permission from de Blok et al..5 No changes have been made to 
this figure. License number: 4983640188172.
3D imaging
3D images were obtained using the VECTRA XT® scanner (Canfield Inc.). The Vectra contains 
six cannon cameras divided into three arms so each arm has two cameras. All the cameras 
simultaneously take a picture. With the build-in software, 3D reconstructions are made and 
can be analyzed. For generating 3D images of the breast, the software was set to the ‘breast 
imaging’ mode. According to the manufacturers’ instructions, participants were placed 
with a bare upper body facing the machine with their feet 70 cm from the scanner. The 
participant’s arms were raised approximately 45 degrees corresponding with the reference 
lines in the program. As the software has trouble with analyzing images through hair or 
other material, the participants were requested to put their hair in an updo and take of 
their jewelry. To study breast development during hormone treatment, breast volume (in 
cubic centimeter, cc), sternal notch to nipple distance (in cm), nipple to inframammary fold 
(IMF, in cm) distance, breast width (lateral mammary fold [LMF] to medial mammary fold 
[MMF] distance, in cm) , internipple distance (in cm), and intermammary distance (MMF 
to MMF, in cm) were measured using the assessment software (version 5.7.1.) of the 




the abovementioned measurements. Areolar diameter was manually determined using the 
VECTRA XT® Mirror software as shown in Figure 2.
Figure 2. Placement of the landmarks (red dots) and measurement of the areolar diameter (purple 
line).
Abbreviations: SN=sternal notch; (r)= right, (l)=left, C=clavicle; A=areola; N=nipple; MMF=median 
mammary fold; LMF=lateral mammary fold; IMF= inframammary fold
Questionnaires
In this thesis, a total of three different questionnaires were used. In the breast 3D imaging 
study, two questionnaires were used to gain more insight in the satisfaction of the breast 
development by the participants. The first questionnaire contained questions about the 
satisfaction with the gained breasts and used a four-point Likert scale (very dissatisfied, 
somewhat dissatisfied, somewhat satisfied, very satisfied). This questionnaire included the 
following questions: (1) How do you rate the development of your breasts between now and 
your last visit? What do you think of the (2) size, (3) shape, and (4) symmetry of your breasts? 
What do you think about the (5) size and (6) shape of your nipples? For analyzes, answers 
were scored as satisfied (somewhat satisfied and very satisfied) and dissatisfied (somewhat 
dissatisfied and very dissatisfied). The second questionnaire used was the (Dutch version 
of the) Rosenberg perceived self-esteem scale.6,7 This questionnaire was used as general 
estimator of self-esteem. Using the included scale, self-esteem was rated as low self-esteem 
(0-14 points), average self-esteem (15-24 points), and high self-esteem (25-30 points).
In the breast augmentation study, a questionnaire was send through mail. The questionnaire 
consisted of 5 main questions, which were filled out by both trans women who underwent 
and who did not undergo breast augmentation. These questions included the date of 
answering the questionnaire, current age, year of start of hormone treatment, whether or 
not the respondent underwent breast augmentation (yes/no), and whether the respondent 
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underwent other surgical procedures (yes/no). If the respondent underwent breast 
augmentation, she also filled out the following questions: (1) what was the reason to undergo 
breast augmentation (insufficient breast development/asymmetry of the breasts/other), (2) 
in what year did the breast augmentation took place, (3) in which hospital/clinic was the 
surgery performed, (4) how many times have you had surgery for your breasts, (4a) what was 
the reason for these surgeries (capsule formation/leakage of the implants/infection of the 
implants/other), are you satisfied with the result of your breast augmentation (yes/no), (5a) 
why are you satisfied/dissatisfied, (6) do you experience any complaints of your breasts (yes/
no), (6a) if yes, what kind of complaints (multiple answers possible: pain/capsule formation/
asymmetry/other), and (7) do you experience any (health) complaints you attribute to your 
breast implants (yes/no), (7a) if yes, what kind of complaints (multiple answers possible: 
fatigue/myalgia/arthralgia/sleep problems/neurasthenia/concentration difficulties/other). 
Respondents who did not undergo breast augmentation filled out the following questions: 
(1) have you ever considered to undergo breast augmentation (yes/no), (2) what was the 
reason not to undergo breast augmentation (yet) (multiple answers possible: satisfied with 
the gained breast development/awaiting further breast development/financial reasons/
afraid of complications/other). At the bottom of the questionnaire, there was a space for 
(general) comments as a conclusion. All complaints or reasons stated here were interpreted 
and divided into categories as well.
Laboratory measurements
In our center, serum estradiol concentrations were measured using a competitive 
immunoassay (Delfia, PerkinElmer, Wallac Oy, Turku, Finland) with an inter-assay coefficient 
of variation (CV) of < 13% and a lower limit of quantitation (LOQ) of 20 pmol L-1 until July 
2014. From July 2014, estradiol concentrations were measured using LC-MS/MS (VUmc, 
Amsterdam, the Netherlands) with an inter- assay CV of < 7% and a LOQ of 20 pmol L-1. For 
analyses, Delfia values were converted to LC- MS/MS values using the following formula: 
LC-MS/MS=1.60*Delfia -29. Until January 2013, serum testosterone concentrations were 
measured using a radioimmunoassay (RIA) (Coat-A-Count, Siemens, Los Angeles, CA, USA; 
inter-assay CV: < 10%, LOQ: 1 nmol L-1). After January 2013, testosterone concentrations 
were measured using a competitive immunoassay (Gen III, Architect, Abbott, Abbott Park, 
IL, USA) with an inter-assay CV < 10% and a LOQ of 0.1 nmol L-1. For analyses, RIA values 
were converted to Architect values using the following formulas: Architect=1.1*RIA+0.2 for 
concentrations below 8 nmol L-1, and Architect=1.34*RIA-1.65 for concentrations above 8 
nmol L-1.
Since October 2018, testosterone was measured with a LC-MS/MS (VUmc, Amsterdam, the 
Netherlands8) with an inter-assay CV of < 9% and a LOQ of 0.1 nmol L-1. As the measurements 
of the competitive immunoassay and the LC-MS/MS are comparable to each other, no 




assay (Architect, Abbott, Abbott Park, IL, USA) with an inter-assay CV of < 6% and a LOQ of 
2 nmol L-1.
In the study using the ENIGI cohort, laboratory data from the Ghent hospital were used 
as well. In Ghent, serum estradiol concentrations were measured using E170 Modular (E2 
Gen II, Roche Diagnostics, Mannheim, Germany), until 19th March 2015. Thereafter, serum 
estradiol concentrations were measured using E170 Modular (E2 Gen III, Roche Diagnostics, 
Germany) with an inter-assay CV of 3.2% and a LOQ of 92 pmol L-1. For analyses, values 
measured before 19th March 2015 were converted to Gen III values using the following 
formula: Gen III=6.687940+0.834495*Gen II. Serum testosterone concentrations were 
measured using E170 Modular (E2 Gen II, Roche Diagnostics, Germany) with an inter-assay 
CV of 2.6% and a LOQ of 0.4 nmol L-1. Serum LH concentrations were measured using E170 




Breast development was measured at several times during follow-up. For the tape-measure 
study using ENIGI data this was measured at baseline, after 3, 6, 9, and 12 months of hormone 
treatment. In the breast development study using 3D imaging, the follow-up consisted of 
measurements at baseline, after 3, 6, 9, 12, 18, 24, and 36 months of hormone treatment. 
With this many follow-up points, it is possible to identify individual and population-
level outliers. Population-outliers were defined as mean±3 times the standard deviation. 
Individual-level outliers were identified using the method described by Welch et al.9 with 
a standardized residual cutoff point of ±5. All values of identified population- or individual-
level outliers were replaced by a missing value before analyses. As the shape of the thorax is 
an overstated invert pyramid shape, greater chest than breast circumference measurements 
are highly unlikely. Therefore, all breast and chest values resulting in a negative breast minus 
chest value were replaced by a missing value assuming these were input mistakes in the 
database.
To analyze the effect of hormone treatment on breast growth over time, mixed-model 
analyses were performed with measurements clustered within participants and within 
center for the study using the ENIGI cohort.10 Non-normally distributed data were log-
transformed before mixed-model analyses were performed. For translation of circumference 
measurements and/or volume measurements into bra cup-sizes, the method described by 




To study breast cancer risk, Standardized Incidence Ratios (SIRs) were calculated by dividing 
the number of observed cases by the number of expected cases x 100 (Figure 3). The 
number of expected cases were calculated using age specific incidence rates for cisgender 
males and females from the Netherlands Comprehensive Cancer Organization (IKNL).12 The 
number of expected cases was calculated for the whole study population and for the age 
categories below 30 years, between 30 and 50 years, and over 50 years. Follow-up time for 
the transgender people was calculated as the number of years from the first known start 
date of hormone treatment to the first terminating event: breast cancer diagnosis, death, or 
end of study period (August 31, 2017).
Figure 3. Calculation of standardized incidence ratio (SIR).
For analyses on mortality risk, standardized mortality ratio (SMR) was calculated using 
general population mortality rates stratified by age, calendar year, and sex. Calculation of 
the SMR is similar to the SIR as shown in Figure 3, except in SMR calculation the number of 
deaths is used instead of diagnosed events. When possible, the mortality risk was further 
divided in categories of diseases.
Follow-up time was defined as the number of years from the first known start date of 
hormone treatment to the first terminating event. Terminating events were either death, 
end of study period (December 31, 2018), or last visit at our clinic for the people who could 
not be linked to CBS.
Cohort analyses
In cohorts with long follow-up times, such as the ACOG cohort, the pitfall of time dependent 
varieties may occur. We aimed to adjust for that, by using life tables as described by Dickman 
et al.13,14 in the study on mortality risk. Another way to try to overcome this problem is by 




numbers, as we did in the study on breast cancer risk. For both of these methods, reliable 
(age-adjusted) incidence numbers must be available. Since there are no reliable incidence 
numbers on breast augmentations, we used age- period-time analyses to account for the 
effect of the long follow-up time in that study. For these analyses, people were divided into 
5-year sub-cohorts, based on the year they started hormone treatment. Time after both 
initiation of hormone treatment and eventual breast augmentation was calculated using 
the difference between the stated start date of hormone treatment or date of surgery and 
2018. In that way, sub-cohorts could be analyzed which account for the period in time these 
people started their hormone treatment and the difference in total follow-up time between 
these sub- cohorts.
For statistical analyses, STATA Statistical Software, versions 13.1, 14.1, and 15.1 (Statacorp, 
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Context: Breast development is a key feature of feminization and therefore important to 
transwomen (male-to-female transgender persons). It is not exactly known when breast 
development starts after initiating cross-sex hormone therapy (CHT) and how much growth 
may be expected.
Objective: To investigate breast development in transwomen during their first year of CHT 
and whether clinical or laboratory parameters predict breast development.
Design: This study was performed as part of the European Network for the Investigation of 
Gender Incongruence, which is a prospective multicenter cohort study. 
Setting: Gender clinics in Amsterdam, Ghent, and Florence.
Participants: Transwomen who completed the first year of CHT (n=229).
Intervention: CHT.
Main outcome measures: Breast development in centimeter and cup size.
Results: The median age of the included transwomen was 28 years (range, 18 to 69). Mean 
breast-chest difference increased to 7.9 ± 3.1 cm after one year of CHT, mainly resulting in 
less than an AAA cup size (48.7%). Main breast development occurred in the first 6 months 
of therapy. Serum estradiol levels did not predict breast development after 1 year of CHT 
(first quartile, 3.6 cm [95% confidence interval (CI), 2.7 to 4.5], second quartile, 3.2 cm [95% 
CI, 2.3 to 4.2], third quartile, 4.4 [95% CI, 3.5 to 5.3], and fourth quartile, 3.6 cm [95% CI, 
2.7 to 4.5]).
Conclusion: This study shows that, after 1 year of CHT, breast development is modest and 
occurs primarily in the first 6 months. No clinical or laboratory parameters were found that 
predict breast development.
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Persons diagnosed with gender dysphoria can be treated with cross-sex hormones to reduce 
distress and induce desired physical changes. In transwomen (male-to-female transgender 
persons) treatment consists of antiandrogens and estrogens. Physical changes induced by 
this treatment include breast development, reduced sperm production, reduced number 
of spontaneous erections, and changes in body hair and body composition (1,2), leading to 
feminization.
Breast development is a key feature of feminization and therefore important to transwomen. 
The Clinical Practice Guidelines of the Endocrine Society indicate that breast development 
starts 3 to 6 months after start of cross-sex hormone therapy (CHT). The maximum effect 
may be expected after 2 to 3 years of CHT (1). However, because these time frames are 
estimated and not based on clinical data, it is not exactly known when breast development 
starts after induction of CHT. Besides, the literature is inconsistent about how much growth 
may be expected from CHT alone. The few studies addressing this issue showed modest 
breast development after CHT (3-5). Moreover, because of anatomical differences in the 
male chest compared with the female chest, breast size may appear smaller than the 
actual objectively measured volume (6). Consequently, 60% to 70% of all transwomen seek 
additional breast augmentation besides CHT (7,8). Because a small portion of women with 
silicone breast implants have local and/or systemic health complaints (9), it is important to 
gain more knowledge about breast development in transwomen to be able to reduce the 
number of breast augmentations in this population.
Therefore, this study aims to prospectively examine the absolute breast development in 
centimeters and bra cup sizes in transwomen during their first year of CHT. Furthermore, 
it will be studied whether age, weight change, body mass index (BMI), smoking, treatment 
regimen, or serum hormone levels influence breast development.
Subjects and Methods
Study population
This study was performed as part of the European Network for the Investigation of Gender 
Incongruence (ENIGI) study (10), a collaboration of four centers (Amsterdam, Florence, 
Ghent, and Oslo), to investigate the effects of CHT on different parameters such as breast 
development. A detailed description of the study design and protocol is described by Dekker 
et al. (10). Briefly, persons were eligible for participation in the ENIGI study if they were 
age 18 years or older, had a diagnosis of gender dysphoria confirmed by a psychiatrist or 
psychologist, and were about to start CHT. Persons were not eligible if they had ever used or 
were currently using cross-sex hormones, if they were treated following a different protocol, 
or if there was insufficient knowledge of the nation’s language. Treatment of transwomen 
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consisted of antiandrogens, with either cyproterone acetate (10 to 100 mg daily) or 
spironolactone (100 to 150 mg daily), combined with administration of estradiol valerate (2 
to 6 mg Those older than age 40 were advised to use estradiol transdermally to reduce the 
slightly increased risk of thrombosis (11).
All transwomen included in the ENIGI study between 2010 and April 2016, who completed 
the first year of CHT and for whom baseline breast and chest measurements were available, 
were eligible for analyses. Because there were no breast and chest measurements performed 
in the Oslo clinic, their participants were omitted for analyses in this study. There were no 
data available on serum hormone levels from the Florence clinic; therefore, their patients 
were omitted for analyses including laboratory data.
The overall study protocol was approved by the ethical review board of Ghent University 
Hospital, Belgium. Of the other participating centers, the local ethical review boards 
approved participation to this study. Informed consent from participants was obtained 
following institutional guidelines.
Data collection
In accordance with the study protocol, all persons were evaluated every 3 months at the 
different outpatient clinics. During physical examination, different circumference and length 
measurements in centimeter and weight in kilograms were registered. Breast circumference 
was measured in centimeters with a tape measure horizontally placed around the thorax 
over the fullest part of the bare breasts. Chest circumference was measured with a tape 
measure horizontally placed around the thorax in the inframammary fold (Fig. 1).
Laboratory tests
Blood samples were drawn at baseline, after 3 months, and after 12 months of CHT. In 
Amsterdam, serum estradiol levels were measured using a competitive immunoassay (Delfia; 
PerkinElmer, Wallac Oy, Turku, Finland) with an interassay coefficient of variation (CV) of < 
13% and a lower limit of quantitation (LOQ) of 20 pmol/L-1 until July 2014. From July 2014, 
estradiol levels were measured using liquid chromatography tandem mass spectrometry 
(LC-MS/MS; VUmc, Amsterdam, the Netherlands) with an interassay CV of <7% and an LOQ 
of 20 pmol/L-1. For analyses, Delfia values were converted to LC-MS/MS values using the 
following formula: LC-MS/MS = 1.60 X Delfia – 29.
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Figure 1. Placement of the tape measure for circumference measurements.
For breast circumference measurement, the tape measure was placed around the thorax over the 
fullest part of the breast (dotted line) and for chest circumference measurement in the inframammary 
fold (dashed-dotted line).
Until January 2013, serum testosterone levels were measured using a radioimmunoassay 
(RIA) (Coat- A-Count, Siemens, Los Angeles, CA; interassay CV, <10%; LOQ, 1 nmol L-1). After 
January 2013, testosterone levels were measured using a competitive immunoassay (Gen 
III, Architect, Abbott, Abbott Park, IL) with an interassay CV <10% and an LOQ of 0.1 nmol/L-1. 
For analyses, RIA values were converted to Architect values using the following formulas: 
Architect = 1.1 X RIA + 0.2 for levels <8 nmol/L-1 and Architect = 1.34 X RIA – 1.65 for levels >8 
nmol/L-1. Luteinizinf hormone (LH) was measured using an immunometric assay (Architect) 
with an interassay CV of <6% and an LOQ of 2 nmol/L-1.
In Ghent, serum estradiol levels were measured using E170 Modular (E2 Gen II, Roche 
Diagnostics, Mannheim, Germany), until 19 March 2015. Thereafter, serum estradiol levels 
were measured using E170 Modular (E2 Gen III, Roche Diagnostics) with an interassay CV 
of 3.2% and an LOQ of 92 pmol/L-1. For analyses, values measured before 19 March 2015 
were converted to Gen III values using the following formula: Gen III = 6.687940 + 0.834495 
X Gen II. Serum testosterone levels were measured using E170 Modular (E2 Gen II) with an 
interassay CV of 2.6% and an LOQ of 0.4 nmol/L-1. Serum LH levels were measured using 
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E170 Modular (Roche Diagnostics) with an interassay CV of 2.2% and an LOQ of 0.1 mIU/
mL-1.
Statistical analysis
First, the database was screened for missing, inconsistent, and unreliable breast and chest 
values. Because of the overstated inverted pyramid shape of the thorax, a greater chest than 
breast circumference is highly unlikely. Consequently, all breast and chest values resulting 
in a negative breast minus chest value were replaced by a missing value assuming these 
were input mistakes (3.1%). Subsequently, all population- and individual-level breast and/or 
chest circumference measurement outliers were identified and replaced by a missing value 
(3.1%). Population outliers were defined as mean ± 3 times the standard deviation (SD). 
Individual-level outliers were identified using the method described by Welch et al. (12), 
with a standardized residual cutoff point of ±5. Last, all transwomen with unknown baseline 
breast or chest measurement were removed from the database.
Baseline data are presented as mean with SD for normally distributed data, and median 
with range for nonnormally distributed data. Data on tobacco use and alcohol use are 
presented as percentage of users. To examine the breast growth, chest circumference in 
centimeters was subtracted from breast circumference in centimeters separately for all 
visits. To analyze the effect of CHT on breast growth during the first year of therapy, mixed-
model analyses were performed with observations clustered within patients within center 
(13). Nonnormally distributed data were log-transformed before mixed- model analyses 
were performed. Analyses were stratified to study whether age, weight change, differences 
in BMI, tobacco use, treatment regimen, and serum hormone levels influenced breast 
development during the first year of CHT. Age was analyzed in quartiles and weight change 
was divided in three groups (weight loss, no weight change, and weight gain). Differences 
in BMI were defined as normal weight (BMI < 25 kg/m²), overweight (25 kg/m² ≥ BMI > 30 
kg/m²), and obese (BMI ≥ 30 kg/m²). Analysis for tobacco use was stratified into smokers vs 
nonsmokers. Because most transwomen (99%) in this study received cyproterone acetate as 
antiandrogen treatment, no analyses on treatment regimen other than oral vs transdermal 
estradiol administration route could be performed. Persons were included in this analysis if 
they had received the same administration route for at least 9 months. Analysis for serum 
estradiol levels was stratified for center-specific quartiles.
Analyses for testosterone and LH levels were stratified in suppressed (testosterone levels ≤ 
2 nmol/L, LH levels ≤ 5 IU/L) vs nonsuppressed (testosterone levels > 2 nmol/L, LH levels > 
5 IU/L) based on local female reference values. All data are presented as mean change in 
centimeters with 95% confidence interval (CI). Breast-chest differences after 1 year of CHT 
were translated into bra cup sizes following the method described by Greenbaum et al. (14).
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All analyses were performed using STATA Statistical Software, version 13.1 (Statacorp, 
College Station, TX).
Results
Until April 2016, 926 persons were included in the ENIGI study, of which 53.8% were 
transwomen. Persons who were still in their first year of CHT, who were lost to follow-up, 
or who had unknown baseline breast or chest measurements were excluded for analyses. 
Finally, a total of 229 transwomen were included for analyses (Fig. 2). The median age 
before start of CHT was 28 years (range, 18 to 69 years). At baseline, the mean breast-chest 
difference was 4.1 ± 2.9 cm. All characteristics of the study group are summarized in Table 1. 
Persons who were excluded for analyses did not differ in baseline characteristics from those 
who were included.
Figure 2. Flowchart of the inclusion of participants in the current study.




Table 1. Characteristics of 229 Transwomen Before CHT
Age, y 25 (18-69)
Ethnicity, % Caucasian 95.6
Height, cm 178.6 ± 6.8
Weigth, kg 72.3 (49.9-137.2)
BMI, kg/m2 22.7 (16.5-37.7)
Smoking, % yes 25.3
Alcohol use, % yes 46.0
Breast circumference, cm 92.9 ± 9.3
Chest circumference, cm 88.8 ± 8.9
Breast-chest difference, cm 4.1 ± 2.9
Data are presented as mean ± SD, median (range), or percentages.
Breast development predominantly occurred in the first 6 months of CHT, with an increase 
of 1.8 cm (95% CI, 1.4 to 2.3) over the first 3 months, and 1.3 cm (95% CI, 0.9 to 1.8) over the 
following 3 months. The change in breast-chest difference over the last 6 months was only 
0.5 cm [0.3 cm (95% CI, -0.2 to +0.8) between 6 and 9 months of CHT and 0.2 cm [95% CI, 
-0.3 to +0.7] over the last 3 months (Fig. 3)]. Mean breast-chest difference increased with 3.7 
cm (95% CI, 3.3 to 4.2) from 4.1 ± 2.9 cm at baseline to 7.9 ± 3.1 cm after 1 year of CHT. Mean 
breast development did not change after adjustment for baseline breast-chest difference 
[4.1 cm (95% CI, 3.4 to 4.7)]. After calculating mean breast-chest difference into bra cup size, 
almost half of the transwomen (48.7%) had a bra cup size of less than an AAA cup after 1 
year of CHT (Fig. 4). Furthermore, 52 transwomen (26.4%) had an AAA cup, 28 (14.2%) an 
AA cup, 14 (7.1%) an A cup, and only 7 transwomen (3.6%) gained a bra cup size larger than 
an A cup. As shown in Fig. 5(a) and 5(b), breast development did not vary in different age 
groups or between transwomen who had no weight change, weight loss, or weight gain over 
the study period. Although obese transwomen had a greater breast-chest difference in the 
first 6 months of CHT, total breast-chest difference after 12 months did not differ between 
normal weight, overweight, and obese transwomen [Fig. 5(c)]. There was no difference in 
breast development between smokers and nonsmokers [Fig. 5(d)]. Transwomen treated 
with transdermal estradiol had a faster increase in breast-chest difference until 6 months 
after initializing treatment. However, breast development after 1 year of treatment did not 
differ between oral and transdermal estradiol administration [Fig. 5(e)].
Mean serum estradiol levels in the center-specific quartiles were 110 pmol/L-1 (first quartile), 
184 pmol/L-1 (second quartile), 271 pmol/L-1 (third quartile), and 452 pmol/L-1 (fourth 
quartile) in Amsterdam, and 142 pmol/L-1 (first quartile), 206 pmol/L-1 (second quartile), 
299 pmol/L-1 (third quartile), and 567 pmol/L-1 (fourth quartile) in Ghent. Serum estradiol 
levels did not predict breast development after 1 year CHT [first quartile: 3.6 cm (95% CI, 
2.7 to 4.5); second quartile: 3.2 cm (95% CI, 2.3 to 4.2); third quartile: 4.4 (95% CI, 3.5 
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to 5.3); and fourth quartile: 3.6 cm (95% CI, 2.7 to 4.5); Fig. 5(f)]. Because CHT induced 
suppression of serum testosterone and LH levels in almost all transwomen (testosterone: 
not suppressed in 7.9%; LH: not suppressed in 1.3%), no analyses could be performed on 
these data. Transwomen with an A cup size or larger did not differ in baseline characteristics 
from transwomen with a cup size smaller than an A cup.
Figure 3. Mean breast-chest difference in centimeters over duration of CHT in months. For each time 
point, the mean increase in centimeters (dot) with 95% CI (bars) is shown. Data in the legend are 
shown as mean increase with 95% CI.
Figure 4. Gained bra cup sizes in 197 transwomen after 1 year of CHT. Data are shown as percentage 
of transwomen per cup size.
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Figure 5. Mean breast-chest difference in centimeter over duration of CHT in months, stratified for age 
in four groups. (a) Weight change in three groups (b), normal weight (BMI < 25 kg/m²), overweight 
(25 kg/m² ≥ BMI > 30 kg/m²), and obese (BMI ≥ 30 kg/m²) BMI (c), smokers vs nonsmokers (d), oral vs 
transdermal estradiol administration route (e), and four quartiles of serum estradiol levels (f). Mean 
serum estradiol levels in the center-specific quartiles were 110 pmol/L-1 (first quartile), 184 pmol/L-1 
(second quartile), 271 pmol/L-1 (third quartile), and 452 pmol/L-1 (fourth quartile) in Amsterdam, and 
142 pmol/L-1 (first quartile), 206 pmol/L-1 (second quartile), 299 pmol/L-1 (third quartile), and 567 
pmol/L-1 (fourth quartile) in Ghent. For each time point, the mean increase in centimeters (dot) with 
95% CI (bars) is shown.
 
Discussion
The current study shows a modest increase in breast-chest difference after 1 year of CHT, 
mainly resulting in less than an AAA bra cup size. Age, weight change, smoking, BMI, serum 
estradiol levels, and estrogen administration route did not predict total breast development 
after 1 year of CHT.
This large multicenter cohort study shows slightly less breast development than shown 
in previous studies performed (3,4,11,15). However, these previous studies used other 
measurement methods (e.g., hemi-circumference measurements) and bra cup sizes 
were estimated or self-reported rather than translated or calculated from circumference 
measurements. Moreover, CHT duration in these studies is not always clearly reported and 
varies widely (from 3 to 24 months) (3-5), which makes comparison of these studies with 
the current study difficult. This study found a bra cup size of less than an AAA cup in 48.7% 
of transwomen. Only 10.7% had an A cup or larger after 1 year of CHT. Because only breast 
and chest circumference were measured and converted into bra cup sizes, it was impossible 
to calculate breast volumes in this study. Because cup size consists of more than thorax 
circumferences alone and breast shapes vary widely between different people, cup sizes 
found in this study were probably underestimated.
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Breast tissue consists of both epithelial components, with ducts and lobules, and stromal 
elements, consisting of adipose and fibrous connective tissue. The latter accounts for the 
majority of the total breast volume. The fat distribution of transwomen after 1 year of CHT 
is still developing and is not yet similar to that of ciswomen (women with the birth-assigned 
sex of a female who identify themselves as female) (16). This may contribute to the modest 
breast development measured in this study. Another explanation for the modest breast 
development found could be that exposition to high testosterone during male puberty 
induces some structural changes that inhibit breast development. There were transwomen 
in this study who had substantial breast development during the first year of therapy and 
had passed normal male puberty.
An interesting finding is that main breast development occurred in the first 6 months of CHT. 
The flattening of the breast development curve in this study suggests no further increase 
in breast-chest difference after the first year of CHT. However, the maximum effect of CHT 
on breast development may be expected after 2 to 3 years, as also seen during pubertal 
development in girls (1,5,17).
Because the follow-up of the current study is 2 year, no conclusions can be drawn on final 
breast development induced by CHT. Moreover, a recent study by Fisher et al. showed 
breast development to Tanner stage 3 after 2 years of CHT, which emphasize the need for 
studies with longer follow-up (18).
Levy et al. state that transwomen with a higher BMI seem to have better breast development 
(15). Moreover, Coltman et al. showed that breast volumes in overweight or obese 
ciswomen were greater compared with ciswomen with a normal weight BMI (19). However, 
the current study found no differences in breast development in different BMI categories, 
which may be due to the small number of overweight (18.1%) and obese (8.3%) persons in 
this study. Another possible explanation may be that the overweight and obese transwomen 
in this study were encouraged to lose weight during the first year of CHT in view of surgical 
treatment thereafter. Furthermore, this study did not find any differences in characteristics, 
treatment regimen, or serum estradiol levels in transwomen with a breast development of 
an A cup or larger compared with transwomen with a development of smaller than an A cup. 
Consequently, no clinical or laboratory parameters were found to be predictive for breast 
development in this study. Although an explanation for the difference in breast development 
between persons may be genetic variation (20,21), further studies are required.
This study provides more insight in how much breast development can be expected of CHT 
during the first year of therapy. Other strengths are the prospective, multicenter design of 
the study and the large number of participants with a wide range of age. Moreover, this 
study had fixed measurement moments every 3 months with relatively few missing values 
(12.1% of all breast and/or chest measurements). However, this study has some limitations 
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as well. First, thorax circumferences were used for estimation of breast development, which 
probably provide a less reliable reflection of the actual breast development compared with 
volume measurements. Pechter suggested a hemicircumference measurement method to 
calculate bra cup sizes (22), which may be a better estimator than thorax circumference 
measurements (23). Furthermore, McGhee et al. showed that respiration affects 
circumference measurements and, consequently, cup size estimations up to four sizes 
discrepancy (23). Because respiration was not standardized in this study, measurements 
were likely to be affected by the respiration of the transwomen measured and thereby it 
probably affected the accuracy of the measurements. On the other hand, because of the 
lack of standardization, some values will be overestimated and some underestimated 
resulting in an overall reliable mean. Second, this study was performed during regular care; 
as a consequence, participating centers were not always able to collect all data needed 
due to limited resources. Nevertheless, we had access to a large sample with relatively 
few missing values. Third, all data regarding other medication use, comorbidities, tobacco 
use, and alcohol use were self-reported and therefore might be incomplete. Last, this 
study only reported objective outcomes of breast development. This however says nothing 
about the satisfaction of transwomen with the gained breast development. Van de Grift 
et al. (24) showed that body satisfaction increased with hormone treatment, but that in 
transwomen who received breast augmentation surgery, body satisfaction was higher. 
Moreover, transpersons with high overall body dissatisfaction at baseline showed persistent 
higher dissatisfaction after treatment. Future studies should incorporate body and/or breast 
satisfaction scales to relate the clinical observed breast development to the satisfaction of 
the transwomen themselves.
In conclusion, this large multicenter cohort study shows modest breast development after 
1 year of CHT in transwomen. No predictive markers in clinical and laboratory parameters, 
including serum estradiol levels, were identified. It would be interesting for future studies 
to search for other parameters and study whether these predict breast development in 
transwomen during CHT. Studies with longer follow-up are needed to determine the final 
breast development gained with CHT alone. Furthermore, it would be worthwhile for 
future studies to use volume measurements for examining hormonally induced breast 
development in transwomen.
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Context: Breast development is important for most trans women. An important limitation 
of current breast development measurement methods is that these do not allow for 3D 
volume analyses. 
Objectives: To examine breast development and change in anthropometry during the first 
3 years of gender-affirming hormone treatment using 3D imaging. Associations with clinical 
or laboratory parameters and satisfaction with the gained breast development were also 
studied.
Design: Prospective cohort study.
Setting: Specialised tertiary gender identity clinic in Amsterdam, the Netherlands.
Participants: Participants were 69 adult trans women with a median age of 26 years 
(interquartile range, 21-38).
Interventions: Gender-affirming hormone treatment.
Main outcome measures: Volumetric and anthropometric breast development and satisfaction.
Results: Breast volume increased by 72 cc (95% confidence interval [CI], 48-97) to 100 
cc (standard deviation 48). This resulted in a cup-size <A cup in 71% of the participants. 
Although the change in breast-chest difference plateaued after approximately 9 months, 
sustained increase in breast volume was observed during the 3-year observation period. 
Sternal notch to nipple distance increased by 1.3 cm (95% CI, 0.9-1.7) and internipple 
distance increased by 1.0 cm (95% CI, 0.4-1.5). At least 58% of trans women were satisfied 
with the gained breast size.
Conclusions: Sustained breast growth and development during hormone treatment 
was observed during the full 3-year observation period. The breasts of transwomen are 
positioned more laterally and caudally on the chest compared with cis women. Although 
modest breast volumes were observed, breast development was satisfactory to most trans 
women.
Breast development after 3 years of gender-affirming hormone treatment
59
4
In Western societies, breasts are considered an important symbol of femininity. From 
embryologic development until puberty, mammary tissue development in cis boys and 
cis girls is similar. During typical cis female puberty, breast development is induced due to 
exposure to estrogen. With each menstrual cycle, breast tissue develops until approximately 
18 to 20 years of age.[1-3] Mammary tissue only becomes active during pregnancy, after 
which it regresses again. In addition to (active) glandular tissue, breasts consist of adipose 
tissue, which largely determines breast volume.[1, 2, 4] Up to 30% of cis boys in early 
puberty experience mild to modest mammary gland development but due to increasing 
testosterone levels during typical cis male puberty, no further mammary development 
occurs in cis boys.[1, 5] Aside from differences in mammary tissue, the anatomy of the 
chest between the adult cis male and cis female bodies differs as well. For instance, cis 
men have a wider sternum compared to cis women and often a longer chest. Due to these 
differences, the nipples on the cis male chest are more caudally and laterally located on the 
chest compared to the placement of the nipples on the cis female chest.[6-8]
Analogous to endogenous sex hormones, hormone treatment can induce breast development 
in transgender people.[9] Gender dysphoria is defined as an incongruence between one’s 
assigned sex at birth and one’s gender identity.[10, 11] To gain physical changes in line 
with gender identity, transgender people may seek gender-affirming treatment which may 
include hormone treatment. In trans women (male sex assigned at birth, female gender 
identity), hormone treatment to induce feminization, including breast development, usually 
consists of anti-androgen and estrogen treatment.[10, 11]
Previously, we reported on breast development during the first 12 months of gender-
affirming hormone treatment and found a modest increase of breast volume using 
breast-chest circumference differences.[12] Additionally, other studies showed modest, 
histologically normal[5] breast development during 3 to 24 months of treatment.[12-15] 
In prospective studies hitherto, no clinical or laboratory parameters that accurately predict 
the outcome of the total breast development gained with hormone treatment have been 
found.[12, 13] In most of these studies, breast development was measured with a tape 
measure as a derivative estimator of breast volume. A more appropriate way to study 
breast development is to measure breast volumes. This can be performed, for instance, 
by ultrasound or magnetic resonance imaging (MRI).[16] More recently, three-dimensional 
(3D) technology, which can also be used to measure breast volumes, has been developed.
[17, 18] In addition, 3D technology allows for high-quality anthropomorphic measurements, 
further aiding comparison of breast development in cis and trans women. Interestingly, 
no studies investigating satisfaction of trans women with the gained breast development 
during hormone treatment have been reported in literature.
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With this study, we aimed to investigate all aspects of breast development owing to gender-
affirming hormone treatment. Therefore, we examined breast growth and development 
(including anthropometrics) with 3D imaging during the first 3 years of hormone treatment 
and compared this with tape measure measurements. Furthermore, we studied whether 
clinical or laboratory parameters were associated with the observed breast volume. Lastly, 
the satisfaction of trans women with the gained breast development was studied.
Methods
Study population
All adult trans women who started hormone treatment between February 2017 and 
December 2017 were eligible for participation in this study. People were excluded if 
they ever used female sex hormones before, if it was considered too much of a burden 
to participate because of psychological reasons, or if there was insufficient knowledge of 
the Dutch language. If hormone treatment was discontinued or the participant underwent 
breast surgery during follow-up, the participant was excluded from that point onward.
Hormone treatment consisted of anti-androgen treatment with cyproterone acetate (a 
progestogenic anti-androgen, 25 mg daily), combined with either estradiol valerate (4-6 mg 
daily) or estradiol patches (50-150 mcg/24 hours twice a week). People over 40 years of age 
were advised to use transdermal estradiol to reduce the risk of thromboembolic disease.
[19] Anti-androgenic treatment was ceased after vaginoplasty or orchiectomy.
The study protocol was assessed by the Ethical Review Board of the Amsterdam UMC, 
VU University Medical Center Amsterdam. It was determined that the Medical Research 
Involving Human Subjects Act (WMO) does not apply to this study. Written informed consent 
was acquired from all participants.
Data collection
Participants were evaluated at baseline, and after 3, 6, 9, 12, 18, 24, and 36 months of 
hormone treatment. During outpatient clinic visits, data regarding medical history, 
intoxications, medication use, and biometrical data such as height (in centimeters, cm) 
and weight (in kilograms, kg) were collected. The 3D images were obtained using the 
VECTRA XT scanner (Canfield Inc.). Breast volume, sternal notch to nipple distance, nipple 
to inframammary fold (IMF) distance, breast width (lateral mammary fold [LMF] to medial 
mammary fold [MMF] distance) , internipple distance, and intermammary distance (MMF 
to MMF) were measured using the assessment software (version 5.7.1.) of the VECTRA XT. 
Manually placed landmarks (Fig. 1) allowed for the software to calculate the abovementioned 
measurements. Areolar diameter was manually determined using the VECTRA XT Mirror 
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software as shown in Fig. 1. Subsequently, breast and chest circumference measurements 
were performed using a tape measure. Breast circumference was measured in centimeters 
with a tape measure horizontally placed around the chest over the fullest part of the bare 
breasts. Chest circumference was measured with a tape measure horizontally placed around 
the chest in the IMF.
Figure 1. Placement of the landmarks (gray dots) and measurement of the areolar diameter (light gray 
line).
Abbreviations: A, areola; C, clavicle; IMF, inframammary fold; (l), left; LMF, lateral mammary fold; 
MMF, medial mammary fold; N, nipple; (r), right; SN, sternal notch.
At time of the visits, participants filled out 2 questionnaires. The first questionnaire 
contained questions about the satisfaction with the gained breasts and used a four-point 
Likert scale (very dissatisfied, somewhat dissatisfied, somewhat satisfied, very satisfied). 
This questionnaire included the following questions: (1) How do you rate the development 
of your breasts between now and your last visit?
What do you think of the (2) size, (3) shape, and (4) symmetry of your breasts? What do you 
think about the (5) size and (6) shape of your nipples? For analyzes, answers were scored as 
satisfied (somewhat satisfied and very satisfied) and dissatisfied (somewhat dissatisfied and 
very dissatisfied). The second questionnaire used was the (Dutch version of the) Rosenberg 
perceived self-esteem scale.[20, 21] This questionnaire was used as general estimator 
of self-esteem. Using the included scale, self-esteem was rated as low self-esteem (0-14 




Laboratory testing was performed at baseline, after 3, 12, 24, and 36 months. Serum estradiol 
levels were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
(Amsterdam UMC, Amsterdam, the Netherlands) with an interassay coefficient of variation 
(CV) of < 7% and a limit of quantification (LOQ) of 20 pmol/L. Until October 2018, testosterone 
levels were measured using a competitive immunoassay (Gen III, Architect, Abbott, Abbott 
Park, IL, USA) with an interassay CV < 10% and a LOQ of 0.1 nmol/L. Thereafter, testosterone 
was measured using LC-MS/MS (Amsterdam UMC, Amsterdam, the Netherlands) with an 
interassay CV of 4% to 9% and a LOQ of 0.1 nmol/L.[22] No conversion of values between 
the 2 testosterone measurement methods was necessary. Lastly, luteinizing hormone was 
measured using an immunometric assay (Architect, Abbott, Abbott Park, IL, USA) with an 
interassay CV of < 6% and a LOQ of 2 nmol/L.
Statistical analysis
Baseline data are presented as mean with standard deviation (SD) for normally distributed 
data, and median with interquartile range (IQR) for nonnormally distributed data. Data on 
tobacco and alcohol use are presented as percentage of current users.
To analyse the effect of hormone treatment on breast development, mixed-model analyses 
with measurements clustered within participants were performed. Nonnormally distributed 
data were log- transformed before mixed-model analyses were performed. Analyses were 
adjusted for age, body mass index (BMI, kg/m2) defined as underweight (BMI < 18 kg/m²), 
normal weight (18 kg/m² ≥ BMI > 25 kg/m²), and overweight (BMI ≥ 25 kg/m²), tobacco use 
(current vs noncurrent), treatment regimen (oral vs transdermal), serum estradiol levels 
(<200 pmol/L, 200-400 pmol/L, >400 pmol/L), serum testosterone levels (suppressed [≤ 2 
nmol/L] vs nonsuppressed [> 2 nmol/L]), and serum lunteinizing hormone levels (suppressed 
[≤ 5 IU/L] vs nonsuppressed [> 5 IU/L]). Participants were included in the analysis comparing 
estradiol treatment regimen if they used the same administration route for at least 1.5 years.
All data are presented as mean change in cm, cubic centimeter (cc), or millimeter (mm) with 
95% confidence interval (CI). Breast volume after 36 months of follow-up was extrapolated 
into bra cup- sizes in which an increase of 150 cc was considered as an increase of 1 bra 
cup-size.[23]
All analyses were performed using STATA Statistical Software, version 15.1 (Statacorp, 
College Station, Texas, USA).




In total, 69 trans women were included for analyses (Fig. 2). The median age at start of 
hormone treatment was 26 (IQR, 21-38) years, and most trans women had a normal BMI 
(n = 44 [64%]) at baseline. Forty-two (61%) of the participants had average self-esteem 
at baseline. All baseline characteristics are summarized in Table 1. During follow-up, 25 
trans women underwent vaginoplasty after median 24 months (IQR, 20-26) of hormone 
treatment. Furthermore, trans women gained a median 4.9 kg (IQR 0.9-10.7) weight during 
the 36 months of follow-up.
Figure 2. Study flowchart.
Table 1. Baseline Characteristics of the 69 Included Trans Women 
Characteristic Value
Age, y 26 (21-38)
Height, m 1.81 (1.74-1.85)
Weight, kg 71.3 (64.3-83.0)
BMI, kg/m2 22.1 (20.0-24.3)
Smoking, n(%)a 27 (39)
Alcohol, n(%)a 36 (52)
Self-image, n(%)b 42 (61)
Data are presented as median with interquartile range or number with percentage. Abbreviations: 
BMI, body mass index.




Breast volume increased in the right breast by 72 cc (95% CI, 48-96) to 101 cc (SD 48) and 
in the left breast by 72 cc (95% CI, 48-97) to 100 cc (SD 48) (Fig. 3). As shown in Fig. 3, mean 
breast development was comparable between the right and left breast and no difference in 
breast size was observed. Breast-chest difference increased by 6 cm (95% CI, 4-7). However, 
the mean increase in breast-chest difference stabilized after approximately 9 months of 
hormone treatment despite the further increase in breast volume measured with 3D imaging 
(Fig. 3). Furthermore, as shown in the figure, mean breast volume decreased between 24 
and 36 months of follow-up. As trans women in this study underwent a vaginoplasty after 
median 24 months after start of hormone treatment, and anti-androgenic treatment with 
cyproterone acetate is ceased after that, we stratified the analyses for people who did and 
did not undergo a vaginoplasty. In this analysis, a decrease of mean breast volume between 
24 and 36 months was only observed in the people who had undergone a vaginoplasty. 
However, after adjustment for differences in age and serum hormone levels, this effect was 
no longer observed (data not shown). No associations were found between increase in 
breast volume and age, BMI, tobacco use, treatment regimen, and serum hormone levels.
After 36 months, most trans women (71%) had a breast volume corresponding to a bra cup-
size smaller than an A-cup. Only 9% had an A-cup (130 to 150 cc), 16% a B-cup (150 to 300 
cc), 3% a C- cup (300 to 450 cc), and 1% an E-cup (600 to 750 cc).
Figure 3. Mean breast volume and breast-chest difference during hormone treatment.
For each time point, the mean volume (dots) in cc or mean breast-chest difference (triangles) in cm 
with 95% confidence interval (bars) is shown.
Abbreviation: brch, breast-chest difference




Figure 4 shows the changes in anthropometric measures during follow-up. The dotted lines 
in these figures represent (reference) values in cis women.[24-27] Sternal notch to nipple 
distance increased by 1.3 cm (95% CI, 0.9-1.7) to 20.7 cm (SD 7.2) at the end of the follow-
up period. Nipple to IMF distance increased by 1.7 cm (95% CI, 1.2-2.2) and breast width 
by 1.3 cm (95% CI, 0.7-1.9). Areolar diameter increased by 4.5 mm (95% CI, 2.8-6.2) to a 
total of 28.6 mm (SD 12.8). Internipple distance increased by 1.0 cm (95% CI, 0.4-1.5), and 
intermammary distance decreased with -0.9 cm (95% CI - 1.8 to -0.1).
Figure 4. Anthropometric measures of mean sternal notch to nipple (a) distance, nipple to 
inframammary fold (b) distance, breast width (c), areolar diameter (d), internipple distance (e), and 
intermammary distance (f). Data are presented as mean distance (dots) with 95% confidence intervals 
(bars) for each time point. The dotted lines represent mean reference values of cis women.[24-27]
Abbreviation: IMF, inframammary fold.
Satisfaction
Most trans women in this study (58%) were satisfied with the size of their breasts after 
treatment. Moreover, most trans women were satisfied with the symmetry of their breasts 
(ranging from 63% after 3 months of treatment to 92% after 36 months), and the shape of 
the breasts (ranging from 51% to 83%). Corresponding with the smaller increase of breast 
volume after longer treatment duration, satisfaction with the gained breast development 
between 2 measurements declined from 88% after 3 months of treatment to 42% after 36 
months. During follow-up, approximately three-quarters of the trans women in this study 




Perceived self-esteem remained average in most of the trans women (range, 48 % to 73%) 
during follow-up. Self-esteem was low in 14 trans women (21%) at the start of hormone 
treatment. Of these trans women, 6 people experienced an increase in perceived self-
esteem, 2 people fluctuated between low and average self-esteem, and the self-esteem of 6 
people remained low. Only 2 trans women in this study experienced a decline in self-esteem 
form average to low during follow-up.
Discussion
Principal findings
This study shows sustained breast development in trans women during the first 3 years of 
hormone treatment, resulting in a mean breast volume of 100 cc, which corresponds to a 
bra cup-size of <A-cup in most individuals. Furthermore, in this study, breast development 
measured with 3D images appears to be a better reflection of hormone treatment-induced 
breast development compared with breast- chest differences measured with a tape 
measure. No clinical or laboratory parameters could be identified that explained the extent 
of mean breast volume increase during hormone treatment.
Anthropometric measures changed during treatment, with an increase in sternal notch 
to nipple distance, nipple to IMF distance, breast width, internipple distance, and areolar 
diameter and a decrease in intermammary distance. Breast development with hormone 
treatment was satisfactory to most trans women in this study. Moreover, in 6 individuals, 
perceived self-esteem increased during treatment from low self-esteem to average self-
esteem.
Comparison with other studies
As in previous studies, we observed breast development during the entire follow-up time 
of this study.[12-14] This study was the first with a follow-up up until 36 months after the 
start of hormone treatment. This shows that breast development in trans women receiving 
hormone treatment may take more time than previously thought following the estimations 
in the Endocrine Society guidelines.[10] This is also supported by the study of Fisher et al 
[13] who showed that mean breast development in trans women reached a Tanner stage 
3 after 24 months of treatment, suggesting that breast development has not reached 
maximum growth after 2 years of hormone treatment. These observations are in line with 
breast development during typical cis female puberty which may take up to 5 to 7 years[1-3]. 
As shown in this study, the curve of breast development measured with a tape measure 
flattened prematurely compared to the breast volume increase measured with 3D imaging.
This is in line with the study of Kovacs et al, who showed that breast volume measurements 
using 3D imaging better agreed with volume calculations using MRI than did anthropomorphic 
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measurements.[28] This may also explain why we found a plateau of breast development 
between 6 and 12 months of treatment in our previous study.[12] Although this observation 
may lead to a preference for using 3D imaging over breast-chest circumference measurement, 
a tape measure could be a good alternative for centers with fewer resources.
Still, no clinical or laboratory parameters have been identified which can predict or explain 
the differences in breast development among trans women. Some breast volume decrease 
was observed between 24 and 36 months, which we cannot explain based on the available 
data. Underlying this effect might be several factors that may change during hormone 
treatment (and therefore also during the follow-up of this study) such as hormone treatment 
(ie, cessation of androgen deprivation therapy after vaginoplasty), therapeutic compliance, 
breast tissue hormone susceptibility, and changes in other medication used, which may 
affect breast development directly or indirectly via changes in estrogen metabolism. These 
factors could not be investigated or did not show an effect in the current study, but they may 
be interesting topics for future research.
Compared with (reference) values of cis women[24-27], the breasts of the trans women in this 
study were placed relatively low on the chest, as shown by the larger sternal notch to nipple 
distance in trans women. Furthermore, at the start of hormone treatment, the internipple 
distance was already greater compared with cis women and increased even further during 
follow-up. This shows that the mammary glands of trans women are positioned more 
laterally and caudally on the chest relative to cis women. This difference is probably due 
to different anatomic make-up between cis men and cis women.[6-8] Cis men have a wider 
sternum compared to cis women and often a longer chest as well. Since all trans women in 
this study went through typical cis male puberty before they started their transition, they 
already experienced these anatomical changes in line with typical cis male puberty, which 
are not influenced by gender-affirming hormone treatment. Moreover, areolar diameter in 
trans women remains rather small during treatment compared to cis women. This might 
be explained by the modestly gained mean breast volume and the understanding that 
areolar diameter is greatly associated with breast volume.[29] Regarding anthropometrics, 
it can be postulated that start of hormone treatment at a younger age may contribute to 
characteristics more comparable to the chest of cis women.
Perhaps surprisingly, we observed that most trans women in this study were satisfied with 
their gained breast size, irrespective of the gained breast volume. As described earlier, a 
single ideal breast size does not exist and is dependent on the size of the chest, the height 
of the person, and cultural influences.[7, 24, 30] The literature on breast size satisfaction in 
cis women is limited. The authors of one study report that approximately one-quarter of 
their sample of cis women is satisfied with their breast size.[31] Although this is a far lower 
number than observed in our study, comparison is difficult, as satisfaction was calculated 
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by subtracting the ideal from the current breast size image. People might be satisfied with 
their breasts as they are, but ideally see themselves with a different size or shape. As we did 
not incorporate ideal breast size questions in our study, satisfaction may be overestimated 
compared with the study in cis women. Satisfaction rates in our study may also be influenced 
by the fact that trans women were excluded after breast augmentation surgery, leading to 
exclusion of probably the least satisfied people.
Strengths and limitations
This is the first study that uses 3D images to investigate breast development during the 
first 3 years of hormone treatment. Because of the measurement method used, we were 
able to not only study breast volume but also anthropometrics of the breast. Moreover, 
satisfaction questionnaires were incorporated in this study. The use of these combined 
methods allowed us to study different aspects of breast growth and development during 
hormone treatment. However, this study has some limitations as well. First, this study was 
limited by the relatively small sample of participants. Second, the follow-up time of this 
study still may have been too short. Although this study has the longest follow-up time 
of any so far, full breast development probably takes more than 3 years after the start of 
hormone treatment. This is supported by the fact that we saw an increase in breast volume 
during complete follow-up in this study, and by the fact that breast development during 
female puberty may take up to 7 years. Therefore, it would be worthwhile for future studies 
to increase the follow-up time to 5 or even 7 years after the start of hormone treatment. 
Third, the satisfaction questionnaire we used in this study was not validated. Still, we believe 
that the answers provided valuable insights on satisfaction in this study, especially since 
this was the first study to incorporate satisfaction data in breast development research in 
trans women. Last, measurements could have been influenced by the placement of the 
landmarks. The VECTRA XT software needs landmarks to calculate (volume) measurements. 
If the landmarks are placed differently, other values will be calculated by the program. To 
reduce this risk, all landmarks were placed manually by one researcher in a standard fashion 
in order to make sure that the same method was used in all measurements.
Conclusions
This study shows that breast development during gender-affirming hormone treatment 
probably takes longer than the estimations stated in the Endocrine Society guidelines, as 
we observed breast development during the entire 3-year study period. Anthropometric 
measurements showed a more lateral and caudal position of the breasts on the chest of 
trans women compared to cis women, which should be kept in mind when interpreting 
breast aesthetics and when performing breast augmentation procedures in trans women. 
Although modest breast volumes were observed during the first 3 years of hormone 
treatment, breast development was satisfactory to most trans women in this study. As 
breast development was observed during the complete follow-up time period of this study, 
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studies with longer follow-up times are needed to determine final hormone treatment-
induced breast development.
Furthermore, it would be worthwhile for future studies to investigate whether there are 
modifiable clinical parameters which are associated with breast development in order to 
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Introduction: As breast development in trans women (male sex assigned at birth, female 
gender identity) who receive gender-affirming hormone treatment is often moderate, they 
may choose breast augmentation as part of their treatment.
Aim: The aim of the study was to investigate the frequency, determinants, and satisfaction 
of breast augmentation among trans women receiving hormone treatment.
Methods: Trans women who started hormone treatment between 1972 and 2018 at our 
center received an anonymous questionnaire.
Main Outcome Measure: The questionnaire contained questions about the start date of 
hormone treatment, the current age of the respondent, whether or not she underwent 
breast augmentation, what her considerations in this decision were, and, if the respondent 
did have breast implants, whether she was satisfied with the result and/or experienced 
health complaints she attributed to her breast implants.
Results: A total of 3,073 questionnaires were distributed, of which 773 were retrieved 
back (median age of the respondents: 50 years, interquartile range 35-59). Age and year of 
start of hormone treatment was comparable between responders and nonresponders. The 
frequency of breast augmentation varied from 70% in trans women who started hormone 
treatment between 1980 and 2000 to 20% in those who started between 2010 and 2015. 
Trans women underwent breast augmentation median 2 years after the start of hormone 
treatment (interquartile range: 2-4), and 80% was satisfied with the result. Approximately 
one-third experienced health complaints they attributed to their breast implants. People 
who considered breast augmentation reported financial limitations as an important reason 
not to undergo breast augmentation.
Clinical implications: This study shows that it is important to discuss pros and cons of breast 
augmentation to support trans women in making a well-informed decision.
Strengths & limitations: This is the largest study performed on the frequency and satisfaction 
of breast augmentation among trans women, which also includes health complaints and 
considerations in the decision whether or not to undergo breast augmentation. One of the 
limitations was that we were unable to link other clinical data.
Conclusion: 4 of 5 trans women either chose or considered breast augmentation as part 
of their gender-affirming treatment. Most of the trans women who underwent breast 
augmentation were satisfied with the result, although approximately one-third experienced 
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health complaints they attributed to their breast implants. Reasons not to undergo breast 
augmentation included financial limitations. This study shows that it is important to discuss 
with trans women the positive effects and possible side-effects of breast augmentation to 
help them make a well-informed decision whether or not to undergo breast augmentation.
Background
Transgender people experience incongruence between their sex assigned at birth and their 
experienced or expressed gender, and therefore, may seek gender-affirming treatment to 
align their bodies to their experienced gender. This treatment may include gender-affirming 
hormone treatment. Hormone treatment can reduce distress and induce desired physical 
changes, such as changes in body hair and composition.1 2 Hormone treatment in trans 
women (male sex assigned at birth, female gender identity) usually consist of antiandrogen 
and estrogen treatment to induce feminization, which includes breast development.
Breast development in men and women is the same until puberty. During puberty, the 
female breast develops further under the influence of female sex hormones, where more 
breast tissue is formed with each menstrual cycle until approximately 18 to 20 years of 
age.3-5 The female breast remains in a mature but inactive state until pregnancy. Besides 
functional breast tissue, the mature female breast contains abundant adipose tissues which 
largely determine breast volume.3 4 6 In pubertal men, no further breast development occurs 
due to increasing testosterone levels.3 7
Since breast development is considered an important femininity symbol in Western societies, 
it is important to most trans women. Several studies investigated breast development in trans 
women receiving hormone treatment. Although all studies showed modest, histologically 
normal7, breast development with hormone treatment in trans women8-12, it should be 
noted that these studies have a limited follow-up time varying between 3 to 24 months. As 
described previously, physiological breast development in people assigned female at birth 
takes several years, making it plausible that breast development in trans women receiving 
hormone treatment takes some time as well.
Interestingly, no studies have been performed regarding satisfaction of trans women with 
their breast development during hormone treatment. A derivative measure for satisfaction 
with the gained hormone treatment-induced breast growth can be breast augmentation 
rate. Currently, it is estimated that 60-70% of trans women chose breast augmentation.13-15 
Although breast augmentation can be a solution for people who have small breasts, this 
treatment may have side effects. Studies have shown that a small portion of women 
with silicone breast implants may experience local and/or systemic health complaints.16 
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Furthermore, it is important to gain more knowledge about the considerations of trans 
women in their decision-making process regarding potential breast augmentation, to be 
able to adjust the provided information to trans women.
Therefore, this study aimed to investigate the prevalence and satisfaction of breast 
augmentation among trans women receiving hormone treatment, the considerations in the 
decision whether or not to undergo breast augmentation, and the prevalence of subjective 
health complaints among trans women with breast implants.
Methods
Study Population and Data Collection
All trans women who started hormone treatment between 1972 and 2018 at the center 
of expertise on gender dysphoria at the Amsterdam UMC, the Netherlands, were eligible 
for participation.17 People were excluded if they were known to live in the male gender 
role again, if there was no postal address available, if they passed away, or if they were 
younger than 18 years at the time of this study (Figure 1). Most trans women were treated 
with either cyproterone acetate or spironolactone as antiandrogen, which was often ceased 
after orchidectomy. In addition, estrogen was prescribed as ethinylestradiol, conjugated 
estrogens, estradiol implants or injections, and in recent years mainly estradiol valerate, 
patches, or gel.
The study protocol was assessed by the Ethical Review Board of the Amsterdam UMC, 
VU University Medical Center, Amsterdam. It was determined that the wet medisch-
wetenschappelijk onderzoek met mensen (WMO; Medical Research Involving Human 
Subjects Act) does not apply to this study.
Returning the questionnaire was considered as consent to use the provided data. 
Questionnaire and Variables
All included trans women were sent a questionnaire through mail. The questionnaire 
consisted of 5 main questions, which were filled out by both trans women who underwent 
and who did not undergo breast augmentation. These questions included the date of 
answering the questionnaire, current age, year of start of hormone treatment, whether or 
not the respondent underwent breast augmentation (yes/no), and whether the respondent 
underwent other surgical procedures (yes/no). If the respondent underwent breast 
augmentation, she also filled out the following questions: (1) what was the reason to undergo 
breast augmentation (insufficient breast development/asymmetry of the breasts/other)? 
(2) in what year did the breast augmentation took place? (3) in which hospital/clinic was the 
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surgery performed? (4) how many times have you had surgery for your breasts? (4a) what 
was the reason for these surgeries (capsule formation/leakage of the implants/infection 
of the implants/other)? (5) are you satisfied with the result of your breast augmentation 
(yes/no)? (5a) why are you satisfied/dissatisfied? (6) do you experience any complaints of 
your breasts (yes/no)? (6a) if yes, what kind of complaints (multiple answers possible: pain/
capsule formation/asymmetry/other)? and (7) do you experience any (health) complaints 
you attribute to your breast implants (yes/no)? (7a) if yes, what kind of complaints (multiple 
answers possible: fatigue/myalgia/arthralgia/sleep problems/neurasthenia/concentration 
difficulties/other)? Respondents who did not undergo breast augmentation filled out the 
following questions: (1) have you ever considered to undergo breast augmentation (yes/
no)? and (2) what was the reason not to undergo breast augmentation (yet) (multiple 
answers possible: satisfied with the gained breast development/awaiting further breast 
development/financial reasons/afraid of complications/other)? At the bottom of the 
questionnaire, there was a space for (general) comments as a conclusion. All complaints or 
reasons stated here were interpreted and divided into categories as well.
Since the questionnaires were returned anonymously, no other (clinical) data could be linked 
to the received answers. Questionnaires of people without a stated start date of hormone 
treatment were omitted from analyses. In addition, when the questionnaire was filled out 
ambiguously, for example, both the questions intended for people with and without breast 
implants were filled out, the data were omitted from analyses.
Statistical analysis
Data are presented as numbers with percentage, mean with standard deviation for normally 
distributed data, and median with interquartile range for non-normally distributed data. 
Current age and median time since the start of hormone treatment were compared between 
the entire addressed cohort and the people who returned a filled-out questionnaire. For 
analyses, people were divided into 5-year subcohorts, based on the year they started 
hormone treatment. Time after both initiation of hormone treatment and eventual 
breast augmentation was calculated using the difference between the stated start date of 
hormone treatment or date of surgery and 2018. Health complaints were calculated per 
described symptom, and therefore, the number of symptoms may exceed the number of 
trans women with health complaints they attribute to their breast implants. Trans women 
with and without breast implants were compared with a Wilcoxon rank-sum test on current 
age. Differences with a P value <.05 were considered statistically significant. Furthermore, 
the percentage of trans women who have or have not undergone breast augmentation 
was calculated and compared between trans women who started hormone treatment in 
adolescence (≤18 years), as young adult (between 19 and 30 years), and as adult (≥31 years).
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All analyses were performed using Stata statistical software, version 15.1 (Statacorp, College 
Station, TX, USA).
Results
The median age of the entire cohort of addressed trans women was 48 years (IQR, 31-
58), and they received hormone treatment for a median 10 years (IQR, 3-22). Of the 3,074 
sent questionnaires, 1,030 were received back, of which 236 were received back because 
they were undeliverable (eg, because the stated address was incomplete or incorrect). 21 
returned questionnaires were omitted from analyses, as they were filled out ambiguously 
or the start date of hormone treatment was not clearly stated (Figure 1). The trans women 
of the 773 included questionnaires had a median age of 50 years (IQR, 35-59) and received 
hormone treatment for a median 7 years (IQR, 3-19), which both corresponded with the 
results of the entire addressed cohort.
Figure 1. Study flowchart.
Of the 773 included trans women, 308 (40%) people underwent breast augmentation, 
320 (41%) considered breast augmentation, and 145 (19%) people neither underwent 
breast augmentation nor considered one. As shown in Figure 2, the frequency of breast 
augmentation varied from 70% in trans women who started hormone treatment between 
1980 and 2000 to 20% in those who started between 2010 and 2015. Nevertheless, the 
percentage of trans women who thought about breast augmentation (either considered or 
underwent one) remained constant at approximately 80%. At the time of the survey, trans 
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women who underwent a breast augmentation were older (median, 54 years; IQR, 45-63 
years) than trans women who did not (median, 45 years; IQR, 29-57 years; P <.001). There 
was no difference in the percentage of trans women who had breast implants between 
people who started hormone treatment in adolescence (37%), as young adult (41%), and 
as adult (40%).
Figure 2. Percentage of trans women who either underwent (black bars), considered (dark grey 
bars), or neither underwent nor considered (light gray bars) breast augmentation. Data are shown as 
percentage of trans women (y-axis) over different 5-year periods based on the start year of hormone 
treatment (x-axis).
Trans Women with Breast Augmentation
Trans women who underwent breast augmentation did so after median 2 years after start of 
hormone treatment (IQR, 2-4; range, 1-22 years), whereas 9 people had breast augmentation 
before the start of hormone treatment. Most trans women underwent breast augmentation 
because of insufficient breast development with hormone treatment (n = 262, 85%), and 
the vast majority was satisfied with the result of the augmentation (n = 247, 80%). Reported 
reasons for being dissatisfied with the result of the breast augmentation are stated in Table 
1.102 people (33%) reported (health) complaints they attributed to their breast implants. 
As shown in Figure 3, in all cohorts, there were trans women who experienced health 
complaints they attributed to their breast implants. Most health complaints, however, were 
reported in trans women who started hormone treatment more than 8 years ago.
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Table 1. Reported reasons for trans women to be dissatisfied with the result of the breast 
augmentation 
N = 308
Dissatisfied, N (%) yes 55 (19)
Unfavorable esthetic outcome * 17 (6)
Health complaints † 15 (5)
Breast are (still) too small 10 (3)
Breast are too big 6 (2)
Concerns about the safety of the breast implants ‡ 2 (1)
Other 5 (2)
Data are shown as number of trans women (rounded percentage).
*Such as asymmetry, malformed nipples, and breasts are too far apart from each other.
†Both local health complaints (including capsular formation/contraction, pain) and systemic health 
complaints (including fatigue).
‡Including ‘breast implants are time bombs’ and ‘I have been in unnecessary danger with breast implants.’
Figure 3. Percentage of trans women who reported (health) complaints they attributed to their breast 
implants over different 5-year periods based on start year of hormone treatment.
Trans Women Without Breast Augmentation
The majority of trans women who have not undergone breast augmentation have considered 
it. Reasons not to choose breast augmentation are shown in Figure 4 and included financial 
limitations, satisfaction with the gained breast development with hormone treatment, and 
awaiting further breast development with hormone treatment. As shown, financial limitations 
became a more frequently stated reason not to undergo breast augmentation over time, while 
satisfaction with the gained breast development became less frequent. A distinction between 
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true satisfaction with the breast size and (psychological) acceptance of the breast development 
cannot be made, as this was not included in the questionnaire. In addition, in people who 
started their hormone treatment more recently, awaiting further breast development was a 
frequently stated reason not to undergo breast augmentation yet.
Figure 4. Reported reasons of 320* trans women not to undergo breast augmentation yet, over different 
5-year periods based on start year of hormone treatment (x-axes). Data are shown as percentage. 
Reported reasons included (A) financial reasons, (B) satisfied with the gained breast development, (C) 
awaiting further breast development, (D) afraid of complications of either the surgery or the implants, 
(E) not wanting foreign material in the body, or (F) other reasons which included “breast augmentation 
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is no priority”, “afraid breast implants cause health problems”, and “afraid for esthetical problems”.
*Some trans women stated more than 1 reason while others did not state any reason.
Interestingly, 304 trans women used the space for (general) comments on the questionnaire. 
Comments varied from additional information about undergone surgeries to feedback 
on the hormone treatment-regimen used at our center or feedback on the questionnaire 
itself. 28 people used this space to emphasize the financial limitations some trans women 
face as breast augmentation is not covered by insurance in the Netherlands. An important 
observation was that 17 trans women wrote that their breast volume increased years after 
the start of hormone treatment, even sometimes years after breast augmentation. In some 
cases, this led to a breast size lager than desirable. 
Discussion
This study showed that 4 of 5 trans women either chose or (ever) considered breast 
augmentation as part of their gender-affirming treatment. Trans women chose breast 
augmentation median 2 years after the start of hormone treatment mostly because their 
breast development was perceived as being insufficient. Of the people who underwent 
breast augmentation, the majority was satisfied with the result. One-third of trans women 
with breast implants experienced health complaints they attributed to their breast implants. 
Trans women who have not undergone breast augmentation chose not to because of 
financial limitations, satisfaction with the gained breast development, preferring to await 
further breast development, or because of fear of complications.
Compared with earlier studies performed, this study found a much lower overall prevalence 
of breast augmentation with 40% of trans women who underwent breast augmentation.8 
13 18 However, the frequency of breast augmentation varied strongly over time, with 70% in 
trans women who started hormone treatment between 1980 and 2000 and 20% in those 
who started between 2010 and 2015. In earlier years, breast augmentation was part of 
the transition and was often performed at the same time as vaginoplasty. This may be an 
explanation of the difference in percentage of trans women with breast implants between 
the different cohorts. On the other hand, most of the trans women who have not undergone 
breast augmentation were still awaiting further breast development with hormone 
treatment. Therefore, it is expected that approximately 70% of trans women eventually 
choose breast augmentation as part of their gender-affirming treatment, which is in line 
with earlier studies performed.
It is striking that the median time between start of hormone treatment and breast 
augmentation was only 2 years. As described earlier, breast development is a process which 
takes several years during female puberty. Unfortunately, literature on breast development 
in trans women is scarce, 8 10-12 19 and even lacking with regard to longer follow-up time. 
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Nevertheless, it is expected that breast development in trans women receiving hormone 
treatment is comparable with breast development during female puberty and therefore 
takes several years. This expectation is strengthened by the comments we received on our 
questionnaire of people stating that their breasts still grew (many) years after the start of 
hormone treatment or after breast augmentation, emphasizing the need for educating trans 
women about the effects of hormone treatment.
Most trans women who underwent breast augmentation were satisfied with the result, 
which has been shown previously.18 However, approximately one-third of people 
experienced health complaints. This was slightly higher or comparable to studies performed 
in cisgender women. 20-23 16 24 This difference might be explained by the fact that complaints 
were asked instead of observed during (physical) examination. Although one-third of people 
attributed experienced health complaints to their breast implants, these health complaints 
may be quite severe and may even lead to reduced participation in society. This might be an 
even bigger burden for trans women because they may also be struggling with acceptance 
in society because of their gender transition. Therefore, it is important to educate trans 
women about the expected positive effects of breast augmentation and the possible side 
effects, especially as the number of trans women who undergo breast augmentation may 
increase over the coming years.
An important reason for trans women to not yet undergo breast augmentation was due to 
financial limitations. Nowadays, breast augmentation is not covered by the medical insurance 
in the Netherlands. Earlier, breast augmentation was considered standard care for trans 
women and therefore covered by insurance. In those years, no financial limitations were 
reported as reason not to undergo breast augmentation. Therefore, it might be expected 
that the number of trans women with breast augmentation will increase if this surgery 
will be covered. Other reasons included fear of complications, fear of health complaints, 
reluctance to foreign material in their body, and fear that the esthetical outcome might be 
disappointing. This shows that pros and cons of (surgical) procedures should be discussed 
openly to support trans women in making a well-informed decision. Although cisgender 
health-care providers may not (always) personally identify with reasons of transgender 
people to choose certain procedures during their transition, they should help them in 
making an educated decision, respect the decision, and facilitate (if possible) the choice.25
This study is the largest study described investigating the prevalence of breast augmentation 
among trans women. Furthermore, the trans women who were included had a wide range 
of age and number of years they received hormone treatment. Another strength of this 
study is that data on health complaints were collected, as well as data on considerations 
whether or not to undergo breast augmentation, which have never been carried out before.
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However, this study has some limitations as well. First, no other (clinical) data could be linked 
to the data of the provided answers, as the questionnaires were returned anonymously. 
Therefore, information about the start of hormone treatment and date of the surgery could 
be missing or inaccurate. However, most trans women filled out these questions and clinical 
practice teaches us that most people exactly know when they started hormone treatment or 
underwent surgery. Therefore, we believe that the retrieved data are accurate and reliable. 
Second, owing to the structured form of the questionnaire, topics which are important to 
trans women, and thereby for our interpretation, could have been missing. However, there 
was a space for remarks on the form, which was used by a lot of people, making it less 
likely that important information was missed. Third, as we only had access to the completed 
questionnaires, all data were subjective, making it difficult to draw definite conclusions on 
health complaints. However, health complaints after breast augmentation in trans women 
have never been investigated before, making this valuable information nonetheless. Fourth, 
despite the large sample in our study, only 25% of the distributed questionnaires were 
returned completed.
Nevertheless, the people who returned a completed questionnaire probably resembled a 
reliable sample of the whole population, indicated by comparable median age and hormone 
treatment duration between the entire cohort and the trans women who returned a 
completed questionnaire.
In conclusion, 4 of 5 trans women either chose or considered breast augmentation as part 
of their gender-affirming treatment. Most of the trans women who underwent breast 
augmentation were satisfied with the result. Trans women underwent breast augmentation 
after median 2 years of hormone treatment, mostly because of unsatisfactory breast 
development with hormone treatment. As hormone treatment-induced breast development 
probably takes longer than 2 years, this remains an important topic to discuss with trans 
women. As one-third of trans women in this study experienced health complaints after 
breast augmentation, it is important to educate trans women about the positive effects 
and possible side effects of breast augmentation. As the majority of trans women who have 
not undergone breast augmentation said the choice was because of financial limitations, 
it would be interesting to keep monitoring the prevalence of breast augmentations in 
this cohort and the considerations in reaching this decision in the future, especially as 
reimbursement of breast augmentation procedures might change over time. Furthermore, 
future research could explore in more detail aspects of this breast augmentation study, such 
as patient satisfaction, to be able to obtain actionable clinical results.
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No literature is available on the benign versus malignant breast lesion ratio in trans women 
(male sex assigned at birth, female gender identity). As hormone treatment in trans 
women results in breast tissue histologically comparable with cis (non-trans) women, 
breast pathology may be expected. Previously, an increased breast cancer risk compared 
with cis men have been observed. We aimed to investigate the frequency and outcomes of 
breast biopsies in trans women. Therefore, we retrospectively examined the medical files 
of 2,616 trans women. To gain data on breast lesions, we linked our cohort to a national 
pathology database. In this study we found that 126 people (5%) had one or more breast 
biopsies(n=139). Of these, 21 trans women had a breast biopsy before the start of hormone 
treatment, and 53 after the start of hormone treatment. Breast biopsies were performed 
predominantly because of abnormalities during physical examination (37%, n=51/139 
biopsies), or because of capsular formation or contraction (28%, n=16/57 biopsies) in trans 
women with breast implants. The most common breast lesions after the start of hormone 
treatment were fibroadenomas (n=20), breast cancer (n=6), fibrosis (n=5), cysts (n=4), 
and infections (n=4). The benign versus malignant breast biopsy ratio was 88:12, which is 
comparable to the ratio in cis women (90:10). This study shows breast lesions in a limited 
number of trans women. Since the indications and outcomes of biopsies in trans women 
were similar to those in cis women, it seems reasonable to follow breast care guidelines as 
developed for cis women.




Gender dysphoria is defined as an incongruence between one’s sex assigned at birth and 
one’s gender identity.1 To induce physical changes in line with the gender identity, trans 
people may seek gender-affirming treatment which may include hormone treatment. In 
trans women (male sex assigned at birth, female gender identity), hormone treatment 
usually consists of a combination of antiandrogens and estrogens to induce feminization, 
including breast development.2,3
Mammary tissue development is similar in cis boys (alignment of sex assigned at birth 
and gender identity) and cis girls until puberty. During typical female puberty, breast 
development occurs influenced by female sex hormones.4-6 Besides (active) glandular tissue 
with ducts and lobules, the mature cis female breast consists of skin, stromal elements, and 
fat.7 Due to exposure to testosterone during typical male puberty, no further mammary 
tissue development occurs in cis boys.4,8 Eventually, the mature cis male breast consists 
of skin, primitive ducts, stromal elements, and fat tissue.7 Because of the different breast 
structure between cis men and cis women, lobular pathology, such as fibroadenomas and 
cysts, is not expected in cis men. However, some reports of fibroadenomas in cis men 
have been published.9 Benign breast lesions that are more often observed in cis men are 
gynecomastia, dermal cysts, lipomas and angiolipomas, mastitis and abscesses, granular 
cell tumors, and pseudoangiomatous stromal hyperplasia (PASH).7 Influenced by exogenous 
female sex hormones, the male breast can further develop into a histological female breast 
as seen in trans women receiving gender-affirming hormone treatment.8 
As hormone-induced breast development in trans women results in a histological female 
breast with ducts and lobules, lobular pathology in trans women may be expected.10 Indeed, 
cases of lobular pathology in trans women including fibroadenomas have been published.11-13 
However, the incidence of these lesions in trans women is unknown. Moreover, the ratio 
of benign versus malignant lesions in this group, which is 90:10 in cis women14, is also 
unknown. Therefore, the aim of this nationwide study was to describe the frequency and 
outcomes of breast biopsies in a well-defined, large cohort of trans women. 
Materials & Methods
Study population
Trans women who started hormone treatment between 1991 and 2018 at the Center of 
Expertise on Gender Dysphoria at the Amsterdam UMC, the Netherlands were eligible for 
participation.15 People were excluded from analyses if they were younger than 18 years 
of age at the time of this study, if they used testosterone, or if the start date of hormone 
Chapter 6
92
treatment was unknown. The subject selection only partially overlaps between the current 
and our previously published study on breast cancer in trans people.16 For the current study, 
only trans women who started hormone treatment after 1990 were included, whereas in 
our previous study people who started hormone treatment between 1972 and 2018 were 
included. The subject selection in these two studies differed because we used the database 
of the Nationwide Network and Registry of Histopathology and Cytopathology in the 
Netherlands (PALGA) which only has nationwide coverage since 1991. Moreover, medical 
history in the medical files always include past history of cancer, but not necessarily on 
benign breast lesions. Therefore, we only included people who started hormone treatment 
since 1991 to make sure we did not miss any benign breast lesion case.
Most trans women were treated with a combination of antiandrogens and estrogens. 
Antiandrogen therapy usually consisted of cyproterone acetate (a progestogenic 
antiandrogen, 10 to 100 mg daily) or spironolactone (100 to 200 mg daily), and was often 
ceased after orchiectomy. Estrogen was prescribed as ethinylestradiol (25 to 100 mcg daily), 
conjugated estrogens (0.625 to 1.25 mg daily), estradiol patches (50 to 150 mcg/24h twice 
weekly), estradiol implants (20 mg every 3 to 6 months), estradiol injections (10 to 100 mg 
every 2 to 4 weeks), estradiol valerate (2 to 6 mg daily), or estradiol gel (0.75 to 3 mg daily). 
In recent years, mainly estradiol valerate, estradiol patches, or estradiol gel were used. Trans 
women who started with hormone treatment under the age of 18 years often started with 
gonadotrophin-releasing hormone agonists only before addition of estrogen.
This study was reviewed by the Ethical Review Board of the Amsterdam UMC, VU University 
Medical Center Amsterdam. It was determined that the Medical Research Involving Human 
Subjects Act (WMO) does not apply to this study, and necessity for informed consent was 
waived. All data were processed anonymously. 
Data collection
Of all eligible people, data on age at start of hormone treatment, gender-affirming surgery, 
mean body mass index (BMI) during follow-up, and medical history were collected. Data 
on breast pathology diagnoses were retrieved from the Nationwide Network and Registry 
of Histopathology and Cytopathology in the Netherlands (PALGA) after linkage of the study 
cohort to their database.17
Data will not be shared at an individual level to guarantee the anonymity of the people in 
the database.
Statistical analysis
Baseline data are presented as mean with standard deviation (SD) for normally distributed 
data. Non-normally distributed data are presented as median with inter-quartile range 
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(IQR). Breast lesions are presented as number of diagnoses with percentage. Of the people 
who started hormone treatment before their treatment at our clinic, the first known start 
date of hormone treatment was used to calculate treatment duration. Treatment duration 
was calculated from the start date of hormone treatment to either first breast lesion, end 
of study period (31/12/2018), or date of death. As trans women may have more than one 
breast lesions, the number of breast lesions may exceed the number of trans women with 
breast lesions.
All analyses were performed using STATA statistical Software, version 15.1 (Statacorp, 
College Station, Texas, USA). 
Results
In total, 2,616 trans women were included in this study of whom 126 (5%) had diagnosed 
breast lesions. The median age at start of hormone treatment was 30 years (IQR 23 to 41). 
During follow-up, 58% of the included trans women underwent an orchiectomy. No trans 
women underwent orchiectomy before entering the study. The median follow-up time was 
9 years (IQR 3 to 18) which resulted in a total follow-up time of the study cohort of 30,311 
years. The characteristics of the study cohort are summarized in Table 1. 
Table 1. Baseline characteristics 
N=2,616
Age at start of HT, y 30 (23 to 41)
BMI, kg/m2 24.7 (21.2 to 26.5)
Orchiectomy, n (%) yes 1,528 (58)
Median follow-up time, y 9 (3 to 18)
Total follow-up time, y 30,311
Data are presented as median with inter-quartile range, percentage or number of years. Abbreviations: 
HT=hormone treatment; BMI=body mass index
In the 126 trans women with breast lesions, 139 diagnoses were observed. Twenty-one 
trans women had a breast lesion before the start of hormone treatment, 53 after the start 
of hormone treatment, and in 56 trans women breast lesions were associated with the 
presence of silicone breast implants. Some trans women have been diagnosed with multiple 
breast lesions during follow-up. 
In trans women with breast lesions after the start of hormone treatment, biopsies were 
performed after median 20 years (IQR 16 to 22) of hormone treatment. As shown in Table 
2, breast biopsies were performed mostly because of abnormalities observed during 
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physical examination or abnormalities at imaging studies. The most commonly observed 
breast lesions in this group were fibroadenomas, invasive breast cancer, fibrosis, cysts, 
and infections. No cases of gynecomastia could be associated to medication use based on 
the available data. The observed breast cancer cases have been described earlier16, and 
therefore will not be further discussed in this paper. The number of breast cancer cases 
differs from our previous study, because the selection of participants overlaps only partially 
between the two studies (see Methods section). The benign versus malignant lesion ratio in 
trans women with observed breast lesions after the start of hormone treatment was 88:12. 
Table 2. Breast lesions (n=60) in 53 trans women after the start of hormone treatment^
Reason for breast biopsies N (%)
Physical examination abnormalities 27 (45)
Imaging abnormalities 25 (42)
Preventive surgery 3 (5)




Breast cancer 6 (10)
Fibrosis 5 (8)
Cyst 4 (7)







Data are presented as number (%). ^ Some trans women had multiple diagnoses
* breast tissue lift
** Including adenosis (n=2), microcalcification (n=1), duct ectasias (n=1), cystic enlarged ducts (n=1), 
lymph node tissue (n=1), papilloma (n=1), cylindrical cell changes (n=1)
Abbreviations: DCIS=ductal carcinoma in situ
In trans women in whom breast lesions were associated with the presence of silicone 
breast implants, breast biopsies were mostly performed because of capsular formation 
or contraction (28%, n=16/57 biopsies, Table 3). Other reasons for breast biopsy included 
abnormalities during physical examination (19%, n=11/57 biopsies), surgery associated with 
the recall of the Poly Implants Prostheses (PIP) implants (18%, n=10/57 biopsies), implant 
leakage (12%, n=7/57 biopsies),  implant replacement (9%, n=5/57 biopsies), and injection 
with silicone oil (4%, n=2/57 biopsies). In most cases, a histological reaction to silicone 
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was observed (72%, n=41/57 biopsies). Other common diagnoses included visible silicone 
particles (5%, n=3/57 biopsies), sclerosis/calcification (5%, n=3/57 biopsies), and silicone 
granulomas (4%, n=2/57 biopsies). 
Table 3. Breast lesions (n=57) of 56 trans women with silicone breast implants^ 
Reason for breast biopsies N (%)
Capsular formation/contraction 16 (28)
Abnormalities in physical examination 11 (19)
PIP (recall) 10 (18)
Implant leakage 7 (12)
Implant replacement 5 (9)
Injection with silicone oil 2 (4)
Unknown 6 (11)
Diagnoses
Reaction to silicone 41 (72)
No abnormalities 5 (9)
Visible silicone particles 3 (5)
Sclerosis/calcification 3 (5)
Silicone granuloma 2 (4)
Other * 3 (5)
Data are presented as number (%). ^ One trans woman had two diagnoses.
Including no diagnosis (no cells for diagnosis, n=1), silicone oil (n=1), and seroma (n=1) Abbreviations: 
PIP; Poly Implant Prostheses 
Gynecomastia (82%, n=18/22 biopsies) was the most common breast lesion in trans women 
with a breast lesion before the start or hormone treatment (Table 4). Other lesions included 
fibroadenoma (9%, n=2/22 biopsies), cysts (5%, n=1/22 biopsies), and fibrosis (5%, n=1/22 




Table 4. Breast lesions (n=22) in 21 trans women before the start of hormone treatment^ 
Reason for breast biopsies N (%)
Palpable abnormalities 11 (50)







Data are presented as number (%).
^ One trans woman had a lesion in both breasts
Discussion
Principle findings
This study observed a benign versus malignant breast lesion ratio of 88:12 in trans women 
receiving hormone treatment. Breast biopsies were mostly performed because of a palpable 
mass, abnormalities at imaging, or because of capsular formation or contraction in trans 
women with silicone breast implants. Before the start of hormone treatment, the most 
common breast lesion was gynecomastia whereas after the start of hormone treatment 
fibroadenomas, breast cancer, fibrosis, cysts, and infections were most commonly 
diagnosed. In trans women with silicone breast implants, only benign reactions to silicone 
were observed.
Comparison with other studies
The benign versus malignant breast lesion ratio in trans women who underwent breast 
biopsies after the start of hormone treatment was 88:12 in this cohort. It is reassuring that 
this ratio is comparable to the ratio in cis women (90:10).14 Therefore, we advise to follow 
the guidelines for breast care in cis women for trans women as well, without any extra 
precautions or tests for breast lesions or breast cancer. 
Kanhai et al.18 previously described that breast histology in trans women using hormone 
treatment was comparable with histology in cis women. Therefore, we were not surprised 
to observe several cases of fibroadenomas and cysts in our study. With an overall prevalence 
of 0.9% (n=24/2,616) in this cohort of trans women, the prevalence of benign lobular breast 
lesions was lower than reported in cis women populations.19,20 A possible explanation for 
this difference might be that the trans women in our cohort have been exposed to estrogens 
for a shorter period of their lives than cis women. Furthermore, because of hormone 
fluctuations (e.g. during pregnancy) fibroadenomas can grow.20 The usually fixed dose 
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hormone treatment in trans women may therefore also contribute to a lower observed 
prevalence of fibroadenomas in trans women compared with cis women. Trans women 
from 50 years of age who are registered as female will receive an invite to participate in the 
breast cancer screening program in the Netherlands automatically. Maybe, trans women 
participate less in this screening program than cis women. This may contribute to the low 
number of observed (benign) breast lesions in trans women compared with cis women.    
The overall prevalence of gynecomastia in this study was 0.8% (n=20/2616), whereas the 
prevalence of clinical diagnoses of gynecomastia in adult cis men populations (age between 
50-80 years) ranges between 24% and 65%.21,22 Despite the low overall prevalence, the 
prevalence of gynecomastia cases associated with the use of medication in this study was 
comparable with the prevalence of medication use associated cases in cis men (20% and 
10-25%, respectively).21 A possible reason for the difference in gynecomastia prevalence 
between trans women and cis men, is that trans women before the start of hormone 
treatment do not present with complaints of gynecomastia, because breast enlargement is 
in line with their gender identity. On the other hand, 18 breast biopsies for gynecomastia is 
remarkable. Maybe trans women are more focused on their breast and therefore present 
themselves quicker with changes in their breasts which leads to biopsy. Interestingly, three 
fibroadenomas and two cysts were observed in trans women before the start of hormone 
treatment. Although lobular pathology rarely occurs in the male breast7, it has already been 
described in literature.23  
Based on previous research, it is estimated that 70-80% of trans women who received 
hormone treatment also underwent breast augmentation surgery.24-27 Therefore, it is 
estimated that 1,831 to 2,093 trans women have breast implants in this study cohort. 
Of the (estimated) number of subjects with breast implants, only 56 (3%) trans women 
underwent a breast biopsy. With this estimation, breast biopsies were performed in 1:33 
to 1:37 trans women with silicone breast implants. Breast biopsies were mostly performed 
because of capsular formation or contraction (28%), a known and common complication of 
silicone breast implants.28 However, this is probably an underestimation as not all capsular 
formation or contraction will lead to surgery and consequently the opportunity for breast 
biopsies. Moreover, it is very likely that not all removed implant capsules have been sent to 
the pathologist. This may also explain the relative low occurrence of capsular contraction 
observed in this study.28 Importantly, we only observed benign breast lesions in trans women 
with breast implants who underwent breast biopsies and did not observe any case of breast 
implant associated anaplastic large cell lymphoma (BIA-ALCL).29  
Strengths and limitations
This large cohort study allows for an accurate estimation of the prevalence of breast lesions 
in trans women. Furthermore, this study included people with a wide range of ages and had 
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a long follow-up time. However, this study has some limitations as well. First, as most of the 
breast biopsies were performed in other hospitals and the clinical data field in the PALGA 
database was not always filled out, the reasons why breast biopsies were performed was 
not always known. Second, because of the retrospective design of this study, data on for 
instance other medication use may be incomplete or missing. Therefore, it is possible that 
we underestimate the prevalence of gynecomastia associated with medication use in this 
study. 
Conclusions
This study shows breast lesions in a small number of trans women receiving hormone 
treatment. Whereas gynecomastia was the most observed diagnosis in trans women before 
the start of hormone treatment, pathology such as fibroadenomas, breast cancer, fibrosis, 
cysts, and infections were most commonly diagnosed after the start of hormone treatment. 
The benign versus malignant breast lesion ratio was 88:12, which is comparable to the ratio 
observed in cis women. We advise to follow the guidelines for breast care and breast cancer 
screening in cis women for trans women as well. 
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Cancer risk in transgender people
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	 	 Hormonal treatment in transgender people may affect sex-hormone related cancer 
  risk, but reliable epidemiologic data are sparse.
	 	 Based on the available data, the observed cancer risk in transgender people does 
  not exceed known differences in cancer risk between cis- men and –women.
 	 Transgender people may develop cancer in organs that are related to their sex 
  assigned at birth as well as in newly formed organs.
 	 The authors recommend cancer screening according to local guidelines for the 
  organs present.




The risk of certain types of cancer differs between men and women. This is obvious for 
cancers that develop in sex-specific organs such as the breast, cervix, and prostate, 
but cancer incidences of other types of cancer differ between sexes as well. Some of 
these differences are attributed to exposure to sex hormones, especially estrogen and 
testosterone. Transgender people, defined as an incongruence between one`s sex assigned 
at birth and one`s experienced gender identity, often seek (medical) care including gender-
affirming hormone treatment (HT). Although HT is considered safe in general, the question 
regarding (long-term) risk on sex hormone-related cancer remains. With increasing numbers 
of transgender people receiving HT, and increasing follow-up of these people, more data 
become available to assess cancer risk in transgender people. In this overview, cancer risk in 
transgender people and the implications for treatment and screening are reviewed. The 
following topics are discussed: sex differences in cancer, the complexity of cancer risk in 
transgender people, sex hormones as carcinogens, incidence studies (breast cancer, cancer 
of the male reproductive organs, cancer of the female reproductive organs, benign brain 
tumors, cancer related to sexually transmitted infections, other types of cancer), cancer 
treatment in transgender people, implications for cancer screening and prevention, and the 
article ends with a summary.
SEX DIFFERENCES IN CANCER
It is well known that cancer risks of different types of cancer differ between men and women. 
These differences are thought to be multifactorial, but are in the first place determined by 
the presence of the specific organ. Because much of the knowledge used in transgender 
health care is derived from studies performed in cisgender populations, it is important to 
understand the current knowledge of sex differences on cancer risk and survival in general 
before one can understand cancer risk in transgender people. An accessible source of cancer 
incidence statistics are national cancer registries, which report trends on cancer incidences 
and outcomes. The Global Initiative for Cancer Registry Development is an international 
partnership that provides cancer incidence and mortality estimations of 36 cancer types in 
185 countries, the GLOBOCAN estimations. Their latest data showed that prostate cancer 
was the second most incident cancer in men and that breast cancer was the most commonly 
diagnosed cancer in women.1 Compared with women, men were more susceptible to lung, 
liver, and skin cancer, and women were more susceptible to thyroid, breast, and adrenal 
cortex cancer compared with men.2 Obviously, prostate and testicular cancers are specific 
for men and cervical, uterine, and ovarian cancers are specific for women.
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However, not only incidence rates may differ between men and women, also survival rates 
may be different. Overall, men seem to have a lower cancer survival rate than women, 
especially for cancers of the breasts, stomach and esophagus, lung, colorectum, and 
melanoma.2-4 On the other hand, cancer survival rates were lower for bladder and renal 
cancer, and sarcoma in women compared with men.2 3 Furthermore, differences between 
sexes regarding clinical presentation and treatment outcomes for several types of cancer 
have been reported.5 6 The question why there is a difference in cancer incidence, survival, 
clinical presentation, and treatment outcomes for different types of cancer between men 
and women, remains largely unanswered. The most likely explanation is the difference 
in concentrations of circulating sex hormones. However, differences in lifestyle (eg, 
smoking habits and alcohol consumption), age at diagnosis, (cancer driver) genes, and 
sex-chromosomes also may play a role.7-9 Moreover, it is important to realize that available 
incidence and survival data are largely based on data from high-income countries, because 
low- and middle-income countries often do not have high-quality cancer registries.1
THE COMPLEXITY OF CANCER RISK IN TRANSGENDER PEOPLE
The complex interaction between sex and cancer incidence and outcome becomes even 
more complex in transgender people. In transgender people receiving HT, circulating sex 
hormones are changed from sex hormones that belong to their sex assigned at birth to 
sex hormones belonging to their experienced gender. In transwomen (male sex assigned 
at birth, female gender identity), HT consists of estrogen treatment often combined with 
anti-androgens, some of which also have progestogenic properties. Transmen (female sex 
assigned at birth, male gender identity) are treated with testosterone. These (exogenous) 
hormones may not only affect the risk for sex-specific cancers, but also for other types of 
cancer that may contain receptors for sex hormones. Fig. 1 shows an overview of different 
factors that may have an effect on cancer risk in transgender people. As depicted, besides 
sex hormones, the presence of certain organs is also an important factor in cancer risk of 
sex-specific cancers. Transwomen, for example, often undergo vaginoplasty as part of their 
transition, during which the testes are removed. The prostate, however, remains preserved, 
because removal of the prostate is associated with a high chance of urologic complications 
such as incontinence. Most transmen undergo a mastectomy (in literature also referred to 
as chest surgery), but the wish for an oophorectomy and/or hysterectomy varies across 
countries and over time. The change in surgery wishes over time and difference between 
countries may be partly explained by differences and changes in laws, for instance whether 
or not sterilization is required to change one’s legal sex. Besides removal of organs, 
transgender people may undergo surgery that constructs new organs such as a neovagina in 
transwomen or a neophallus in transmen, leading to new possible cancer sites.
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Fig. 1. Cancer risk in transgender people may be influenced by several factors, including genes, 
hormonal treatment, lifestyle factors, sexually transmitted infections, and surgical procedures.
Not only hormones, surgery, and genes (which is discussed later) may have an effect on 
cancer risk in transgender people, also lifestyle factors, such as obesity, smoking habits, 
alcohol use, and sexual risk behavior, might play a role. Lifestyle may vary between 
transgender and cisgender people and between countries, depending on the marginalization 
of transgender people. The literature is inconsistent about whether these factors differ 
between transgender and cisgender people.10-12
Better defined cancer risk factors, are some sexually transmitted infections (STIs), such as 
human papillomavirus (HPV) and human immunodeficiency virus (HIV). The incidence of STIs 
may differ between countries and between cisgender and transgender people. Especially in 
transgender people who work as sex workers the incidence of STI may be increased.
The relation between sex and cancer risk is already multiform and complex. However, cancer 
risk in transgender people is even more complex, because all the above-described factors 
may not only act independently on cancer risk in transgender people, but may also show 
complex interactions.
However, the available information and knowledge is poor. Registration of legal sex changes 
in national cancer registries is nearly absent or unreliable13, and the number of people 
in specific transgender registries are low and often lack long-term follow-up. Therefore, 
caution is needed when considering cancer risk in transgender people.14
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SEX HORMONES AS CARCINOGENS
Through their receptors, sex hormones are involved in proliferative signaling and growth 
suppression in cells, 2 major underlying mechanisms of carcinogenesis.15 Sex hormones 
may either play carcinogenic or tumor-suppressive roles. Whereas the role of estrogens, 
progestogens, and androgens has been comprehensively studied in breast cancer and 
prostate cancer in cisgender people, only in recent years are reports addressing this topic 
emerging in transgender research. The effects of gonadotropin-releasing hormone agonists 
and gonadectomy on cancer risk in transgender people have been explored to a very limited 
extent. DNA mutational landscapes in cancer have been reported to vary significantly between 
men and women.9 However, there are no published studies addressing the role of such sex-
dependent autosomal differences or sex chromosome-specific oncogenes or tumor suppressor 
genes and the risk of tumors that are typical for the assigned gender. Estrogen receptor (ER) 
alpha is a major factor in the diagnosis and treatment of 70% of female breast cancer cases. 
Similar observations have been made in cisgender male breast cancer.16 Most breast tumors in 
transwomen are of luminal type, expressing ER and/or the progesterone receptor (PR).
Estrogens seems to be mainly important for breast cancer progression in cisgender women, 
supported by the results of The Women’s Health Initiative trial, which demonstrated that 
combined use of estrogen and progestin in post-menopausal women resulted in a higher 
incidence of invasive breast cancer. However, use of estrogen alone did not increase this risk, 
suggesting a dominant role for progestogens in tumor initiation.17 As cyproterone acetate, 
a PR-agonist, is used in Europe as anti- androgen in transwomen, this observation may be 
relevant for breast cancer development in transwomen. Further comparative studies are 
warranted to evaluate the use of PR-agonists and breast cancer risk in transwomen.
The androgen receptor (AR) is expressed in most female and male breast tumors, and seems 
to have dual roles in breast carcinogenesis in cisgender women. In luminal tumors, AR has 
growth suppressive properties, whereas in ER-negative breast cancers AR functions as a 
driver of tumor cell proliferation.18 This may be of particular relevance for breast cancer 
arising in remnant breast tissue after subcutaneous mastectomy in transmen receiving 
HT. Moreover, activation of AR signaling is essential for prostate cancer growth. Depletion 
of testosterone levels and disruption of AR function is the mainstay of prostate cancer 
treatment in cisgender men.
INCIDENCE STUDIES
Although the number of transgender people seeking medical care is growing19, data on 
cancer risk in transgender people is scarce. Global and national cancer registries generally 
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do not register data on gender identity, and therefore current knowledge on cancer in 
transgender people largely depends on case reports and case series. However, these cases 
do not provide incidence data. Recently, some cohort studies have been published providing 
information on relative risks for several types of cancers.20-29
Breast Cancer
Globally, breast cancer incidence is high in women, but is quite rare in men. Because 
transwomen use estrogen as part of their HT, one of the main concerns is an increase in 
breast cancer risk. Earlier reports showed a low number of breast cancer cases, leading 
to the opinion that breast cancer risk of transwomen receiving HT was comparable with 
the risk in cisgender men.28 A recent study, however, showed a 46-fold increased risk of 
breast cancer in transwomen compared with reference men.30 Furthermore, an interesting 
observation is that breast cancer in transwomen occurs at a younger age compared with 
cisgender women and occurs after relative short HT duration. Despite the fact that these 
new observations challenge established knowledge, the follow-up of all studies performed 
remain relatively short. Moreover, little is known about the cause of the increase in breast 
cancer risk in transwomen. A possible explanation may be genetic susceptibility; nevertheless 
further research should be performed to study these remaining questions. Moreover, in the 
literature, there is evidence that both testosterone and estrogen may play a role in breast 
cancer risk. Testosterone is thought to have a protective effect, and estrogen a stimulating 
effect. Because transwomen are commonly treated with both estrogen and anti-androgens, 
the increase of circulating estrogen and the loss of circulating testosterone could contribute 
to the observed increased breast cancer risk compared with cisgender men.18
Cancer of the Male Reproductive Organs
An important question is whether HT induces an increase in cancer risk of the male 
reproductive organs. Under the influence of testosterone, the prostate is embryologically 
formed from the mesonephric duct (also known as the Wolffian duct), and is specific for 
men. As described above, the prostate is preserved in transwomen, even after vaginoplasty. 
Therefore, these individuals might still be at risk for prostate cancer. Only one study provides 
incidence data on prostate cancer in transgender people, and reported one case in 2306 
transwomen followed for a total of 51,173 person years.27  A recent literature review 
described 10 prostate cancer cases in transwomen worldwide.31 This indicates that prostate 
cancer risk in transwomen is lower than in cisgender men, which may be explained by the 
anti-androgenic effect of HT and orchiectomy during vaginoplasty, both leading to low 
circulating testosterone levels. However, 6 of the 10 reported cases had metastases at time 
of diagnosis31, indicating either a delay in diagnosis or an more aggressive form of prostate 
cancer in transwomen. The role of estrogen in prostate cancer is unclear. On the one hand, 
prostate cancer cells might have ERs through which estrogen might induce prostate cancer 
in the presence of testosterone.32 On the other hand, estrogens also may contribute to the 
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low prostate cancer incidence in transwomen through the growth inhibitory actions of the 
ER beta or estrogen-related receptors.33
No incidence studies have been performed on testicular cancer in transwomen; in fact, only 
one case report has been described in the literature.34
Cancer of the Female Reproductive Organs
As in male reproductive cancer, the question is whether testosterone treatment increases 
the risk of cancer of the female reproductive organs in transmen. There is little evidence 
for a relation between testosterone treatment and ovarian cancer. Olsen and colleagues35 
showed an increased ovarian cancer risk in cisgender women with a history of testosterone 
treatment; however, the implications of this finding for transmen are unclear. All the more 
because follow-up of transmen receiving testosterone treatment and who still have their 
ovaries is small, since sterilization was required in many countries, and in some it still is, 
to be able to change one’s legal sex. The largest study to date is performed by Grynberg 
and colleagues,36 who studied the ovaries of 112 transmen who underwent hystero-
salpingo-oophorectomy. They observed that mean ovarian volume was increased, with 
histopathological characteristics of polycystic ovaries in 89 transmen. They did not find any 
ovarian cancer case. Nevertheless, to date 6 case reports of transmen with ovarian cancer 
have been published.37-40
In the study of Grynberg and colleagues,36 endometrial atrophy was observed in 45% of the 
investigated cases, but no cases of uterine cancer were seen. In the literature, only one case 
of uterine cancer in a transman has been described.41 Minimal changes in cervical histology 
were observed in the study by Grynberg and colleagues;36 cervical dysplasia was present in 
one case. Because cervical cancer is strongly related to HPV, this topic is further discussed 
in the context of STIs.
One case of vaginal cancer in a transman, who did not receive HT, has been described.42 Two 
case- control studies compared vaginal biopsies from 16 transmen receiving HT with those 
of 32 cisgender women, in whom no cases of vaginal cancer were found.43 44
An increase in the number of transmen who will keep their (female) reproductive organs 
is expected over the following years. Therefore, long-term follow-up studies are needed to 
study cancer risk in these people.
Benign Brain Tumors; Pituitary Adenoma, Meningioma, and Vestibular 
Schwannoma
Meningioma, vestibular schwannoma, and pituitary adenomas, such as non-secretive 
adenomas, prolactinomas, somatotrophinomas, corticotrophinomas, and thyrotrophinomas, 
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are the most common benign brain tumors. Sex differences in the incidence of these 
brain tumors have been described in literature, and might be caused by differences in 
sex hormones or sex hormone receptors.45-47 Therefore, an altered risk in transgender 
people receiving HT could be expected. Since estrogens stimulate prolactin production in 
the pituitary, one of the concerns of estrogen use in transwomen is an increased risk of 
prolactinomas. However, the literature is sparse. Several case reports on prolactinomas 
in transwomen have been published, but only one study provides incidence data.48 This 
study showed an increased prolactinoma risk in transwomen compared with control men 
and women. Knowledge about other pituitary adenomas, megningiomas, and vestibular 
schwannomas is mostly retrieved from case reports as well. Nota and colleagues,48 also 
reported the incidence of these tumors in their above-described study, and found an 
increased meningioma incidence in transwomen compared with a European female and 
male population. An interesting finding and possible explanation for this increased risk was 
that most transwomen still used cyproterone acetate at time of meningioma diagnosis, 
even after orchiectomy.49 Furthermore, in transmen they observed an unexplained 22-fold 
increased risk of somatotrophinomas compared with a general European population.
Cancer Related to Sexually Transmitted Infections
Several STIs have been associated with an increased risk on specific types of cancer. The 
prevalence of STIs in transgender people may vary between different countries. Moreover, 
it differs in people depending on lifestyle factors, such as sexual risk behavior. For cervical 
cancer, there is a strong association with several types of HPV. As described above, minimal 
cervical histology changes have been described in transmen, and cervical dysplasia was rare 
in the study of Grynberg and colleagues.36 Nevertheless, 3 case reports of transmen with 
cervical cancer have been described.39 41 50 Unfortunately, in none of these casus was HPV 
status reported. Human papillomavirus is not only associated with cervical cancer, but also 
with anal and penile cancer. Despite the high prevalence of anal HPV among transwomen51-54 
in both sex workers55 and non-sex workers56, vaccination rates remain low. A higher 
proportional incidence was found for anal cancer in transgender people compared with 
controls of the New York State Cancer Registry57, of whom most cases were HPV positive. 
The risk was not calculated for transwomen and transmen separately. No cases of penile 
cancer in transwomen have been reported.
Although chronic hepatitis B and C infections can cause hepatocellular carcinoma, no cases 
in transgender people have been described.
The prevalence of HIV among transgender people is studied extensively, but is not discussed 
here. People with HIV/AIDS have an increased risk of developing Kaposi sarcoma, non-
Hodgkin’s lymphoma (mostly primary central nervous system lymphoma, primary effusion 
lymphoma, or aggressive large B cell lymphomas), and cervical cancer. Hutchison and 
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colleagues51 found an increased proportional incidence rate for Kaposki sarcoma and non-
Hodgekin’s lymphoma among transgender people, as well as other non-HIV/AIDS-related 
types of cancer. However, analyses were not adjusted for comorbidity or HIV status.
Other Types of Cancer
Several studies investigated cancer prevalence in transgender people and found no overall 
increased cancer risk.20-22 24 25 Asscheman and colleagues20 did find an increased risk of lung 
and hematological cancer in transwomen, but the overall cancer risk was not increased. 
Despite there is no increased cancer risk found in transgender people, several cases have 
been described in literature, including lung cancer, hematological cancers, cancers of the 
gastrointestinal tract, brain tumors, melanomas, and liver and pancreatic cancers.20-25 
Unfortunately, the numbers are too small to derive firm conclusions. Some case reports 
have been published on cancer in newly (surgically) formed organs such as the neovagina in 
transwomen.58 59 Although no incidence data are available here, the incidence seems very 
low. Nevertheless, it is important to keep in mind that cancer can occur in newly formed 
organs as well.
CANCER TREATMENT IN TRANSGENDER PEOPLE
Because there is no literature on cancer treatment outcomes in transgender people 
specifically, there is no knowledge on whether the cancer treatment in transgender people 
should be different from treatment in cisgender people. Although a cancer diagnosis leads 
to significant fears and concerns, thereby affecting the well-being in all people affected, 
in transgender people cancer diagnosis in a sex-specific organ may cause extra distress. 
Furthermore, it should be kept in mind that people in the environment might not always 
know that someone is transgender. This should be discussed with the transgender person 
privately, before diagnosis and treatment options are discussed with family present.
When a hormone-sensitive/ hormone-receptor-positive tumor is diagnosed, the question 
whether or not to withdraw HT raises. This decision has to be balanced between the risk of 
progression or recurrence of the tumor on the one hand, and (further) increasing distress 
on the other hand, because HT in transgender people is very important for maintaining 
secondary sex characteristics and for psychological well-being. For comparison, the decision 
to withdraw HT in transwomen is as difficult for transwomen as the decision whether to 
undergo an oophorectomy is for cisgender women.60 Therefore, lowering the dose of HT 
could be a good compromise between cancer risk and maintaining effects on secondary 
sex characteristics, as the desired effects of HT also might be apparent at lower dosages. 
Moreover (cancer) health care providers need to show that they welcome (gender) diversity 
to be able to discuss openly treatment options, including lowering or withdrawing HT.
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Considering the above-described, it might be clear that, in the care for transgender people 
with cancer, one must strive for a good balance between treatment and progression or 
recurrence risk on the one hand and the wishes and well-being of the affected person on 
the other, just as in any person with cancer.
IMPLICATIONS FOR CANCER SCREENING AND PREVENTION
In many countries, population cancer screening programs are available, including screening 
for breast and cervical cancer, and in some countries for prostate cancer as well. Usually, 
people are invited to participate based on registered sex and age in national or municipal 
registries. These registries, however, rarely register transition status and therefore fail to 
reach people who have changed their legal sex. This is not a problem when the specific 
organ has been removed, but is the more important in people who changed their legal sex 
and who still have the specific organ that is screened.
In transwomen, based on the current knowledge and the incidences described above, it 
seems reasonable to refer transwomen to participate in the population screening for breast 
cancer in the same schedule as cisgender women.61 62 The need for screening for prostate 
cancer has been extensively studied in cisgender men. Although screening induces a slight 
reduction in prostate cancer-related mortality, it has also many disadvantages because 
of the relatively high false-positive rate.63 Overall there is no strong support for prostate-
specific antigen (PSA)-based prostate cancer screening.64 When health care providers 
choose to determine PSA levels in transwomen receiving HT, they should know that the 
levels are probably much lower than in cisgender men because of low testosterone levels 
under anti-androgen treatment as part of HT. Since population-based prostate cancer 
screening is not generally implemented, and the incidence of prostate cancer seems much 
lower in transwomen than in cisgender men, there seems no reason to refer transwomen 
for regular prostate screening or perform regular PSA level measurements. However, health 
care providers and transwomen themselves should be aware that transwomen still have 
their prostate, even after vaginoplasty, and should consider prostate cancer, especially if a 
transwoman presents with lower urinary tract symptoms or hematuria.
In transmen, participation in the population-based screening for cervical cancer is indicated 
when the uterus is still present.65 Recently, the feasibility of other approaches than the 
standard health care provider performed Pap-smear test, including self-testing, has been 
studied in transmen and might be a promising alternative.66
Although, an increased risk for meningiomas and prolactinomas in transwomen and 
somatotrophinomas in transmen has been described, these conditions are quite rare, so 
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regular screenings for these tumors (eg, regular prolactin measurements for identifying 
prolactinomas) seem not to be indicated.
HPV vaccination is recommended for transwomen and transmen given the increased 
incidence of anal cancer67, and increasing awareness of the risks is necessary.68
Given all information available, there seems no need for intensified screening in transgender 
people for breast cancer, cervical cancer, prostate cancer, meningiomas, or prolactionomas. 
However, awareness, especially in transgender people, of the available population screening 
programs is needed. Health care providers and policymakers should ensure that transgender 
people have the opportunity to participate in population screening programs. Furthermore, 
health care providers should educate transgender people about current knowledge on 
screening and vaccination (e.g., HPV) programs, because many transgender people are not 
aware of the importance and availability of screening programs.69
SUMMARY
In summary, HT in transgender people may affect sex hormone-related cancer risk, but 
reliable epidemiologic data are sparse. The available data do not show an increased cancer 
risk in transgender people, and, more importantly, the observed risks do not exceed the 
risks seen in the general male and female populations. However, transgender people may 
develop cancer in organs that are related to their sex assigned at birth (prostate, cervix, 
breasts) as well as in newly formed organs (neovagina or neophallus). We recommend cancer 
screening according to local guidelines for the organs present. When cancer is diagnosed, a 
careful consideration of whether or not to withdraw HT should be made by both the treating 
health care providers and the affected transgender person.
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Objective: To investigate the incidence and characteristics of breast cancer in transgender 
people in the Netherlands compared with the general Dutch population.
Design: Retrospective, nationwide cohort study.
Setting: Specialised tertiary gender clinic in Amsterdam, the Netherlands.
Participants: 2260 adult trans women (male sex assigned at birth, female gender identity) 
and 1229 adult trans men (female sex assigned at birth, male gender identity) who received 
gender affirming hormone treatment.
Main outcome measures: Incidence and characteristics (eg, histology, hormone receptor 
status) of breast cancer in transgender people.
Results: The total person-time in this cohort was 33 991 years for trans women and 14 883 
years for trans men. In the 2260 trans women in the cohort, 15 cases of invasive breast 
cancer were identified (median duration of hormone treatment 18 years, range 7-37 
years). This was 46-fold higher than in cisgender men (standardized incidence ratio 46.7, 
95% confidence interval 27.2 to 75.4) but lower than in cisgender women (0.3, 0.2 to 0.4). 
Most tumours were of ductal origin and oestrogen and progesterone receptor positive, 
and 8.3% were human epidermal growth factor 2 (HER2) positive. In 1229 trans men, four 
cases of invasive breast cancer were identified (median duration of hormone treatment 15 
years, range 2-17 years). This was lower than expected compared with cisgender women 
(standardised incidence ratio 0.2, 95% confidence interval 0.1 to 0.5).
Conclusions: This study showed an increased risk of breast cancer in trans women compared 
with cisgender men and a lower risk in trans men compared with cisgender women. In trans 
women, the risk of breast cancer increased during a relatively short duration of hormone 
treatment and the characteristics of the breast cancer resembled a more female pattern. 
These results suggest that breast cancer screening guidelines for cisgender people are 
sufficient for transgender people using hormone treatment.




Breast cancer is the most common malignancy in females1 but is rare in males. The lifetime 
risk in the general female population is 12% and in the general male population is 0.1%.2 
Several risk factors have been identified for breast cancer, including advancing age, genetics 
(eg, BReast CAncer 1/2 mutations (BRCA1/2)), family history, overweight or obesity, breast 
density, tobacco use, alcohol use, and null parity in females.3 4 The molecular pathogenesis 
of breast cancer differs between sexes.5 For instance, cancers positive for human epidermal 
growth factor receptor 2 (HER2) are rare in males (1.7%) whereas 6-12% of the breast 
cancers in females express HER2.5-7
Transgender people experience an incongruence between the sex assigned to them at 
birth and their experienced or expressed gender. In the Netherlands, an estimated one in 
2800 birth assigned males and one in 5200 birth assigned females identify themselves as 
transgender.8 However, a substantial increase in the number of referrals for psychological, 
for endocrine or surgical treatment, or a combination of those has been seen over the 
past 10 years.8 Transgender people can receive gender affirming hormones (sex steroids) 
to reduce psychological distress and to induce desired physical changes, such as for body 
hair and body composition.9 10 In trans women (male sex assigned at birth, female gender 
identity), treatment usually consists of antiandrogens and oestrogens. In trans men (female 
sex assigned at birth, male gender identity), treatment usually consists of testosterone.
Besides gender affirming hormone treatment, transgender people might also want surgical 
transition, which can consist of breast augmentation and orchiectomy or vaginoplasty in 
trans women and subcutaneous mastectomy and uterus extirpation or oophorectomy, 
or both, and phalloplasty in trans men. Subcutaneous mastectomy in trans men is often 
subtotal to obtain an aesthetic masculine thorax.
Whether (exogenous) sex steroids influence breast cancer risk and pathogenesis in 
transgender people is not fully understood. It is known that sex steroids induce changes in 
breast tissue.2 11 During female puberty and in trans women receiving hormone treatment, 
mammary development includes duct and lobule formation and an increase in deposition 
of fat in the breasts.2 Some structural changes occur in breast tissue under the influence 
of testosterone, such as an increase of fibrous tissue2 11, and the upregulation of potential 
oncogenes.12 Large prospective studies have shown that hormone replacement therapy 
increases the risk of breast cancer in cisgender postmenopausal women13-15, in particular 
in those using both oestrogens and progestogens, which could suggest an increased breast 
cancer risk in trans women receiving hormone treatment compared with cisgender men.
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Currently, information about the risk of breast cancer in transgender people is limited. 
To date, 22 cases of breast cancer in trans women and 20 cases in trans men have been 
published.16-19 However, reliable estimations of the risk in transgender people are lacking 
because of the heterogeneity in the population and study cohorts.20
To gain more insight into the risk of breast cancer in transgender people receiving hormone 
treatment and the influence of (exogenous) sex steroids on the development of breast cancer, 
we investigated the incidence and characteristics of breast cancer in a well documented 
cohort of transgender people receiving hormone treatment in the Netherlands, compared 
with the general Dutch population.
Methods
Study population
For this retrospective cohort study, we identified all transgender people who visited the 
gender clinic of the VU University Medical Centre Amsterdam between 1972 and January 
2016 for either psychological, endocrine or surgical treatment. More than 95% of transgender 
people in the Netherlands receive healthcare at our centre. 8 People were excluded from 
analyses if they never used hormone treatment or the start date was unknown, they were 
younger than 18 years at the time of the study, or they used alternating oestrogen and 
testosterone during the follow-up time because of regret about their transition. As data 
on breast cancer diagnosis were retrieved from the Nationwide Network and Registry of 
Histopathology and Cytopathology in the Netherlands (PALGA), which covers all pathology 
diagnoses since 199121, we also excluded those whose last visit to our gender identity clinic 
was before 1991.
Most trans women were treated with a combination of antiandrogens and oestrogens. 
Antiandrogen treatment usually consisted of cyproterone acetate (a progestogenic 
antiandrogen, 10 to 100 mg daily) or spironolactone (100 to 200 mg daily), and treatment 
was often stopped after orchiectomy.
Oestrogen was prescribed as ethinylestradiol (25 to 100 µg daily), conjugated oestrogens 
(0.625 to 1.25 mg daily), estradiol patches (50 to 150 µg/24 hours twice weekly), estradiol 
implants (20 mg every 3 to 6 months), estradiol injections (10 to 100 mg every 2 to 4 weeks), 
estradiol valerate (2 to 6 mg daily), or estradiol gel (0.75 to 3 mg daily). In recent years, 
mainly estradiol valerate, estradiol patches, or estradiol gel have been used. Trans men were 
treated with either testosterone gel (20 to 100 mg daily), intramuscular testosterone esters 
(150 to 250 mg every 2 to 3 weeks), or oral or intramuscular testosterone undecanoate 
(orally: 40 to 160 mg daily, intramuscularly: 1000 mg every 10 to 14 weeks). Trans men who 
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experienced persistent menstrual blood loss during testosterone treatment were in some 
cases treated with additional progestogens such as lynestrenol (5 to 10 mg daily). People 
who started hormone treatment younger than 18 years often received only gonadotrophin 
releasing hormone agonists before the addition of oestrogen or testosterone treatment.
Data collection
After inclusion of eligible people, we collected data about age at start of hormone treatment, 
type of treatment, gender affirming surgery, and medical history. Subsequently, the data 
were linked to PALGA and Statistics Netherlands (CBS). We retrieved data on year of breast 
cancer diagnosis and breast cancer histology from PALGA. To adequately calculate the 
follow-up time, we retrieved data on mortality from Statistics Netherlands.
Statistical analysis
Data from trans women and trans men were analysed separately. Baseline data are 
presented as means with standard deviations for normally distributed data, and medians 
with interquartile ranges, ranges, or both for non-normally distributed data. For those 
people who had started hormone treatment before treatment at our clinic, we used the 
first known start date of the treatment to calculate the most accurate duration. To calculate 
standardized incidence ratios, we determined the number of observed breast cancer cases 
in this cohort. Person time was calculated as the number of years from the first known start 
date of hormone treatment to the first terminating event: breast cancer diagnosis, death, 
or end of study period (31 August 2017). The number of expected cases were calculated 
using age matched incidence rates for cisgender men and women from the Netherlands 
Comprehensive Cancer Organization (IKNL).22 We calculated the number of expected cases 
for the whole study population and for the age categories younger than 30 years, 30 to 50 
years, and older than 50 years. Finally, standardised incidence ratios with 95% confidence 
intervals were calculated with a Mid-P exact test. Mean oestradiol and testosterone 
concentrations for each participant were calculated by averaging the results from the 
measurements performed during hormone treatment.
Analyses were carried out using STATA statistical software, version 14.1 (Statacorp, College 
Station, TX) and OpenEpi version 3.01 (www.OpenEpi.com).
Patient and public involvement
Owing to the design of this study, there was no patient or public involvement. The results 
of this paper will be shared with the public through our institutions’ website and during an 
open science evening at our centre, which is intended for transgender people, their friends 




Of 6793 transgender people identified, 4432 were birth assigned males and 2361 were birth 
assigned females. After exclusions, 2260 trans women and 1229 trans men were included 
in this study (fig 1). The median age at start of hormone treatment in trans women was 31 
years (interquartile range 23-41 years) and in trans men was 23 (interquartile range 19-31) 
years. The median person time in trans women was 13 (interquartile range 5-23, range 0-63) 
years and in trans men was 8 years (interquartile range 3-20, range 0-47) years. The total 
person time was 33 991 years and 14 883 years, respectively. Table 1 shows the baseline 
characteristics of the study cohort.
Fig 1. Study flowchart.








Age (years) 47 (31-57) 51 (38-60) 39 (26-51)
Age at start of hormone
treatment (years)
28 (21-38) 31 (23-41) 23 (19-31)
% (No) White 96.5* (2509) 96.7† (1579) 96.3ǂ (930)
% (No) ever smokers 38.9 (1356) 39.1 (884) 38.4 (472)
BMI§ 22.9 (20.5-26.2) 22.7 (20.4-25.6) 23.2 (20.7-27.3)
% (No) gonadectomy 68.9 (1556) 68.5 (842)
Oestradiol levels (pmol/L) - 217¶ (129-335) 125** (78-176)
Testosterone levels
(nmol/L)
- 1.3†† (0.8-1.3) 23.3ǂǂ (15.9-35.2)
Person time (years) 12 (4-22) 13 (5-23) 8 (3-20)
Total person time (years) 48 874 33 991 14 883
Data available for *2599 people, †1633 people, ǂ966 people, §2,201 people, ¶1521 people, ††1334 
people, **919 people, and ǂǂ924 people of the cohort.
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In 17 of the 2260 trans women, a total of 18 cases of breast cancer (15 invasive and three 
non- invasive) were diagnosed after a median 18 (interquartile range 12-27, range 7-37) 
years of hormone treatment. The median age at diagnosis was 50 (interquartile range 43-
55) years. The breast cancers were mostly tumours of ductal origin (67%, n=10/15). The 
oestrogen receptor was positive in 83% (n=10/12) of the tumours, the progesterone receptor 
was positive in 67% (n=8/12), and HER2 was positive in 8% (n=1/12). In trans women with 
breast cancer the median oestradiol level was 236 pmol/L (range 20-492 pmol/L) and the 
median testosterone level was 1.3 nmol/L (range 0.8-1.3 nmol/L), both comparable with the 
median levels in the whole cohort of trans women (table 1). Table 2 shows the standardised 
incidence ratios. A higher overall risk of breast cancer was found (standardised incidence 
ratio 46.7, 95% confidence interval 27.2 to 75.4) compared with Dutch cisgender men. A 
lower overall risk of breast cancer was found compared with Dutch cisgender women (0.3, 
0.2 to 0.4).
Table 2. Standardised incidence ratios of 18 cases of breast cancer (15 invasive and three non-invasive) 











Reference: incidence ratio in 
cisgender men
Reference: incidence ratio in 
cisgender women
Trans women (n=2260)
Invasive 15 0.32 46.7 (27.2 to 75.4) 59.95 0.3 (0.2 to 0.4)
Age (years):
<30 0 0.00 - 0.14 -
30-50 9 0.01 659.4 (321.6 to 1210.0) 9.16 1.0 (0.5 to 1.8)
>50 6 0.31 19.5 (7.9 to 40.6) 50.65 0.1 (0.1 to 0.3)
Non-invasive 3 0.03 96.1 (24.5 to 261.6) 12.10 0.3 (0.1 to 0.7)
Age (years):
<30 0 0.00 - 0.01 -
30-50 1 0.00 5288.0 (264.6 to 26080.0) 1.25 0.8 (0.0 to 4.0)
>50 2 0.03 64.5 (10.8 to 213.0) 10.83 0.2 (0.0 to 0.6)
Trans men (n=1229)
Invasive 4 0.07 58.9 (18.7 to 142.2) 18.54 0.2 (0.1 to 0.5)
Age (years):
<30 0 0.00 - 0.14 -
30-50 2 0.01 282.3 (47.3 to 932.5) 4.78 0.4 (0.1 to 1.4)
>50 2 0.06 32.9 (5.5 to 108.8) 13.62 0.2 (0.0 to 0.5)
Non-invasive 0 0.01 - 3.55 -
In four of 1229 trans men, four cases of invasive were diagnosed at a median age of 47 
(range 35-59) years and after median 15 (range 2-17) years of hormone treatment, but 
no cases of non-invasive breast cancer. Three of the four cases of breast cancer were of 
ductal origin. Two cases were oestrogen and progesterone receptor positive, one was HER2 
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positive, and one was androgen receptor positive. Three of the four cases of breast cancer 
were diagnosed several years after subcutaneous mastectomy, the other at the time of 
mastectomy. The median oestradiol level in trans men with breast cancer was 116 pmol/L 
(range 60-191 pmol/L), comparable with the median level in the whole cohort of trans men. 
The mean testosterone level in trans men with breast cancer was lower than the median 
level in the whole cohort (13.2 nmol/L (range 12.8-16.0 nmol/L) v 23.3 (range 15.9035.2) 
nmol/L, respectively). With an overall standardised incidence ratio of 0.2 (95% confidence 
interval 0.1 to 0.5) in trans men, the risk of breast cancer was lower compared with Dutch 
cisgender women. Compared with Dutch cisgender men, trans men had a higher overall 
risk of breast cancer (58.9, 18.7 to 142.2). Table 2 shows the standardised incidence ratios.
We were unable to perform analyses on different types of hormone treatment, because 
treatment was often changed over the follow-up period or there was too little variation in 
treatment regimen (this was particularly the case for antiandrogen treatment).
Discussion
This study found an increased risk of breast cancer in trans women in the Netherlands 
compared with Dutch cisgender men. In both trans women and trans men, the risk of breast 
cancer was lower than in Dutch cisgender women. This suggests that hormone treatment 
alters the risk of breast cancer in transgender people compared with initial risk based on 
their birth assigned sex. The median age at breast cancer diagnosis was 52 years in trans 
women and 46 years in trans men, both lower than the average age of 61 years in Dutch 
cisgender women. HER2 receptor status in trans women was higher than expected in male 
breast cancer.
Comparison with other studies
The overall incidence of breast cancer for trans women and trans men combined in the 
current study was 43.0 per 100 000 person years, which is higher than the numbers found 
in two previous studies (20.0 per 100 000 person years and 4.5 per 100 000 person years).23 
24 Both studies concluded that the risk of breast cancer in transgender people is comparable 
to the risk in cisgender men. The incidence in the first of the studies, however, was 31.4 
per 100 000 person years in people who underwent hormone treatment, which is in line 
with our results. In the other study, the breast cancer risk could have been underestimated 
because of technical limitations resulting in overestimation of the total follow-up time and 
not including people who underwent treatment for breast cancer in other hospitals. We 
addressed these limitations in our study. None of the reported cases in this study have been 
previously published.
Breast cancer risk in transgender people
129
8
In accordance with previous studies, we observed a younger age at time of breast cancer 
diagnosis in transgender people compared with cisgender women.25 Moreover, the exposure 
to hormone treatment before breast cancer diagnosis was relatively short in trans women, 
at a median of 18 years, suggesting a rapid development of breast tumours in a subset of 
people. This observation could be explained by genetic susceptibility. Genetics data were 
available for one trans woman who is a carrier of a BRCA 1 germ line mutation. Another 
explanation might be the presence of undiagnosed hormone sensitive cancer before 
treatment, which could become apparent when stimulated by hormones. In trans women, 
most breast tumours were of the luminal type, suggesting that the tumours are driven in 
a cell autonomous fashion by the growth stimulatory actions of oestrogens as well as the 
progestogenic characteristics of the predominantly used antiandrogen cyproterone acetate. 
As androgens are known to inhibit the progression of luminal breast cancer, antiandrogenic 
treatment and orchiectomy might have contributed to tumour initiation in the affected 
people.26
Breast cancer screening advise
Current recommendations suggest that trans women and trans men who have not 
undergone mastectomy should be biennially screened with mammography from the age 
of 50 years and if they are using hormone treatment for more than five years.27-29 After 
subcutaneous mastectomy, monitoring of trans men with mammography is not considered 
feasible owing to the minimal remaining breast tissue, and therefore self examination is 
advised, although there is no evidence for effectiveness.2 27 29 The absolute risk of breast 
cancer in transgender people is still low in this study, and, more importantly, is not increased 
compared with cisgender women. We believe therefore that awareness in both doctors and 
transgender people30 is of more importance than the start of screening at a younger age 
or intensifying available screening, even though the median age at diagnosis in the current 
study was lower than in cisgender women. Besides, discontinuation of hormone treatment 
in older transgender people can be considered, which might from then decrease the risk of 
breast cancer.31 Trans women and trans men who have not had a mastectomy are advised to 
undergo the same intensified breast surveillance as their close female relatives if the risk of 
breast cancer is increased because of a familial predisposition. It is important to remember 
that transgender people who changed their legal sex might not be automatically invited for 
population based screenings, including breast cancer screening.
Strengths and limitations
This study provides novel insights into the risk of breast cancer in transgender people. The 
reported risk in the current study is higher than estimates from previous studies, possibly 
related to cohort size and data quality, including the use of a national pathology database. 
Furthermore, this study included people with a wide range of ages. This study does, however, 
have some limitations. Owing to the retrospective design of the study, information about 
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hormone use, family history, genetic mutations, benign breast lesions and breast density, 
tobacco and alcohol use, and body mass index is missing or incomplete. Although these 
risk factors for breast cancer should not be underestimated, the most important difference 
between transgender people and cisgender men and women is the use of hormone 
treatment. It would be interesting to study these risk factors in more detail, to investigate 
whether certain factors determine the observed increased risk in trans women. The study 
participants with breast cancer did not necessarily undergo treatment in our centre, and 
thus detailed data about type and outcome of the treatment are lacking in most of the 
cases. Although this would be interesting to study in more detail, it was not the purpose 
of this study. It would be worthwhile for future studies to investigate whether treatment 
outcomes of breast cancer in trans women are comparable to those of cisgender women.
Conclusions
This large nationwide cohort study in the Netherlands showed an increased risk of breast 
cancer in trans women compared with cisgender men. The risk in trans women is still lower 
than in Dutch cisgender women and resembles a more female type of breast cancer and 
hormone receptor status. In trans men, a lower risk compared with Dutch cisgender women 
was observed. Based on this study, we conclude that the absolute overall risk of breast 
cancer in transgender people remains low and therefore it seems sufficient for transgender 
people using hormone treatment to follow screening guidelines as for cisgender people. 
As the risk of breast cancer in trans women increased during a relatively short duration of 
hormone treatment, it would be worthwhile for future studies to investigate in more detail 
the cause of breast cancer in transgender people receiving hormone treatment.
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Background: Increased mortality in transgender people has been described in earlier studies. 
Whether this increased mortality is still present over the last decades is unknown. Therefore, 
we aimed to investigate trends in mortality over five decades in a large cohort of adult 
transgender people in addition to the cause-specific mortality.
Methods: Data of transgender people who received hormone treatment were linked to 
Statistics Netherlands. Standardized mortality ratios (SMRs) were calculated using general 
population mortality rates stratified by age, calendar period, and sex. Furthermore, cause-
specific mortality was calculated.
Findings: 2,927 trans women and 1,641 trans men were included, with a total follow-up 
time of 40,232 and 17,285 person-years, respectively. During follow-up, 317 (10·8%) trans 
women died, which was higher than expected compared with general population men (SMR 
1·8, 95%CI 1·6-2·0) and general population women (SMR 2·8, 95%CI 2·5-3·1). Cause-specific 
mortality was high for cardiovascular disease, lung cancer, HIV-related disease, and suicide. 
In trans men, 44 people (2·7%) died which was higher than expected compared with general 
population women (SMR 1·8, 95%CI 1·3-2·4). Cause-specific death was high for non-natural 
causes of death. No decreasing trend in mortality risk was observed over the five decades 
studied.
Interpretation: This observational study showed an increased mortality risk in transgender 
people using hormone treatment, regardless type of treatment. This increased mortality 
risk did not decrease over time. The cause-specific mortality risk because of lung cancer, 
cardiovascular disease, HIV-related disease, and suicide indicate that monitoring, optimizing, 
and, if necessary, treating medical morbidities remain important in transgender healthcare.




Transgender people experience an incongruence between their sex assigned at birth and their 
gender identity. In 2015, it was estimated that 1:2,800 birth-assigned males and 1:5,200 birth-
assigned females received medical treatment for gender dysphoria in the Netherlands. Over 
the last years, a significant increase in the number of referrals for transgender healthcare, for 
either psychological, endocrine, and/or surgical treatment, is seen1,2
Transgender people can be treated with gender-affirming hormone treatment to induce 
desired physical changes.3 Trans women (male sex assigned at birth, female gender 
identity) are usually treated with antiandrogens and oestrogens to induce feminization. 
To induce masculinization, trans men (female sex assigned at birth, male gender identity) 
are usually treated with testosterone. After one year of hormone treatment, transgender 
people may choose gender-affirming surgery as part of their transition. In trans women, 
this may include orchiectomy with or without vaginoplasty, breast augmentation, and facial 
feminization surgery. In trans men, this may include mastectomy, removal of uterus with or 
without ovaries, and metaidoioplasty or phalloplasty. After orchiectomy in trans women, 
antiandrogen treatment is ceased. 
Hormone treatment in transgender people is thought to be safe.4 However, data about long-
term effects on safety of hormone treatment are scarce leading to insufficient evidence to 
determine (long-term) safety, especially on cancer and hormone sensitive cancer specifically 
as well as cardiovascular disease. Recently, studies showed an increased risk of strokes5,6, 
myocardial infarctions5, and venous thromboembolisms5,6 among trans women who were 
treated with hormone treatment. In trans men using testosterone treatment, an increased 
risk of myocardial infarctions was described.5 Furthermore, it has been suggested that trans 
women using long-term, high dose cyproterone acetate (a progestogenic antiandrogen) have 
a higher risk of meningioma.7 While it is not fully established whether hormone treatment 
increases the risk of cancer in general and hormone sensitive cancer specifically8, a strongly 
increased breast cancer risk in trans women compared with general population men 
(alignment of sex assigned at birth and gender identity) has been observed.9 Nevertheless, 
the observed risk was still lower than the breast cancer risk in general population women. 
The risk of certain diseases may be increased in trans people using hormone treatment.10 
Although a decreasing trend over time was observed, the risk of death by suicide was 
increased in trans people compared with cis people.11 However, it remains unclear whether 
hormone treatment in transgender people influences overall mortality risk and especially 
cancer as well as cardiovascular associated mortality. Several studies have addressed this 
topic in the past12-16, however they were limited because of short follow-up time, a high 
number of missing data, and heterogeneity in study cohorts and control populations. 
Chapter 9
138
Therefore, this study focused on the trends in mortality risk in five decades of transgender 
people receiving hormone treatment using general Dutch mortality rates stratified by age, 
calendar period, and sex as reference.
Subjects and methods
Study population and data collection
All adult transgender people who visited the gender identity clinic of the Amsterdam 
UMC, the Netherlands, were identified. People were included if they had started hormone 
treatment between 1972 and 2018, and were excluded if they used alternating testosterone 
and oestradiol treatment, if they started treatment below 17 years of age, if they ever used 
puberty-blockers (i.e. GnRH-analogues) before gender-affirming hormone treatment, or if 
they were lost to follow-up. People were excluded if there was no data available of at least 
one visit after the start of hormone treatment. After the study cohort was formed, data about 
age at start of hormone treatment, type of hormone treatment, smoking habits (current 
or former smoker vs never smoker), medical history, and the last date of follow-up were 
retrieved from medical files. Subsequently, the data were linked to Statistics Netherlands 
(CBS), a Dutch governmental institution that gathers statistical information about the 
Netherlands and its inhabitants. Data about cause of death were retrieved from CBS and 
were available since 1996. Cause of death was determined from the death certificates which 
are filled out by the medical doctor at time of death. If the cause of death was not known, 
the cause of death is registered on these forms as ‘unknown’. Each deceased person is 
registered with a single death cause (primary cause of death).
The study protocol was assessed by the Ethical Review Board of the Amsterdam UMC, location 
VUmc, Amsterdam. It was determined that the Medical Research Involving Human Subjects 
Act (WMO) does not apply to this study, and necessity for informed consent was waived. 
Gender-affirming hormone treatment regimen
Most trans women were treated with either cyproterone acetate (10 to 100 mg daily) 
or spironolactone (100 to 200 mg daily) as antiandrogen, which was often ceased after 
orchiectomy. Besides antiandrogens, oestrogen was prescribed in the form of ethinyl 
oestradiol (25 to 100 mcg daily), conjugated oestrogens (0.625 to 1.25 mg daily), oestradiol 
patches (50 to 150 mcg/24h twice weekly), implants (20 mg every 3 to 6 months), injections 
(10 to 100 mg every 2 to 4 weeks), valerate (2 to 6 mg daily), or gel (0.75 to 3 mg daily). In 
recent years (from 2001 onwards), oestradiol valerate, patches, or gel were mainly used. 
Trans men were treated with either testosterone gel (20 to 100 mg daily), intramuscular 
testosterone esters (125 to 250 mg every 2 to 3 weeks), or testosterone undecanoate (either 
oral (40 to 160 mg daily) or intramuscular (1000 mg every 10 to 14 weeks)). Some trans men 
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who experienced persistent menstrual blood loss during testosterone therapy were treated 
with additional progestogens such as lynestrenol (5 to 10 mg daily). 
Statistical analysis
All analyses were performed using STATA Statistical Software, version 14.1 (Statacorp, College 
Station, Texas, USA). The data of trans women and trans men were analysed separately. 
Standardized mortality ratios (SMRs) were calculated using an actuarial life table approach 
as described by Dickman et al.17,18 In order to calculate the SMRs, we first calculated age- and 
sex-specific mortality incidence rates in the adult Dutch population. Thereafter, the number 
of expected death cases in the cohort was calculated by multiplying the age- and sex-specific 
incidence rates of the general population by the number of individuals within a specific 
age and sex group. The number of expected cases was calculated twice in trans women 
and trans men; once using the reference numbers of birth-assigned males and once using 
reference numbers of birth-assigned females. Finally, SMRs were calculated by dividing 
the number of observed cases by the expected cases. Data are presented as percentage, 
mean with standard deviation (SD), median with interquartile range (IQR), or SMR with 95% 
confidence intervals (95%CI). Absolute numbers of people who died because of a certain 
cause are only presented if the number exceeds 10 cases to guarantee anonymity of the 
people in the CBS database. 
For analyses, the date of start of hormone treatment at our centre was used. Person-time 
was defined as the number of years from the start date of hormone treatment to the first 
terminating event. Terminating events were either date of death, end of study period 
(December 31, 2018), or last visit at our clinic for the people who could not be linked to CBS 
(e.g. if a person was no longer resident of the Netherlands). When possible, the mortality 
risk was further divided in categories of diseases including cardiovascular disease, infection, 
cancer, and non-natural causes of death (only for deaths between 1996 and 2018). In 
addition, analyses were repeated if possible for different types of hormone treatment 
regimen (including trans women who ever used ethinyl oestradiol). 
For expediency the control populations are referred to as general population men and 
general population women, although we were unable to verify that none of these people 
was transgender.
Results
Between 1972 and 2018, 8,831 people visited our gender identity clinic, of which 5,350 
were birth-assigned males and 3,481 birth-assigned females. After exclusion, the total study 
population consisted of 2,927 trans women and 1,641 trans men (Figure 1). 
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The median age at start of hormone treatment was 30 years (IQR 24 to 42) in trans women 
and 23 years (IQR 20 to 32) in trans men. The median follow-up ti me was 11 years (IQR 4 
to 22) in trans women and 5 years (IQR 2 to 17) in trans men, leading to a total follow-up 
ti me of 40,232 and 17,285 person-years, respecti vely. Table 1 shows the characteristi cs of 
the study populati on. During follow-up, 317 (10·8%)  trans women and 44 (2·7%) trans men 
died, resulti ng in an overall mortality of 478/100,000 person-years.
Figure 1. Study fl owchart.





Age at start of HT, y 30 (24 to 42) 23 (20 to 32)
Ethnicity, % (n) white 90·6+ (1,967) 92·6n (1,307)
Smoking, % (n) ever smokers 43·8^ (815) 44·2i (503)
BMI, kg/m2 23·6$ (±4·3) 25·4ii (±5·7)
Gonadectomy, % (n) yes 64·6 (1,891) 61·3 (1006)
Median oestradiol levels during HT, pmol/L 215a (126 to 345) 119c (81 to 177)
Median testosterone levels during HT, nmol/L 0·9b (0·6 to 1·3) 21·0d (14·0 to 32·0)
Median person-ti me, y 16 (7 to 22) 13 (7 to 24)
Total person-ti me, y 40,232 17,285
Data are presented as mean with standard deviati on, median with inter-quarti le range, percentage or 
number of years. Data available for +2,171 people, ̂ 1,861 people, $1,858 people, a2,253 people, b1,802 
people, n1,411 people, i1,138 people, ii1,209 people, c1,435 people, and d1,427 people of the cohort. 
Abbreviati ons: HT=hormone treatment; BMI=body mass index.
The overall mortality risk in trans women was increased compared with general populati on 
men (SMR 1·8, 95%CI 1·6 to 2·0) and general populati on women (SMR 2·8, 95%CI 2·5 to 3·1). 
As shown in Table 2, mortality risk did not decrease over the studied decades. Trans women 
20
Figure 1. Study flowchart.
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who died during follow-up received hormone treatment for a median of 16 years (IQR 7 to 
22). Cumulati ve mortality shows impaired survival in trans women compared with general 
populati on men and women (Figure 2). Mortality risk in trans women was further divided in 
causes of death as shown in Table 3.
Table 2. Standardized mortality rati os in trans women and trans men over 10-year periods based on 
start year of hormone treatment.





general populati on 
women
N Compared with 





Overall 317 1·8 (1·6 to 2·0) 2·8 (2·5 to 3·1) 44 1·8 (1·3 to 2·4) 1·2 (0·9 to 1·6)
<1980 51 1·7 (1·3 to 2·2) 2·7 (2·0 to 3·5) # 2·3 (0·9 to 4·3) 1·5 (0·6 to 2·9)
1980-1990 125 1·8 (1·5 to 2·1) 2·8 (2·3 to 3·3) 10 1·0 (0·5 to 1·7) 0·7 (0·3 to 1·1)
1990-2000 74 1·7 (1·3 to 2·1) 2·5 (2·0 to 3·1) 15 2·6 (1·5 to 4·1) 1·8 (1·0 to 2·9)
2000-2010 41 1·8 (1·3 to 2·9) 3·2 (2·5 to 4·0) # 2·1 (0·9 to 2·8) 1·5 (0·7 to 2·8)
2010-2018 26 3·7 (2·4 to 5·2) 5·2 (3·4 to 7·4) # 2·4 (0·7 to 5·3) 1·6 (0·4 to 3·4)
Data are presented as standardized mortality rati o (SMR) with 95% confi dence interval. #=N < 10 and 
could therefore not be shared.
Compared with general populati on men, trans women died more frequently because of 
either cardiovascular disease (SMR 1·4, 95%CI 1·0 to 1·8), lung cancer (SMR 2·0, 95%CI 1·4 
to 2·8), infecti on (SMR 5·4, 95%CI 2·9 to 8·7), or non-natural causes of death (SMR 2·7, 
95%CI 1·8 to 3·7). In the infecti on causes of death category, SMR was high for deaths related 
to Human Immunodefi ciency Virus (HIV)-related disease (SMR 14·7, 95%CI 1·8 to 41·9). In 
mortality because of non-natural causes of death, SMR was highest for suicide deaths (SMR 
3·1, 95%CI 1·8 to 4·7). Compared with general populati on women, trans women died more 
frequently because of either cardiovascular disease (SMR 2·5, 95%CI 1·7 to 3·4), lung cancer 
(SMR 3·1, 95%CI 2·1 to 4·2), infecti on (SMR 8·8, 95%CI 4·7 to 14·1), or non-natural causes 
of death (SMR 6·1, 95%CI 4·2 to 8·4). In the cardiovascular disease category, risk of death 
because of myocardial infarcti on (SMR 3·0, 95%CI 1·7 to 4·5) showed the largest SMR. HIV-
related disease (SMR 47·6, 95%CI 5·8 to 132·6) and suicide (SMR 6·8, 95%CI 4·1 to 10·3) 
showed the largest SMRs in the infecti on and non-natural causes category, respecti vely. 
Restricted analyses only to trans women who ever used ethinyl oestradiol (n=717) similar 
results were found (SMR 1·8, 95%CI 1·5 to 2·1 compared with general populati on men and 
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In trans men, the overall mortality risk was comparable with general population men (SMR 
1·2, 95%CI 0·9 to 1·6) and increased compared with general population women (SMR 1·8, 
95%CI 1·3 to 2·4). The increased overall mortality risk compared with general population 
women was mainly because of increased mortality risk in people who started hormone 
treatment between 1990 and 2000 (Table 2). Trans men who died during follow-up received 
hormone treatment for a median 13 years (IQR 7 to 24). Figure 2 shows impaired overall 
survival in trans men compared with general population men and women. In Table 3, the 
cause-specific mortality risk for trans men compared with general population men and 
general population women is shown. Trans men had higher risk of death from non-natural 
causes (SMR 3·2, 95%CI 1·2 to 6·4) compared with general population women. No increased 
risk compared with general population men was observed. 
No analyses could be performed on different types of hormone treatment in both trans 
women and trans men, because treatment was often changed over the follow-up period, 




Figure 2. Cumulative survival in trans women and trans men during follow-up.
Abbreviations: SMR=standardized mortality ratio; N=number
Discussion
This study showed an approximately two-fold increase in mortality risk in transgender 
people compared with people from the general population. This risk did not decrease over 
the five decades studied. Increased mortality in trans women showed high risks of death 
because of cardiovascular disease, HIV-related disease, lung cancer, and suicide. In trans 
men, the observed increased mortality compared with general population women showed 
a high mortality risk because of non-natural causes of death. 
The overall mortality in transgender people in the current study was 478/100,000 person-
years which is slightly increased12,14 or lower15 compared with earlier studies in the 
transgender population. In accordance with previous studies, we observed an increased 
mortality due to HIV-related disease and suicide in trans women.12-15,19 Interestingly, most 
of the deaths because of HIV-related disease in this study occurred in the first decades 
 
 Trans women   Trans men 
 SMR (general population men): 1·8 (1·6 - 2·0) 
SMR (general population women): 2·8 (2·5 - 3·1) 
  SMR (general population women): 1·8 (1·3 - 2·4) 
SMR (general population men): 1·2 (0·9 - 1·6) 
Follow up 0 10 20 30   0 10 20 30 
N at risk 2927 1569 915 387   1641 615 363 169 
Events 104 86 75 52   15 13 12 4 
Censored 1254 568 453 353   1011 239 182 165 
 
Figure 2. Cumulative survival in trans women and trans men during follow-up. 
Abbreviations: SMR=standardized mortality ratio; N=number 
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studied, indicating an effect of the improved HIV treatment over recent years. Moreover, 
we observed that most suicide cases occurred in the first decades studied as well. This 
may be due to increased awareness among health care providers regarding suicide risk 
in transgender people and improved suicide prevention strategies. Furthermore, it is 
possible that a reduction of psychological distress among transgender individuals because 
of improvement of social acceptance may have contributed to the decreased number of 
suicides over the last years as well as the increased availability and accessibility of medical 
treatment. 
In accordance with earlier studies performed12, an increased risk of cardiovascular related 
death in trans women was observed in this study. This increased risk was particularly observed 
compared with general population women. This observed increased risk may be associated 
with metabolic changes such as an change in serum lipids, blood pressure, glucose/insulin 
metabolism, and changes in body composition as described earlier.20,21 Another explanation 
may be lifestyle factors and increased psychological distress because of minority stress and 
the marginalized position they sometimes have in society.22,23 Although social acceptance 
of transgender people in society is improved over the last years, acceptance was impaired 
when the people in the first cohorts of this study started their treatment. This may have 
contributed to the observed increased risk. Furthermore, the lack of acceptance of 
transgender people in society during that time may have led to a more withdrawn life from 
society with increased risk of substances use (such as nicotine), and obesity. Also, in that 
time, transgender people may have felt a barrier to visit a doctor when they experienced 
health complaints24, which could have led to delayed diagnosis and impaired cardiovascular 
risk management. This may not only have contributed to the increased cardiovascular 
mortality risk, but also to the increased mortality from lung cancer. There are studies that 
suggest a higher incidence of smoking among transgender people compared with cisgender 
people25, although there are studies that show the contrary as well.26,27 In the present 
study, we were able to distinguish (former) smokers from never smokers, which with 
44% (former) smokers in trans women and trans men was not increased compared with 
the general Dutch population (56% (former) smokers in general population men, 48% in 
general population women).28 Besides, it is important to keep in mind that the transgender 
population is a very diverse group, not only regarding type of hormone treatment but also 
regarding non-hormone-related risk factors such as smoking and alcohol use and the use of 
co-medication.4,29,30 As we were not able to study these differences in the present study, it 
would be interesting for future studies to examine and compare mortality risk in subgroups 
of transgender people to be able to formulate specific prevention recommendations.
Surprisingly, an even higher mortality risk was observed in people who started treatment 
in the past 10-20 years. This difference in mortality risk between different decades may 
be because of differences in comorbidity and lifestyle factors between people who started 
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treatment in earlier years (1970-1990) and more recently (2000-2018). In the past, health 
care providers at our centre were reluctant to provide medical treatment to people with for 
instance a known history of cardiovascular disease or hormone sensitive cancer. Nowadays, 
comorbidities rarely result in a complete denial or withdrawal of hormone treatment. Because 
of the change in clinical practice over time, the people in this cohort who started hormone 
treatment in the early years probably had a better overall health and less comorbidity than 
the people who started hormone treatment more recently. This may be an explanation for 
the higher SMR in people who started treatment in the last decades. Although mortality risk 
was increased in this cohort, this risk does not seem to be caused by hormone treatment 
itself as increased mortality showed highest risks for non-hormone related causes of death 
(such as suicide, lung cancer, and HIV-related disease). Nonetheless, monitoring, optimizing, 
and, if necessary, treating comorbidity, such as cardiovascular disease, tobacco use, and HIV, 
remain important in transgender healthcare.
This large, nationwide cohort study consisting of people in a wide age range and with a long 
follow-up time, provides new insight in the trends in mortality risk in transgender people 
which is useful for clinical practice. However, this study has some limitations as well. First, 
this is a retrospective study, and although the occurrence and causes of death were well 
documented, information about treatment regimen, comorbidity, lifestyle, and other risk 
factors were retrieved from medical files and are therefore incomplete. These lifestyle 
and other factors may contribute to an increased morbidity and mortality risk in general. 
We also cannot rule out an effect of other parts of gender-affirming treatment, such as 
psychological help and surgery. Second, due to the used method to study mortality in this 
cohort, no information about morbidity was available. Although this was not the aim of this 
study, it would be interesting to study morbidity in transgender people receiving hormone 
treatment as well. Third, in trans men, the number of observed deaths was relatively small. 
Therefore, it was more difficult to perform subgroup analyses on cause-specific deaths. 
Fourth, although the included people in this cohort had a wide age rage, the population 
was overall relatively young. Fifth, we were not able to analyse data on trans youth in this 
study as the trans youth population in our cohort is a very diverse group in which people 
started treatment at different ages and stages of puberty. Moreover, trans youth included 
in this cohort have been exposed to different duration of puberty blockers before the start 
of gender-affirming hormones. Therefore, very small sub-groups will occur. Because of a lot 
of missing data, we were not able to analyse this subgroup at the moment. Last, the results 
of this study may not apply to people in other global regions, as only people who received 
treatment in the Netherlands were included. Differences in access to healthcare but also in 
for instance BMI ranges might differ globally, and therefore these data should be interpreted 
with caution in other regions.
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In conclusion, a two-fold increased mortality risk in transgender people was observed. 
This increased mortality risk did not decrease over time. Increased mortality in this cohort 
showed highest cause-specific risks for death because of cardiovascular disease including 
myocardial infarction, HIV-related disease, lung cancer, and non-natural causes of death 
including suicide. Most of these factors are non-hormone related. In the coming years, it 
remains important to improve the knowledge of health care providers about the hormone 
treatment of transgender people. Moreover, increasing social acceptance and treatment of 
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Summary and general discussion
In this thesis we aimed to study different aspects of breast development and breast pathology 
in transgender people. This chapter summarizes the main findings of the performed studies 
and discusses the results, methodological issues, clinical implications, and perspectives for 
future research.
Summary of main findings
Breast development in trans women
In Chapter 3, modest breast development, measured with a tape measure, was observed 
after one year of hormone treatment. Breast development seemed to primarily take place 
in the first six months of treatment after which the development curve flattened. The mean 
breast – chest difference after one year of treatment translated in a bra cup-size of less 
than an AAA-cup in most trans women. Contrary to our hypothesis, we could not identify 
clinical or laboratory determinants, such as age, body mass index (BMI), serum estradiol 
concentrations, and estrogen administration route, that were associated with total breast 
size after the first year of hormone treatment.
In Chapter 4, breast development during the first three years of hormone treatment was 
studied using 3D imaging. This study showed that volumetric breast development continued 
after the first year of hormone treatment, although the breast – chest difference curve 
flattened prematurely in the first year of hormone treatment. After three years of hormone 
treatment, most trans women had a breast volume of 100 cc, which translates to a bra cup-
size between an AA-cup and an A-cup. Again, no clinical or laboratory parameters could be 
identified associated with breast development. Besides breast volume measurements, 3D 
imaging allowed for precise breast anthropomorphic measurements. These measurements 
showed a more lateral and caudal position of the breasts on the chest of trans women 
compared with cis women.
Satisfaction
Unlike our expectations, most participants in the study on breast development (Chapter 
4) were satisfied with their gained breast size after three years of treatment. They also 
were satisfied with the symmetry and shape of their breasts and the size and shape of their 
nipples. However, 13% of the trans women included in this study already underwent breast 




In Chapter 5, we studied the frequency, determinants, and satisfaction of breast 
augmentation in trans women receiving hormone treatment. This study showed that four 
out of five trans women either chose or (ever) considered breast augmentation as part of 
their gender-affirming treatment. Most trans women who underwent breast augmentation 
chose to do so because their breast development was perceived as being insufficient. The 
majority of trans women who underwent a breast augmentation was satisfied with the 
result. Trans women who have not undergone breast augmentation, chose not to because 
of financial limitations, satisfaction with the gained breast development, preferring to await 
further breast development, or because of fear of complications.
Benign and malignant breast disease
As glandular breast tissue develops during hormone treatment in trans women, breast 
lesions may also occur. In Chapter 6, we described breast lesions observed in trans women. 
We observed a benign versus malignant breast disease ratio of 88:12, which is comparable 
to the ratio in cis women unlike our hypothesis. After the start of hormone treatment, 
mostly lobular pathology was observed, whereas before the start of hormone treatment the 
most common observed lesion was gynecomastia. Although several silicone breast implant 
related lesions were observed, the observed lesions were all benign.
In Chapter 7, an overview of the existing literature on (breast) cancer is provided and 
showed no increased cancer risk in transgender people. However, reliable epidemiologic 
data are sparse.
In Chapter 8, we studied breast cancer risk after long-term hormone treatment in a well-
defined documented cohort of transgender people. Contrary to our expectations, this study 
showed an increase of breast cancer risk in trans women compared with cis men. However, 
the risk remained lower than in cis women. An interesting observation though, was that the 
trans women with breast cancer developed cancer relatively short after the start of hormone 
treatment. In trans men, breast cancer risk also was in- between the risks observed in cis 
men and cis women.
Mortality risk
In Chapter 9, we observed no increased risk of (breast) cancer related death, as expected. 
However, the overall mortality was still two-times higher in trans people compared with 
cis people. This increased mortality risk did not decrease over time. The cause-specific 
mortality risk because of lung cancer, cardiovascular disease, HIV-related disease, and 
suicide indicate that monitoring, optimizing, and, if necessary, treating medical morbidities 
remain important in transgender healthcare.




Breast development in trans women
In the Endocrine Society Guidelines for transgender healthcare, it is estimated that breast 
development starts two to three months after the start of hormone treatment. The 
estimated time before maximum effect is reached is two to three years.1,2 The studies on 
breast development in this thesis showed indeed that breast development starts relatively 
soon after the initiation of hormone treatment. In the one-year follow-up study, the breast 
development curve seemed to flatten after six months of treatment, whereas the curve 
flattened after nine months of treatment in the three-year follow-up study. In the three-
year follow-up study, it was also observed that the breast-chest difference curve flattened 
prematurely compared with the breast volume curve. This indicates that the modality in 
which breast development is studied may affect the measurement of the observed breast 
development. To date, several measurement methods in gender-affirming hormone 
treatment induced breast development research have been used, including breast (hemi-)
circumference measurements, Tanner stages, and imaging methods such as ultrasound 
or magnetic resonance imaging (MRI).3-6 The usage of all these different measurement 
methods makes comparison challenging. Nonetheless, all studies showed modest breast 
development during hormone treatment.
To date, the longest follow-up time in this field of research is three years. During follow-up, all 
studies showed some kind of flattening curve in extend of breast development.3,4 Therefore, 
it is unknown if breast development continues after three years of hormone treatment. 
However, several studies, including the three-year follow-up study described in this thesis, 
suggest that breast development may take longer than the estimated two to three years in 
the Endocrine Society Guidelines.1-3 Based on knowledge about breast development during 
typical cis female puberty, it may be expected that breast development in trans women also 
takes longer than three years.7-9 Therefore, studies with longer follow-up are necessary to 
determine the time that is needed to evaluate maximum effect of hormone treatment on 
breast development.
In the breast development studies described in this thesis, we were unable to identify clinical 
or laboratory parameters that were associated with the extend of breast development during 
follow-up. Parameters that have been studied include serum sex-hormone concentrations, 
weight changes, age, estradiol treatment regimen (oral vs transdermal), tobacco use, and 
BMI. Although these parameters could not explain the extent of breast development, there 
were differences in observed size between trans women. Maybe this observed difference is 
just an observation of normal variance, as breast size in cis women differs which might be 
explained by genetic variation.10-12 However, the observed mean breast size in trans women 
in this thesis was modest. A possible explanation for the observed small breast sizes may 
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be that the breast tissue is negatively influenced by testosterone during male puberty7,13-15, 
which all participants in our studies experienced.
Comparing breast development studies in adults with studies in adolescents who are 
treated with puberty suppression before hormone treatment, could teach us something 
about the influence of testosterone on breast tissue and the susceptibility for the breasts 
to development. Several studies in adolescents reported on breast development (in Tanner 
stages) with antiandrogen treatment or puberty suppression only.16,17 These studies 
showed already some breast Tanner stage increase in trans girls who only received puberty 
suppression in the form of either cyproterone acetate or bicalutamide.16,17 As these studies 
do only report on Tanner stages and not on breast size, it is unknown whether there are 
differences in hormone treatment induced breast sizes between adolescent and adult trans 
women. Therefore, it would be worthwhile for future studies to study breast development 
and size in trans girls receiving puberty suppression before the start of hormone treatment. 
Moreover, no data are available on the position of the breasts on the chest of trans girls. In 
the 3D imaging study described in this thesis, we observed a more caudal and lateral position 
of the breast on the chest of trans women who went through typical male puberty before 
the start of hormone treatment compared with cis women. We think that this difference 
might be explained by the (sex- hormone induced) different anatomic makeup of the chest 
between cis males and cis females.18-20 Therefore, it is expected that the position of the 
breasts in trans girls would be more comparable with the position in cis women. As no data 
is available on the position of the breasts in trans girls, it is interesting to incorporate this in 
future studies as well.
Satisfaction
Studies on satisfaction of trans women with their gained hormone induced breast 
development were lacking. The studies on satisfaction in trans women that are published, 
present data on satisfaction with breast augmentation procedures, which show satisfaction 
with the result.19,20 In the study on breast augmentation described in this thesis, we also 
observed that most trans women were satisfied with their breast implants. However, 
some trans women reported dissatisfaction because the breasts are (still) too small, too 
big, because of esthetical reasons, or they experienced complications or health complaints 
they attributed to their breast implants. Derivative markers for satisfaction may be body 
image and self-esteem. Van der Grift et al.21 showed that body satisfaction increased after 
hormone treatment. Trans women who also underwent breast augmentation had higher 
scores on body satisfaction than trans women who did not undergo breast augmentation.21 
This may imply that breast size is important for body satisfaction in trans women.
In the three-year follow-up study described in this thesis, we also incorporated satisfaction 
and self- esteem questionnaires. This study showed increase in self-esteem during follow-up 
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in six of the 14 people with low self-esteem at baseline. Moreover, most trans women in this 
study were satisfied with their breast size, shape, and symmetry as well as with the size and 
shape of their nipples.
Interestingly, satisfaction and breast volumes were not correlated, indicating that 
satisfaction is not only determined by breast size. The results of this study indicate the need 
for an open conversation between trans women and their healthcare providers about breast 
development expectations, observed changes, and experienced changes.
Benign and malignant breast disease
As described earlier, breasts of trans women using hormone treatment were histologically 
comparable with cis women.22 Therefore, we were not surprised to observe several cases of 
fibroadenomas and cysts in trans women after the start of hormone treatment. While we 
mostly observed gynecomastia in breast biopsies before the start of hormone treatment, 
also some fibroadenomas and cysts were observed in trans women before the start of 
hormone treatment. Although lobular pathology rarely occurs in the anatomic cis male 
breast23, it already has been described in literature.24
Based on previous research, it was thought that breast cancer risk in transgender people 
was comparable with the risk in cis men.25-27 Although the breast cancer risk observed in our 
study was still lower than observed in cis women, we observed an increased risk compared 
with cis men. Moreover, we observed breast cancer at a relatively young age in trans women. 
At the time of breast cancer diagnosis, trans women have only been exposed to female 
sex-hormones for an average of 18 years, which is a shorter period than cis women before 
they are on average diagnosed with breast cancer. Why trans women are diagnosed after 
a relative short duration of hormone treatment is unknown. Maybe genetic susceptibility 
could be an explanation, but information on genetics was not available for most individuals. 
Therefore, it would be worthwhile for future studies to investigate breast cancer histology 
(e.g. receptor status, mutational status) in trans women in more detail. Although breast 
cancer occurred at a relatively young age in trans women, the overall incidence was still 
lower than in cis women. Moreover, it is reassuring that the benign versus malignant breast 
disease ratio is comparable in trans women compared with cis women.28 Therefore, we do 
not advise intensified breast cancer screening in trans women but advise trans women to 
participate in general population based breast cancer screening programs.
In trans men, it was interesting that breast cancer also occurred (years) after mastectomy. 
Although most breast glandular tissue is removed during subcutaneous mastectomy, some 
tissue remains to be able to gain an esthetical masculine thorax. Despite that the remaining 
tissue will mostly become atrophic due to testosterone treatment15, breast cancer may 
develop (later in life). Although breast cancer risk decreases after mastectomy, trans men 
still have an increased breast cancer risk compared with cis men. It is important to discuss 
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this with trans men, as our experience in clinical practice shows that most trans men are 
unaware of this risk.
Mortality risk
In literature, studies on mortality in transgender people focused on overall mortality 
or cardiovascular related mortality as transgender people have an increased risk of 
cardiovascular disease.29-32 Cancer related mortality is more difficult to study, as some organs 
in which hormone sensitive cancer may develop are either not present (e.g. prostate in trans 
men) or removed during surgery (e.g. ovaries in trans men and testes in trans women). In 
the Netherlands, it was mandatory to have the gonads removed before one could change 
his or her legal sex until 2014. Therefore, long-term effects of hormone treatment on gonads 
are unknown.
Breast tissue is present in both trans women and trans men. Many trans men do chose 
mastectomy as part of their gender-affirming treatment, but even after mastectomy there 
is still some breast tissue remaining. This theoretically makes it possible to study (long-
term) breast cancer related outcome in transgender people. However, breast cancer risk 
in both trans women and trans men in earlier performed studies was low and was thought 
to be comparable with cis men.25-27 Moreover, no studies have been performed on breast 
cancer treatment outcome in transgender people. Therefore, breast cancer mortality is 
the only derivative marker for long-term breast cancer outcome. Since no to a few breast 
cancer cases were observed in these studies, breast cancer specific mortality was difficult to 
study.30-32 Overall cancer mortality did not seem to be increased compared with cisgender 
populations30-32, which is in line with the results of the mortality study described in this thesis. 
However, most of these studies29,30,32 did show an increased mortality risk in transgender 
people compared with their cisgender counterparts. This risk was mainly increased 
because of increased rates of suicides in transgender people. Also, increased mortality 
risk because of Human Immunodeficiency Virus (HIV)-related disease, cardiovascular 
disease, drug abuse, infections and parasitic disease, diseases of the digestive system, and 
unknown causes of death was observed. In the mortality study described in this thesis, 
we also observed an increased mortality risk in transgender people compared with general 
numbers. An explanation for the increased observed mortality risk may be lifestyle factors 
(e.g. smoking increases the risk of cardiovascular disease and related mortality). However, 
information on these factors were incomplete or missing in the described study. There are 
studies that suggest a higher incidence of smoking among transgender people compared 
with cisgender people33, although there are studies that show the contrary as well.34,35 In 
the mortality study described in this thesis, we were able to distinguish (former) smokers 
from never smokers, which with 44% (former) smokers in trans women and trans men was 
not increased compared with the general Dutch population (56% (former) smokers in cis 
men, 48% in cis women).36 Besides, it is important to keep in mind that the transgender 
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population is a very diverse group, not only regarding hormone treatment but also regarding 
non-hormone-related risk factors such as smoking and alcohol use.37-39 Therefore, it would 
be interesting for future studies to examine and compare mortality risk in subgroups of 
transgender people to be able to formulate specific prevention recommendations and to 
study the effect of lifestyle differences on mortality risk.
Methodological issues
Strengths
The strengths of the studies described in this thesis include the large sample in most studies 
with a long follow-up time and a wide range of age of the included people. Furthermore, 
we experienced few missing data in the prospective cohort studies. To optimize our data 
we included data from multiple centers and linked our cohort to the the Nationwide 
Network and Registry of Histopathology and Cytopathology in the Netherlands (PALGA)40 
and Statistics Netherlands (CBS). Lastly, we incorporated satisfaction questionnaires in some 
studies described in this thesis.
Limitations
However, the studies described in this thesis have some limitations as well. First, in the 
retrospective studies data about intoxications, other medication use, or other diagnoses 
could be missing or incomplete because of the retrospective design. Furthermore, in the 
study on breast augmentation procedures, clinical data could not be linked because the 
questionnaires were returned anonymously. Second, we did not standardize breathing in 
the breast development studies, which could have influenced the measured breast – chest 
differences or volumes. However, as respiration was not standardized, some values will be 
overestimated and some underestimated probably resulting in an overall reliable mean. 
Third, the treatment outcomes of for instance breast cancer were unknown, as treatment 
was provided in different hospitals in the country. Although this would have been very 
valuable information, studying breast cancer treatment outcome was no aim of this thesis. 
Last, in some studies we used self-reported data or non-validated questionnaires, which 
makes it hard to draw definitive conclusions on health complaints or satisfaction. Although 
this is a limitation of these studies, we believe that we gained valuable data from these self-
reported outcomes and the non-validated questionnaire, as these outcomes have never 




Breast development in trans women was observed during the first three years of hormone 
treatment in our studies. However, it may even take longer than that, similar to cis female 
puberty. The Endocrine Society Guidelines currently state that breast development may take 
two to three years after the start of hormone treatment. Based on the breast development 
studies in this thesis, it advisable to prepare trans women who start hormone treatment 
that it may take longer than this estimation. Especially, since breast development and breast 
size are important topics for trans women.41 Moreover, it is important to discuss the fact 
that breasts are different in every person. Not only breast size differs between people, also 
shape and position of the breast on the chest may differ. In clinical practice, we observe that 
many trans women are not aware of these differences. During breast development, breast 
size and shape change almost constantly. It is important to discuss these normal fluctuations 
during development to manage trans women’s expectations on hormone treatment results.
The notion that breast size is an important topic for (most) trans women, is also reflected 
by the high number of trans women who chose or (ever) considered breast augmentation. 
A frequently mentioned reason no (yet) to choose breast augmentation was financial 
limitations as this procedure is not covered by insurance in the Netherlands. Since 2019, 
there is a subsidy provided by the Dutch government for trans women to (partially) pay 
for breast augmentation. The subsidy provides a one- time payment, which trans women 
can use to pay for planned breast augmentation surgery. As this subsidy consists of a one-
time payment, eventual future procedures need to be paid by the trans woman herself. A 
reasons for re-operation may be capsular contracture, which occurs commonly in people 
with breast implants.42 Other reasons for re-operation include breast implant rupture or 
leakage. Moreover, some people with silicone breasts implants experience systemic health 
complaints which they attribute to their breast implants.43 These potential problems arising 
from breast augmentation surgery should be taken into account when the subsidy program 
is evaluated.
One can also discuss the timing of eventual breast augmentation procedures in gender-
affirming treatment. Currently, trans women may apply for the Dutch government subsidy 
if they use hormone treatment for at least one year. Based on the breast development 
studies in this thesis, one may argue that this may be too early. Even more as some trans 
women commented on how their breasts grew even (years) after breast augmentation in 
the breast augmentation study described in this thesis. Sometimes this extended growth 
resulted in larger breasts than wanted which eventually could be a reason to remove the 
breast implants. Based on the results of the studies described in this thesis, we advise to 
discuss the benefits and possible side-effects of breast augmentation explicitly before breast 
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augmentation takes place, as many people are not aware of some unwanted (side-)effects 
and often do not have the financial resources to pay for eventual extra surgeries themselves.
Based on the studies on breast pathology in transgender people, we advise to follow cis 
women breast care guidelines for trans women as well. Also, all trans people with breast 
tissue are advised to participate in breast cancer screening programs as for cis women. In 
the Netherlands, all people who are registered as ‘female’ will automatically receive an 
invite for breast cancer screening from the age of 50 years. Individuals with breast tissue 
who are registered as ‘male’ (e.g. trans women without legal sex change, or trans men who 
did not undergo mastectomy (yet)) will not be automatically invited. Therefore, we call on 
healthcare providers to discuss the advice for participation in breast cancer screening with 
transgender people and make sure they are aware of the opportunity to participate.
Future research
For future research, it would be worthwhile to increase follow-up time on breast development 
studies even further, to gain insight in the time after which maximum breast development 
after the start of hormone treatment is reached. Furthermore, breast development studies 
in adolescents should be performed to examine the effect of anatomical changes during 
typical cis male puberty on mammary tissue, mammary position, and eventually breast 
development. Also, different hormone treatment regimens should be incorporated in new 
studies, as we see an increasing group of gender variant people with partial treatment 
wishes. As we were not able to identify clinical or laboratory parameters that were 
associated with breast development in this thesis, it would be worthwhile to investigate this 
further and also include estradiol metabolites (e.g. estrone) and the role of progesterone. 
Even more because there is debate on the role of progesterone in breast development. 
Based on the role of progesterone on breast development during typical cis female puberty, 
it is expected that progesterone might have a role on breast development in trans women 
as well. However, no (large) studies on the addition of progesterone in gender-affirming 
hormone treatment have been performed. In breast cancer research, future studies may 
focus on histologic characteristics of the tumors (hormone receptor status), and genetic 
susceptibility as explanation of the short time between start of hormone treatment and 
breast cancer diagnosis in our study. Such more basic/translational studies may not only be 
of use for breast cancer research, but can also teach us something about the receptors in 
mammary tissue in transgender people. It would also be worthwhile to incorporate cancer 
treatment outcome (survival) in future breast cancer studies in transgender people, to help 




This thesis showed modest breast development during hormone treatment in trans women, 
which on average resulted in a bra cup size of less than an A-cup. We were not able to 
identify any clinical or laboratory determinants that were associated with the extent of 
breast development. Interestingly, most trans women were satisfied with their breast 
shape, size, and symmetry, independent of measured breast volume. Although we observed 
high breast development satisfaction rates, four out of five trans women either chose or 
considered breast augmentation as part of their gender-affirming treatment. As expected, 
benign lobular pathology was observed after the start of hormone treatment in trans 
women. Besides benign lesions, also breast cancer cases were observed. The benign versus 
malignant breast lesion ratio in trans women was comparable with the ratio in cis women. 
Breast cancer risk in both trans women and trans men was in-between the risks observed 
in cis men and cis women. Despite this changed breast cancer risk compared with the risk 
before the start of hormone treatment, no increased breast cancer-related mortality was 
observed.
So, while hormone treatment seems safe regarding breast cancer development and breast 
cancer related mortality, objective breast development with the current hormone treatment 
regimens seems limited. The objective measured breast size may be interpreted as (very) 
limited, resulting in the assumption that most trans women would be dissatisfied with their 
gained breast development. However, we observed that most trans women participating in 
our studies were satisfied with their breasts, irrespective of breast size. This shows that it 
is important to openly discuss expectations, objectively observed changes, and subjectively 
experienced changes following hormone treatment. Furthermore, eventual wish, timing, 
and finances for breast augmentation should also be discussed. So, as the title of this thesis 
says: let’s talk about breasts!
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Voor niet-ingewijden
Inleiding
In de Westerse cultuur worden borsten als een belangrijk symbool van vrouwelijkheid gezien. 
Daardoor zijn borsten een belangrijk onderwerp voor veel transvrouwen. Als je naar de titel 
van dit proefschrift kijkt, dan denk je misschien al snel aan borstkanker, borstprothesen 
of seks. Echter, borsten zijn interessante organen die zowel mannen als vrouwen hebben. 
Borsten kunnen ook verschillende (gezondheids)problemen veroorzaken, zowel lichamelijk 
als psychisch. Daarom willen wij met dit proefschrift de kennis vergroten over factoren die 
borstgroei en de tevredenheid met borstgrootte beïnvloeden. Daarnaast onderzoeken wij 
mogelijke gezondheidsproblemen van zowel borstweefsel als borstprothesen. De studies 
die beschreven staan in dit proefschrift richten zich op borstzorg bij transgender personen 
vanuit het perspectief van de interne geneeskunde. Deze kennis kan bijdragen aan het 
voeren van een open gesprek over borsten op de polikliniek en draagt mogelijk bij aan de 
manier waarop er in het algemeen naar borsten wordt gekeken. Dus, let’s talk about breasts!
Transgender personen
Transgender personen ervaren een verschil tussen het geslacht dat is toegewezen bij de 
geboorte en hoe zij zich van binnen voelen (genderidentiteit). Mensen bij wie het geslacht 
dat is toegewezen bij de geboorte overeenkomt met hun genderidentiteit worden cisgender 
personen genoemd.
Transgender personen kunnen een medische behandeling ondergaan om het lichaam 
aan te passen aan hun genderidentiteit. Deze medische behandeling kan bestaan uit 
hormoonbehandeling en operaties.
Transvrouwen zijn personen die het geslacht ‘man’ hebben toegewezen gekregen bij de 
geboorte, maar die zich identificeren als vrouw. De hormoonbehandeling die transvrouwen 
kunnen ondergaan bestaat uit een combinatie van anti-mannelijke hormonen (anti-
testosteron of anti-androgenen genoemd) en vrouwelijke hormonen (oestrogenen). Deze 
combinatiebehandeling zorgt voor veranderingen van het lichaam, zoals het zachter 
worden van de huid, afname van haargroei op het lichaam, een vrouwelijke vetverdeling 
en borstgroei. Nadat transvrouwen minimaal één jaar hormoonbehandeling hebben gehad, 
kunnen zij (indien gewenst) operaties ondergaan. Deze operaties kunnen bestaan uit een 
vaginaplastiek (waarbij de penis en zaadballen worden verwijderd en er een vagina en 
schaamlippen worden gecreëerd), verkleinen van de adamsappel, een gezichtsoperatie, 
borstvergroting, of stemoperatie. Alle behandelingen en operaties, behalve een 
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borstvergroting, worden momenteel (soms onder bepaalde voorwaarden) vergoed door de 
zorgverzekering.
Transmannen zijn personen die het geslacht ‘vrouw’ hebben toegewezen gekregen bij 
de geboorte, maar die zich identificeren als man. Hormoonbehandeling bij transmannen 
bestaat uit het gebruik van mannelijke hormonen (testosteron). Door de behandeling 
met testosteron ontwikkelt het lichaam meer mannelijke kenmerken zoals onder andere 
baardgroei, een mannelijke vetverdeling, een lagere stem en meer spierkracht. Ook 
transmannen kunnen naast de hormoonbehandeling operaties ondergaan. Deze operaties 
kunnen bestaan uit een borstverwijderende operatie, het verwijderen van de baarmoeder 
en eierstokken, het verwijderen van de vagina en een operatie waarbij er een penis wordt 
gecreëerd. Alle behandelingen worden (soms onder bepaalde voorwaarden) vergoed door 
de zorgverzekering.
Zoals beschreven ontstaat er borstgroei bij transvrouwen die hormoonbehandeling krijgen. 
Bij transmannen kan er juist een (kleine) afname van het borstweefsel ontstaan. Om de 
veranderingen in het borstweefsel door hormoonbehandeling te kunnen begrijpen, zal er 
eerst wat meer uitleg gegeven worden over de ontwikkeling van borstweefsel tijdens de 
puberteit bij cisvrouwen en cismannen.
Borstweefsel
Tijdens de ontwikkeling in de baarmoeder vindt de eerste aanleg van het borstweefsel 
plaats. De ontwikkeling van dit vroege borstweefsel is tot aan de puberteit hetzelfde bij alle 
kinderen, onafhankelijk van het geslacht. Tijdens de puberteit ontstaan er veranderingen 
in het borstweefsel onder invloed van geslachtshormonen (oestrogenen en testosteron). 
Bij cismeisjes gaat het borstweefsel verder groeien en ontwikkelen onder invloed van 
vrouwelijke hormonen. Er vormt zich borstklierweefsel met melkklieren en melkgangen. 
De borsten groeien en ontwikkelen afwisselend tijdens de menstruele cyclus. Hierbij 
ontwikkelt het borstweefsel telkens verder tot ongeveer 18-20 jarige leeftijd. Behalve het 
borstklierweefsel ontwikkelen de tepel en het tepelhof ook verder tijdens de vrouwelijke 
puberteit. Naast borstklierweefsel bestaat de vrouwelijke borst voor een groot deel uit 
vetweefsel. Dit opgeslagen vetweefsel bepaalt voor het grootste deel de grootte van de 
borst (het borstvolume). De vorm en grootte van borsten tussen vrouwen onderling verschilt 
sterk en wordt waarschijnlijk bepaald door genetische aanleg.
In het borstklierweefsel kunnen ook afwijkingen ontstaan, zowel goedaardig als kwaadaardig. 
Een veelvoorkomend goedaardig knobbeltje in de borst wordt fibroadenoom genoemd. 
Andere voorkomende goedaardige afwijkingen zijn bijvoorbeeld cysten, ontstekingen of 
vetbultjes. In de melkklieren en melkgangen kunnen ook kwaadaardige afwijkingen ontstaan 
welke tot borstkanker kunnen leiden.
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Bij cisjongens stopt de borstontwikkeling tijdens de puberteit door invloeden van mannelijke 
hormonen. Sommige cisjongens ervaren toch een soort borstgroei in het begin van de 
puberteit. Deze ‘borstgroei’ wordt gynaecomastie genoemd. Dit komt door een tijdelijke 
verstoorde balans tussen mannelijke en vrouwelijke geslachtshormonen in het lichaam, 
waarbij er relatief meer vrouwelijke hormonen zijn. Deze verstoorde balans is tijdelijk, 
waarna de gynaecomastie vaak vanzelf weer verdwijnt.
Doordat cisjongens bijna geen melkklieren en melkgangen in hun borstweefsel hebben, 
worden er bij hen zelden afwijkingen in de borst gezien. Afwijkingen die wel eens voorkomen 
in de borst bij cisjongens zijn bijvoorbeeld ontstekingen en vetbultjes. Ook zijn er cismannen 
die borstkanker hebben, maar dit is zeldzaam.
Behalve invloed op het borstklierweefsel, hebben geslachtshormonen ook invloed op 
andere lichamelijke veranderingen in de puberteit. Zo wordt de borstkas van cisjongens 
bijvoorbeeld breder en krijgen zij bredere schouders. Doordat de borstkas breder is, staan 
de tepels van cisjongens ook verder naar de zijkant op de borstkas dan bij cismeisjes. Verder 
is het bovenlijf bij cisjongens (vaak) langer dan bij cismeisjes, waardoor de tepels ook lager 
op de borstkas lijken te zitten.
Doelen van dit proefschrift
Dit proefschrift had verschillende doelen. Het eerste doel was om borstontwikkeling bij 
transvrouwen gedurende de hormoonbehandeling te onderzoeken. Daarbij is onderzocht 
of er factoren waren, zoals leeftijd, gewicht en toedieningsvorm van hormonen, die de 
borstgroei konden beïnvloeden. Onze hypothese was dat transvrouwen kleinere borsten 
zouden hebben dan cisvrouwen en dat het borstvolume met name bepaald zou worden 
door de hoeveelheid vrouwelijke hormonen (oestrogeen) in het bloed en door iemands 
BMI. Ten tweede is er in dit proefschrift onderzocht in welke mate transvrouwen tevreden 
zijn met de borstgroei door hormonen. Onze hypothese was dat de meeste transvrouwen 
ontevreden zouden zijn met de borstgroei, aangezien we verwachten dat het borstvolume 
door hormoonbehandeling klein zal zijn. Het derde doel was om goedaardige en 
kwaadaardige afwijkingen in de borsten te onderzoeken bij transgender personen. Bij deze 
vraag verwachtten wij dat het borstkankerrisico van transvrouwen vergelijkbaar zou zijn met 
dat van cismannen. Ook dachten wij dat goedaardige afwijkingen minder vaak voor zouden 
komen dan bij cisvrouwen. Ten slotte is het overlijdensrisico van transgender personen 
onderzocht. Hierbij werd zowel gekeken naar het algemene overlijdensrisico als naar het 
specifieke risico op basis van bepaalde ziekten zoals borstkanker. Onze hypothese was dat 
het algemene overlijdensrisico van transgender personen hoger was dan dat van cisgender 
personen, maar dat het borstkanker-gerelateerde overlijden niet was verhoogd.
Resultaten en discussie
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Borstontwikkeling bij transvrouwen
In hoofdstuk 3 hebben we borstgroei bij transvrouwen gedurende het eerste jaar van 
hormoonbehandeling onderzocht. De borstgroei werd gemeten door met een meetlint het 
verschil in omtrek van de borstkas over de borsten (ter hoogte van de tepels) en net onder 
de borsten te meten. In deze studie zagen we dat de borstgroei met name in de eerste 
zes maanden van de hormoonbehandeling plaatsvond. Daarna vlakte de groeicurve af. Als 
we de borstgrootte na dit eerste jaar hormoonbehandeling omrekenden naar een cup-
maat, zagen we dat de meeste transvrouwen een cup-maat van kleiner dan AAA hadden. 
Anders dan verwacht, konden wij in deze studie geen factoren (zoals leeftijd, gewicht of 
toedieningsvorm van hormonen) vinden die een verschil in mate van borstgroei tussen 
transvrouwen konden verklaren.
In hoofdstuk 4 onderzochten we borstgroei tijdens de eerste drie jaar van de 
hormoonbehandeling. Naast dat we de borstgroei langer hebben gevolgd dan in de vorige 
studie, hebben we borstgroei ook op een andere manier gemeten dan in hoofdstuk 3; namelijk 
met 3D foto’s. Met deze 3D foto’s kun je niet alleen het borstvolume onderzoeken, maar ook 
kijken naar de positie van de borsten op de borstkas. In deze studie zagen we borstgroei 
gedurende de hele studie, waarbij de groei het meest uitgesproken was in de eerste negen 
maanden van de behandeling. Als we de borstvolumes na drie jaar hormoonbehandeling 
omrekenden naar cup-maat, zagen wij dat de meeste transvrouwen een cup-maat tussen 
AA en A hadden. Verder zagen wij dat de borsten van transvrouwen iets lager en meer naar 
de zijkant op de borstkas zitten vergeleken met cisvrouwen. Ook in deze studie vonden wij 
geen factoren die een verschil in mate van borstgroei tussen de transvrouwen kon verklaren.
Deze twee studies laten zien dat de manier van meten van borstgroei uitmaakt voor het 
resultaat. Hierbij wordt gedacht dat 3D foto’s betrouwbaarder zijn dan meten met een 
meetlint, omdat de 3D foto’s objectiever zijn. In de huidige richtlijn voor transgenderzorg 
staat dat borstgroei 2-3 maanden na de start van hormoonbehandeling begint en dat het 
maximale effect na 2-3 jaar mag worden verwacht. Omdat wij in ieder geval in de eerste 
drie jaar hormoonbehandeling borstgroei hebben gezien in onze studie, is de vraag of 
het maximale effect echt na 2-3 jaar is. Zeker ook aangezien de borstgroei in de pubertijd 
van cismeisjes wel 5-7 jaar kan aanhouden. Langere studies dan drie jaar na de start van 
hormonen bestaan er op dit moment niet. Het zou goed zijn om in de toekomst studies te 
doen met een langere vervolgduur, om te onderzoeken hoe lang de borstgroei doorgaat na 
het starten van de hormoonbehandeling.
Een mogelijke verklaring voor het verschil van de positie van de borsten op de borstkas 
tussen transvrouwen en cisvrouwen kan worden gezocht in verschillen in de bouw van de 
borstkas. De transvrouwen die hebben meegedaan aan onze studies, zijn allemaal gestart 
met hormonen toen zij ten minste 18 jaar oud waren. Hierdoor hebben zij allemaal al de 
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mannelijke puberteit, met bijbehorende veranderingen in de borstkas, doorgemaakt voordat 
zij zijn gestart met de hormoonbehandeling. Doordat de tepels van transvrouwen hierdoor 
wat lager en meer naar buiten staan voor de start van hormonen (zoals bij een mannelijke 
borstkas), groeien de borsten waarschijnlijk ook meer naar buiten. Het zou interessant 
zijn om in de toekomst een zelfde soort onderzoek te doen bij transvrouwen die vóór de 
puberteit gestart zijn met hormoonbehandeling. Je zou dan verwachten dat de borsten van 
deze transvrouwen op een meer met cisvrouwen vergelijkbare positie op de borstkas zitten.
Tevredenheid met borstontwikkeling
In hoofdstuk 4 hebben we ook gekeken naar hoe tevreden transvrouwen zijn met de 
borstgroei gedurende de eerste drie jaar van de hormoonbehandeling. Dit hebben we 
onderzocht door de deelnemers bij ieder bezoek een vragenlijst in te laten vullen waarin 
werd gevraagd naar de tevredenheid met de grootte van de borst en tepel, de symmetrie 
van de borsten en tepel, de vorm van de borsten en de mate van groei ten opzichte van de 
vorige meting. Anders dan verwacht zagen wij in deze studie dat de meeste transvrouwen 
tevreden waren met deze aspecten van de borsten. Echter, 13% van de deelnemers heeft 
een borstvergroting ondergaan gedurende de studie, wat kan betekenen dat deze vrouwen 
toch niet tevreden waren met de grootte van hun borsten.
In hoofdstuk 5 hebben we met behulp van een anonieme vragenlijst onderzocht hoeveel 
transvrouwen een borstvergroting hebben ondergaan. In deze studie zagen wij dat 4 op de 5 
transvrouwen een borstvergroting had ondergaan of overwoog om er een te ondergaan. De 
meeste transvrouwen die een borstvergroting hadden ondergaan, kozen hiervoor omdat zij 
ontevreden waren met de grootte van hun borsten. Na de borstvergroting waren de meeste 
transvrouwen tevreden met het resultaat. Transvrouwen die wel een borstvergroting 
overwogen maar deze niet hebben ondergaan, gaven aan deze keuze met name te maken 
omdat ze de financiële middelen niet hadden om een borstvergroting te betalen. Andere 
redenen waren: ‘ik ben tevreden met de borstgroei’, ‘ik wil verdere borstgroei (nog) 
afwachten’ en ‘ik ben bang voor complicaties van een borstvergroting’.
Een aantal transvrouwen in deze studie gaf aan dat zij de borstprothesen weer hadden laten 
verwijderen. Sommige transvrouwen hebben dit laten doen omdat zij lichamelijke klachten 
hadden waarvan werd gedacht dat deze verband hielden met de prothesen. Anderen kozen 
voor een borstprotheseverwijdering omdat de borsten (nog) verder gegroeid waren na de 
borstvergroting, waardoor zij vonden dat hun borsten te groot waren geworden. Dit laat 
zien dat het belangrijk is om alle mogelijke voor- en nadelen van een borstvergroting te 
bespreken, zodat iemand een goede afweging kan maken voordat iemand overgaat tot een 
dergelijke operatie.
Goedaardige en kwaadaardige afwijkingen in de borst
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In hoofdstuk 6 hebben wij afwijkingen in de borsten bij transvrouwen onderzocht. Dit hebben 
wij gedaan door de uitkomst van alle afwijkingen die naar de patholoog waren gestuurd 
te verzamelen. We zagen dat de meeste afwijkingen die gevonden zijn, goedaardig waren. 
Ongeveer 1 op de 9 gevonden afwijkingen was kwaadaardig. Anders dan verwacht is deze 
verhouding tussen goedaardige en kwaadaardige afwijkingen vergelijkbaar met de verhouding 
die bij cisvrouwen wordt gezien. We zagen een duidelijk verschil in het soort afwijkingen bij 
transvrouwen voor ze waren gestart met de hormoonbehandeling en afwijkingen gevonden 
bij transvrouwen na de start van de hormoonbehandeling. Bij transvrouwen voor de start van 
hormoonbehandeling zagen wij met name gynaecomastie (een goedaardige borstzwelling), 
terwijl bij transvrouwen na de start van hormoonbehandeling met name afwijkingen in de 
melkklieren en melkgangen (zoals fibroadenomen en cysten) werden gezien. In onderzoek 
bij transvrouwen die borstprothesen hadden, werden alleen goedaardige reacties op de 
borstprothesen gezien.
In hoofdstuk 7 wordt er een overzicht gegeven van de bestaande literatuur over (borst)
kanker. Dit onderzoek liet geen verhoogd risico op borstkanker zien bij transgender 
personen. Echter waren er weinig grote, langdurige studies beschikbaar om hier een goede 
uitspraak over te kunnen doen.
In hoofdstuk 8 is het risico op borstkanker bij transgender personen onderzocht, in een 
groep mensen die tussen 1972 en 2016 gestart is met hormoonbehandeling. Hierdoor zijn 
deze mensen lang gevolgd en was er een grote groep beschikbaar om dit onderzoek bij uit 
te voeren. In deze studie zagen wij dat het risico op borstkanker bij transvrouwen groter was 
dan bij cismannen. Dit was anders dan verwacht. Het risico bleef wel lager dan bij cisvrouwen. 
Opvallend was dat transvrouwen gemiddeld gezien op jongere leeftijd borstkanker kregen 
dan de gemiddelde leeftijd bij cisvrouwen. Bij transmannen was het risico op borstkanker 
juist lager dan bij cisvrouwen, maar nog wel hoger dan bij cismannen.
In tegenstelling tot eerder beschreven onderzoek zagen wij voor transvrouwen een verhoogd 
risico op borstkanker in vergelijking met cismannen. Voorheen werd gedacht dat het 
borstkankerrisico in zowel transvrouwen als transmannen vergelijkbaar was met cismannen. 
Wij zagen echter dat dit risico tussen de risico`s van cismannen en cisvrouwen in ligt. Dit is niet 
direct reden tot zorg, zeker niet aangezien slechts ongeveer 1 op de 9 gevonden afwijkingen 
kwaadaardig was. Deze verhouding tussen goedaardige en kwaadaardige afwijkingen is 
hetzelfde als bij cisvrouwen. Daarom adviseren wij transvrouwen die hormonen gebruiken 
deel te nemen aan het bevolkingsonderzoek naar borstkanker. Transmannen die (nog) 
geen borstverwijderende operatie hebben ondergaan worden ook geadviseerd deel te 
nemen aan het bevolkingsonderzoek. Indien er wel een borstverwijderende operatie heeft 
plaatsgevonden, heeft screening niet veel zin meer. Er is namelijk te weinig borstweefsel 
over na een dergelijke operatie om de borstfoto goed te kunnen maken. Daarom worden 
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transmannen na een borstverwijderende operatie geadviseerd zich bij de huisarts te melden 
als zij veranderingen of afwijkingen bemerken aan hun borstkas.
Overlijdensrisico
In hoofdstuk 9 vonden we geen verhoogd (borst)kanker-gerelateerd overlijdensrisico. Wel 
zagen we een toegenomen overlijdensrisico bij transgender personen vergeleken met 
cisgender personen. Dit toegenomen risico daalde niet over de looptijd van de studie. 
De verhoogde oorzaak-specifieke sterfte door longkanker, hart- en vaatziekten, HIV-
geassocieerde ziekten, en zelfdoding laten zien dat het monitoren, optimaliseren en, indien 
nodig, behandelen van medische aandoeningen belangrijk zijn in de transgender zorg.
Een mogelijke verklaring voor een verschil in overlijdensrisico tussen transgender personen 
en cisgender personen zou mogelijk een verschil in leefstijl kunnen zijn. Dit wordt ook mede 
ondersteund door het toegenomen overlijdensrisico als gevolg van longkanker en hart- en 
vaatziekten. Toch konden we in deze studie geen duidelijke verklaring voor de toename in 
overlijdensrisico vinden, omdat er weinig gegevens over leefstijl beschikbaar waren. Wel 
waren er gegevens over roken beschikbaar, waarin er geen verschil werd gezien tussen het 
aantal (voormalig) rokers tussen transgender en cisgender personen.
Net als de algemene (Nederlandse) bevolking, is de transgender populatie een diverse groep 
mensen met verschillende achtergronden, opleidingsniveaus en leefstijlen. Het is belangrijk 
om dit in gedachten te houden als je onderzoek doet in deze groep of als je behandelaar 
bent van een transgender persoon. De resultaten van dit onderzoek zijn daardoor mogelijk 
niet op alle transgender personen even goed van toepassing. Het zou dan ook interessant 
zijn om in te toekomst verschillen in bijvoorbeeld leefstijl mee te nemen in het onderzoek, 
zodat er gerichtere adviezen over gezondheid gegeven kunnen worden.
Adviezen voor de praktijk
In de onderzoeken in dit proefschrift hebben we gezien dat borstgroei bij transvrouwen 
ten minste in de eerste drie jaar van de hormoonbehandeling plaatsvindt. Gebaseerd op 
wat we weten van borstontwikkeling tijdens de puberteit van cismeisjes, bestaat er een 
mogelijkheid dat de borstgroei bij transvrouwen langer duurt dan deze drie jaar. Daarnaast 
hebben we in dit proefschrift gezien dat de positie van de borsten en tepels anders is bij 
transvrouwen dan bij cisvrouwen. Behalve de positie van de borsten op de borstkas, verschilt 
de grootte van de borsten ook sterk tussen verschillende personen (zowel bij transvrouwen 
als bij cisvrouwen). Al deze punten zijn belangrijk om te bespreken met transvrouwen die 
starten met een hormoonbehandeling, zodat zij goed weten wat zij kunnen verwachten van 
deze behandeling. Zeker aangezien borsten een belangrijk symbool van vrouwelijkheid zijn 
in onze Westerse maatschappij en daardoor ook belangrijk zijn voor veel transvrouwen.
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In de studies in dit proefschrift hebben we ook gezien dat veel transvrouwen (willen) kiezen 
voor een borstvergroting. Een groot aantal transvrouwen die nog geen borstvergroting had 
ondergaan, maar dit wel wilde, gaf aan dat zij dit nog niet gedaan had omdat zij de financiële 
middelen hier niet voor had. Zoals eerder in dit hoofdstuk besproken, wordt momenteel 
– ook in het kader van een genderbehandeling - een borstvergroting niet vergoed door 
de zorgverzekering. Vanaf 2019 heeft de overheid daarom een subsidie opengesteld voor 
transvrouwen die een borstvergroting willen. Zij kunnen dan, als zij ten minste één jaar 
hormoonbehandeling hebben gehad, een aanvraag doen voor een eenmalige bijdrage voor 
een borstvergroting. De keerzijde van deze eenmalige bijdrage is dat transvrouwen eventuele 
operaties in de toekomst, bijvoorbeeld vanwege problemen met de borstprothesen (deels) 
zelf moeten betalen. Veel transvrouwen zullen hier naar verwachting geen geld voor hebben. 
Daarnaast kan iemand nu aanspraak maken op deze subsidie als zij tenminste één jaar 
hormoonbehandeling heeft gehad. Gebaseerd op de studies naar borstgroei die beschreven 
zijn in dit proefschrift, kun je bediscussiëren dat dit misschien te vroeg is en dat je wellicht 
minstens drie jaar moet wachten voordat gezegd kan worden dat de maximale borstgroei 
door hormoonbehandeling is bereikt. Wij willen de beleidsmakers adviseren deze keerzijdes 
van de subsidieregeling mee te nemen bij de evaluatie van de huidige subsidieregeling.
Gebaseerd op de studies die beschreven zijn in dit proefschrift adviseren wij iedereen met 
borstweefsel deel te nemen aan het bevolkingsonderzoek naar borstkanker. Hierbij wordt 
iedereen die bij de gemeente geregistreerd staat als ‘vrouw’ automatisch opgeroepen 
voor screening vanaf het 50e levensjaar. Transvrouwen die hun wettelijke geslacht (nog) 
niet hebben aangepast of transmannen die geen borstverwijderende operatie hebben 
ondergaan maar al wel hun wettelijk geslacht hebben aangepast, worden bijvoorbeeld niet 
automatisch opgeroepen. Wij willen een beroep doen op de zorgverleners van deze mensen 
om te zorgen dat zij de kans krijgen om (alsnog) deel te nemen aan dit bevolkingsonderzoek.
Conclusie
In dit proefschrift hebben we gezien dat de borstgroei door hormoonbehandeling bij 
transvrouwen bescheiden is. Gemiddeld is de borstgrootte na drie jaar behandeling kleiner 
dan een A-cup. In de onderzoeken in dit proefschrift hebben we geen factoren (zoals leeftijd 
en gewicht) kunnen vinden die de mate van borstgroei kunnen beïnvloeden. Ondanks de 
bescheiden mate van borstgroei door hormonen, waren de meeste transvrouwen tevreden 
met hun borstgroei. Toch geeft 4 op de 5 transvrouwen aan een borstvergroting te hebben 
gehad of te overwegen. Bij transvrouwen was de verhouding tussen gevonden goedaardige 
en kwaadaardige afwijkingen in de borst hetzelfde als bij cisvrouwen. Het borstkankerrisico 
bij transgender personen lag tussen het risico van cismannen en cisvrouwen in. Ondanks 
dat het borstkankerrisico anders is dan in cisgender personen, zagen we geen verhoogd 
borstkanker-gerelateerd overlijdensrisico in transgender personen.
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Hoewel de hormoonbehandeling dus veilig lijkt als je kijkt naar borstkankerrisico en 
borstkanker- gerelateerd overlijdensrisico, is de borstgroei met deze behandeling bescheiden. 
Aangezien in de Westerse cultuur borsten een belangrijk symbool van vrouwelijkheid zijn, 
zou je verwachten dat veel transvrouwen ontevreden zouden zijn met deze borstgroei. 
Toch geven de meeste transvrouwen in onze studies aan tevreden te zijn met de borstgroei 
door hormoonbehandeling. Deze bevindingen laten het belang zien van een open en eerlijk 
gesprek over verwachtingen van hormoonbehandeling, de lichamelijke veranderingen 
die gezien worden (objectieve veranderingen) en de veranderingen die iemand ervaart 
(subjectieve veranderingen). Daarnaast is het belangrijk om te praten over een eventuele 
wens voor borstvergroting, waarin ook gesproken wordt over de timing in het traject en de 




Na 5 jaar onderzoek doen, een paar keer mijn promotie-plan wijzigen en (uiteindelijk) 
accepteren dat niet alles in mijn boekje hoeft, komt er met dit schrijven nu toch echt een 
einde aan mijn promotietraject. Hoewel het enige voeten in de aarde heeft gehad, ben ik 
stiekem best trots op het resultaat. Dit was zonder de hulp van vele mensen niet gelukt en 
daarvoor wil ik hen graag bedanken.
Allereerst wil ik alle deelnemers aan de verschillende studies bedanken. Zonder jullie 
belangeloze deelname was dit proefschrift er nooit geweest.
Geachte prof. dr. den Heijer, beste Martin, mijn promotie-traject bij jou had geen doorsnee 
start. Ik zou eigenlijk bij Prabath gaan promoveren, maar daar was toen geen geld voor 
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